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Abstract 
Background: Currently there is no widely accepted test to diagnose AD. The involvement 
of the lysosomal system in Alzheimer’s disease (AD) progression provides an 
opportunity to develop associated biomarkers. The lysosomal enzyme Cathepsin D 
(CatD) has been shown to be over-expressed in the AD brain before clinical onset. We 
have developed a dual modality contrast agent (CA) to detect CatD activity which 
consists of an HIV-1 Tat Cell Penetrating Peptide (CPP) conjugated to a CatD cleavage 
sequence and two imaging moieties consisting of a fluorescently- tagged probe and a 
DOTA cage for chelating Gallium-68. The purpose of this work was to validate CatD as 
an AD biomarker across multiple AD disease models and to test our novel CA in-vivo by 
means of optical near infra-red (NIR) fluorescence imaging and positron emission 
tomography (PET).  Methods: Three transgenic (Tg) mouse AD model strains were tested 
for CatD expression by Western blot and immunohistochemistry analysis. The chosen 
mouse line (5XFAD) and controls were imaged at 5 and 12 months of age using an 
eXplore Optix scanner (GE Healthcare, Milwaukee, WI, USA).  Next, mice at 2, 6 and 9 
months of age were tested using an Inveon microPET system (Siemens Medical 
Solutions, Knoxville TN, USA) using a 68Ga-labeled CatD targeted CA.  Results: All 3 
AD mice demonstrated an elevation of CatD expression in parallel with AD pathology. 
The 5XFAD had the highest levels of CatD, making it the best mouse model to study 
CatD upregulation. The rate of the NIR CatD Targeted CA washout was significantly 
slower in the 5XFAD mice (p<0.05) at 5 and 12 months of age compared to controls. The 
control CAs showed no differences in washout. MicroPET imaging of the 5XFAD Tg 
mice showed significantly higher uptake rate of the CatD targeting CA in the forebrain 
relative to hindbrain at 2, 6 and 9 months of age compared to controls. Conclusion: Both 
the optical and the microPET data demonstrated increased retention of our agent in the 
brain of 5XFAD mice compared to age-matched controls. These studies show that this 
agent may be useful for AD early detection. 
 
Keywords:  Alzheimer’s disease, Early detection, Cathepsin D, Optical Imaging, 
positron emission tomography, contrast agent, Magnetic Resonance Imaging. 
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Preface 
 
Alzheimer’s disease (AD) is a terrible, incurable, insidious neurodegenerative 
disorder. It is the most common form of dementia and is responsible for a crippling 
economic burden on the health care system and grave emotional, physical, and mental 
burden on family care-givers and patients. The disease slowly disintegrates an 
individual’s identity, their memories, capacity to perform daily tasks and eventually leads 
to death. Currently, there are no definitive tests to detect AD. A probable AD diagnosis is 
made by a clinician based on clinical presentation: memory impairment, cognitive 
decline, and family and individual medical history. Ironically, the budget allocated by 
western-world countries to develop a cure and improve diagnostic approaches is 
approximated to be well below 1% of the budget assigned for the care of those affected 
by the disease. Sadly, the most popular and sought after diagnostic tactics still rely either 
on a century old, albeit momentous, observation of β Amyloid (Aβ) plaques and 
neurofibrillary tangles (NFT) in post-mortem brains from people with the disease, or 
other downstream pathogenic changes in-vivo.  The latter includes cerebral spinal fluid 
biomarker tests and structural or functional changes in the brain as measured by magnetic 
resonance imaging (MRI) /fMRI, 18F Fluorodeoxyglucose (FDG), and contrast agents 
(CA) targeting Aβ/ NFT for use with either MRI or positron emission tomography (PET). 
To complicate things further, many tests lack the ability to differentiate AD from other 
pathologies, or normal aging unless used in tandem with a large number of 
complimentary tests. While early results are promising based on on-going observations, 
targeting the two hallmark pathologies (Aβ and NFT) may be inherently flawed due to 
the very high prevalence of these pathologies in cognitively normal older adults (80% of 
adults over the age of 80). Although not commonly acknowledged, the lysosomal system 
has been proven to play an important, yet not fully elucidated, role in the development of 
the disease. It is the main objective of this work to provide an alternative early diagnostic 
paradigm for AD. The hypothesized approach was successfully demonstrated in this 
thesis using AD model mice that are shown to recapitulate increased levels of Cathepsin 
D (CatD) and are differentiated from age-matched controls using both optical and the 
more clinically-relevant positron emission tomography imaging systems.  
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The thesis core chapters are organized as follows: First an introduction provides 
background information about the disease. Second, the search for an appropriate animal 
model is reported. Third, the first in-vivo attempt at using a targeted, as well as two 
control (a non-targeting, and a non-penetrating) CAs to differentiate diseased animals 
from controls is described. Forth, a more clinically translatable imaging modality 
evaluation is reported using only the targeted CA. Finally, a conclusion and integration of 
all the data collected is reported together with a description of future directions. By 
carefully reviewing the introduction, the reader is expected to learn first about AD 
pathology, prevalence, the involvement of the lysosomal system, and the common 
diagnostic / treatments models. The reader will learn about the power of molecular 
imaging, the utilization of targeted CAs and the benefit of using a cell penetrating peptide 
to cross the blood-brain-barrier (BBB). In addition, the reader will learn the basics of the 
modalities and assays used in this study such as microscopy, fluorescence optical 
imaging, positron imaging, magnetic resonance imaging and finally, histology and 
Western blot protein quantification. Following the introduction, the reader will be 
presented with findings that summarize the planning, execution, analysis, and successful 
implementation of a molecular imaging approach for the detection of increased CatD 
levels in an AD model mouse. First the evaluation of CatD levels as well as Aβ (as a 
measure of disease progression) is performed in three different strains of AD mouse 
models. These data lead to the selection of the 5XFAD model, which was found to be 
very aggressive, yet provides several advantageous characteristics for the testing of our 
novel CatD targeting probe in-vivo. Next the 5XFAD model is examined in-vivo using 
optical imaging techniques and specially designed control CA (lacking the cell 
penetrating peptide, or lacking the targeting moiety). The CA is modified to have a Near 
Infrared dye that allows the detection of minute concentrations (10-12) at depths up to 1 
cm. The results are conclusive and indicate that the preferential uptake and retention of 
our CA require both penetration across the BBB and the targeting of CatD. The 
sensitivity of this approached allowed the differentiation of transgenic (Tg) mice from 
wild-type controls at not only 12 months of age but also at 5 months of age. Finally, a 
more clinically translatable approach examined a slightly modified CA structure to 
accommodate imaging the mice longitudinally using microPET. This was accomplished 
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by incorporating 68Ga, a positron emitting radioisotope with a short half-life that can be 
made readily available at any clinic without the use of a cyclotron. This tomographic 
approach allowed the measurement of activity over time directly in the brain of the mice 
as well as other body regions. It was shown that Tg mice could be differentiated from 
age-matched non-Tg littermates as early as 2 months of age by measuring the rate of 
change of activity in the forebrain relative to the hindbrain. Similarly, significant 
differences were noted at 6 and 9 months of age.  
This study showcases several important findings and achievements.  First, 
significantly increased levels of CatD (compared with controls) correlate with Aβ 
pathology, and are detected in multiple mouse models that already recapitulate other AD-
like pathologies. Second, the HIV-1 tat peptide provides an adequate penetration of a 
large (>3kDa) CA across the BBB into the brain for successful molecular targeted 
optical, MRI, or PET imaging. Finally, CatD targeting allows the differentiation of AD 
mice from controls using multiple modalities, and at multiple ages, as early as 2 months. 
  
1 
 
Chapter 1 : Introduction 
1  Introduction 
The work accomplished and documented here is motivated by the lack of clinical 
standards for a conclusive, ante mortem, early diagnosis of Alzheimer’s disease (AD). 
This initial chapter is meant to provide a concise review of relevant background 
information with respect to AD and the different tools developed to better understand its 
pathogenesis including animal models, contrast agent (CA) development, and imaging 
modalities. 
1.1 Mild Cognitive Impairment 
Mild Cognitive Impairment (MCI) is a state at which an individual experiences 
mild but noticeable changes in some aspects of cognitive function (e.g. thinking abilities). 
These changes do not immediately pose a threat to the individual’s capability to perform 
daily activities, but may represent a transitional stage from normal aging to early 
dementia [1]. Amnestic MCI, the most common subtype of MCI, requires a memory 
complaint, preferably with objective corroboration but no significant change in daily 
functioning [2]. MCI prevalence is estimated to be approximately 16% in non-demented 
geriatric individuals [3] with an annual conversion rate to dementia ranging up to 15%, or 
50% over 5 years [2]. All subtypes of MCI are associated with increased risk for 
dementias; however, individuals with this diagnosis may remain stable or even revert to 
normal, suggesting the course of MCI is quite heterogeneous [4]. Regardless, it has been 
shown that people with amnestic MCI are more likely to develop AD [5]. 
1.2 Dementia and Alzheimer’s Disease 
By definition, dementia is a neurocognitive disorder severe enough to interfere 
with performing social or occupational daily basic tasks [5]. There are many types of 
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dementia, with increasing evidence indicating that many people with dementia have 
mixed dementia – that is, the combination of more than one single pathology [6]. AD is 
an insidious disease, and the most common cause of dementia [5]. It was first described 
over 100 years ago by Dr. Alois Alzheimer who presented his early findings to the 
medical community in Tübingen, Germany [7]. Since then large research efforts have 
focused on understanding the cause of AD, developing tools to diagnose it in the clinic, 
and attempting to treat or even cure the disease [5]. Research advances have underscored 
the complex pathology of the disorder requiring additional studies to elucidate the 
intricate processes involved in its development.  
AD symptoms can present differently in different people [6]. However, the most common 
early symptom is the gradual loss of short term memory. This symptom is thought to be 
caused initially by loss of synapses in areas of the brain responsible for forming new 
memories [5]. As AD progresses, patients present with impairment with other spheres of 
cognition, including impairments in language and an increasing inability to plan or solve 
problems. They have difficulty completing familiar tasks and they have difficulty 
understanding visual images, spatial relationships and motor movements. In the mid stage 
of the disease, patients lose their independence and have difficulty with basic daily 
activities such as bathing, dressing and eating. This eventually evolves into an “akinetic 
mute” end stage. A concise simplified summary of some other common forms of 
dementia and their respective clinical presentation is shown in Table 1. It is worth noting 
that Parkinson and Dementia of Lewy Body share the pathology of α-synuclein 
aggregates, Frontotemporal lobe dementia and AD share the pathology of tau tangles, but 
only AD (from the list above) exhibits β-amyloid plaques. 
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Table 1-1. Common types of dementias. 
Type of dementia Clinical presentation Pathology 
Alzheimer’s disease Early symptoms: Impaired short term 
memory, e.g. difficulty remembering 
recent conversations, names, or events; 
apathy and depression. 
Late symptoms: Impaired 
communication, disorientation, 
confusion, poor judgment, behavior 
changes and ultimately difficulty 
speaking swallowing and walking. 
Protein fragment β-amyloid 
(plaques) outside neurons in 
the brain and twisted strands of 
the protein Tau (tangles) inside 
neurons. 
Vascular dementia Impaired judgment or ability to make 
decisions, plan or organize. 
Typically also have signs of stroke 
Blood vessel blockage or 
damage leading to infarcts 
(strokes) and/or bleeding in the 
brain. 
Dementia of Lewy Body Sleep disturbances, well-formed visual 
hallucinations, slowness, gait imbalance 
and visuospatial impairment.  Motor 
features of Parkinson’s disease 
Brain neurons accumulate 
Lewy bodies and lewy 
neurites, abnormal 
aggregations of the protein α-
synuclein. (Especially in the 
Cortex). 
Frontotemporal lobe dementia Changes in personality and behavior and 
difficulty with producing or 
comprehending language. 
Frontal and temporal lobes 
become atrophied; upper layers 
of the cortex develop protein 
inclusions (e.g Tau protein). 
Parkinson’s disease Slowness, rigidity, intention tremor and 
changes in gait. 
α-synuclein aggregates in 
substantia nigra believed to 
cause degeneration of nerve 
cells that produce dopamine. 
Table has been adapted from the 2014 Alzheimer's disease facts and Figures [5]. 
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1.2.1 Alzheimer’s Disease Epidemiology and Risk Factors 
AD is the most common form of dementia accounting for 50-60% of all dementia 
cases. The prevalence of AD is less than 1% in people over 60 and under 65 years of age. 
However there is an exponential increase in AD with age, to 1 out of 3.5 people affected 
in the age group of 85 years and over and living in the western world [8]. It is expected 
that by 2050 there will be 115 million people living with AD in the world including more 
than one million Canadians [9, 10]. This surge is due to the anticipated increase in life 
expectancy [8] with the greatest risk factor for AD being aging. Despite the prevalence, 
AD is not a normal part of aging. The main risk factors for developing AD are age and 
education.  Other risk factors include, but are not limited to, stroke/vascular risk factors, 
family history, environmental and lifestyle factors, genetic mutations, and MCI.  
Over 20 years ago, two separate research groups made an association between the 
apolipoprotein E (ApoE) ε4 allele and sporadic AD [11, 12]. Since then, many other 
genes have been associated with sporadic AD, although these genes account for only a 
small amount of relative risk [13]. However, the ApoE ε4 allele has been corroborated 
now by many groups in a very large cohort of AD patients and is the largest known 
contributor of genetic risk for the development of sporadic AD [14]. In fact, a meta-
analysis showed that the ApoE ε4 allele increases the risk of developing AD by three 
times in heterozygotes and by 15 times in homozygotes [15]. Regardless of ApoE 
involvement, it is estimated that 60-80% of AD risk may be heritable [16]. Therefore, 
when AD runs in a family, heredity and shared environmental and lifestyle factors play a 
role as is evident by the significantly higher risk (nearly double) in those with a first 
degree relative such as parent or sibling that have the disease [17].  
AD can be either sporadic or familial. Only 1% of cases are familial, with the 
majority due to mutations in genes encoding the proteins amyloid precursor protein (APP 
on chromosome 21), presenilin 1 (PSEN1 on chromosome 14) and presenilin 2 (PSEN2 
on chromosome 1) and are referred to as familial AD (FAD). In FAD, an individual 
inheriting the associated gene mutations usually develops the disease much earlier than in 
the sporadic form of the disease, often in their 40’s. For FAD cases, the PSEN1 mutation 
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accounts for the largest number of known mutations (177) implicated with the 
development of the disease, followed by APP (32), and lastly PSEN2 (14). Three main 
categories of FAD APP mutations exist: one that increases the rate of production of all 
isoforms of amyloid species [18] (e.g. Swedish), another increases the relative amount of 
the more toxic Aβ42 produced [19] (e.g. London), and finally one that decreases α-
cleavage by increasing the stability of Aβ or increases its propensity to aggregate [20] 
(e.g. Arctic mutations). 
 Other risk factors have been suggested and include low cognitive reserve (e.g. low 
education and occupation attainment, social and cognitive engagement), high cholesterol, 
high blood pressure, atherosclerosis, coronary heart disease, smoking, obesity and 
diabetes [21].  
1.2.2 Alzheimer’s Disease Pathology 
Brain changes leading to AD may begin 20 years or more before symptoms 
appear [22]. A healthy adult brain has billions of neurons, each with long branching 
extensions connecting neurons with other neurons. These connections, called synapses, 
create the cellular basis for memories, sensations, emotions and movements. Earlier in 
life, before clinical presentation, AD disrupts proper functioning of neurons and 
synapses. In AD, information transfer at synapses begins to fail, with the number of 
synapses declining, in a potentially reversible phase of AD.  Eventually neurons also 
begin dying, leading to tissue atrophy and irreversible cognitive decline. The hallmark 
pathologies used for a conclusive post-mortem diagnosis involves the accumulation of 
the protein β-amyloid (Aβ) in plaques [5] and an abnormal form of the protein Tau in 
brain cells [5]. Additionally and allegedly because of the former pathologies, 
neurotransmitter systems impairment and neuroinflammation have been implicated in 
AD.  
1.2.2.1 Amyloid plaques 
At the microscopic level, there are characteristic lesions, known as senile plaques 
in the brains of AD patients (Figure 1-1). It was only in the 1980’s that Aβ protein was  
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Figure 1-1. Cellular processing and environment of AD pathology. The APP (top-left) 
is cleaved to produce the Aβ segment which can then aggregate into small oligomers or 
longer peptides that cause the Endoplasmic Reticulum (ER) or mitochondria to activate 
caspase leading to cell death. Alternatively these oligomers may affect a variety of 
receptors that may also lead to cell death. Extracellularly, Aβ are also found in senile 
plaques, nearby interacting microglia, and astrocytes, presumably perpetrating 
inflammation and oxidative stress. Downstream from Aβ production, potentially due to 
the effect of Aβ on Tau synthesis, there is destabilization of microtubules as well as the 
eventual formation of neurofibrillary tangles (NFT). 
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identified as the major constituent of these plaques [23]. This discovery in turn led to the 
amyloid cascade hypothesis, which is the leading model of the pathophysiology of 
Alzheimer’s disease [24]. Aβ is produced by the cleavage of the large transmembrane 
APP (Figure 1-1) at the β site by an aspartyl proteinase [25] called beta-site APP-cleaving 
enzyme (BACE). Alternatively, APP may be cleaved by a family of enzymes referred to 
as α–secretases that prevent the production of Aβ [26]. This latter pathway is less 
common in neurons [27]. The leftover fragment from BACE cleavage is then cleaved at 
an additional γ cleavage site, which is variably located along the APP segment (Figure 1-
1 Adapted from [28]) by the intramembranous protease complex referred to as the γ-
secretase. The γ-secretase consists of four components: PSEN-1 , nicastrin, PEN-2 and 
APH-1 with PSEN-1 occupying the active site [29]. The central dogma states that an 
imbalance between the production and clearance of Aβ in the brain is the initiating event, 
ultimately leading to synaptic loss, neuronal degeneration, and dementia [30].  
While senile plaques have remained the key feature of AD, it is the oligomers that 
should be considered the culprit of AD-related synapse loss and probably eventual 
neuronal cell death [31]. Despite the indisputable connection between Aβ and AD, which 
has yet to be completely understood – amyloid plaque load does not correlate well with 
cognitive function or disease progression in humans [32]. This lack of correlation has 
highlighted the potential drawbacks of the original amyloid hypothesis. Consequently, 
some researchers believe that the abnormal Tau protein formations, described next, could 
be the critical causative agent in AD since the latter correlates better with cognitive 
impairment [32].  
1.2.2.2 Tau 
Almost in parallel with the identification of Aβ in plaques, intracellular 
neurofibrillary tangles were also described. These tangles are composed of abnormally 
hyperphosphorylated Tau protein [33] processed as described below and shown in Figure 
1-1. Normal Tau is an axonal protein that binds to microtubules promoting assembly and 
stability of microtubules, which are structural elements and enable the transport of 
organelles and other essential molecules within all cells in the brain (and elsewhere). 
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Abnormal Tau is believed to contribute to cell death by disrupting the normal function of 
microtubules by forming paired helical filaments (PHF) that aggregate to form 
neurofibrillary tangles or NFT [5]. Tau phosphorylation is regulated by the balance 
between multiple kinases and phosphatases [34]. Hyperphosphorylation in AD leads to 
sequestration of normal Tau and other microtubule-associated proteins. These 
microtubules are destabilized and the abnormal Tau aggregates into insoluble fibrils, then 
larger tangles, ultimately compromising neuronal function and leading to cell death [34]. 
While NFTs correlate well with AD onset and progression [35], to date no Tau 
mutations have been found in FAD cases [24] implying that Tau plays a secondary role to 
Aβ in AD progression. In fact, Tau mutations have been found in association with other 
distinct diseases such as frontotemporal dementia (which lacks Aβ pathology) [36, 37]. 
The secondary role of Tau is further supported by the order of appearance of Aβ plaques 
prior to NFTs in Down syndrome [38]. Moreover, experimental changes (reductions, or 
increases) in Aβ oligomers in mice resulted in directly proportional changes in Tau [39, 
40]. Therefore, it is likely that Tau effects are downstream from Aβ and yet still have an 
important role in AD progression and severity [24].  
1.2.2.3 Lysosomal System and Cathepsin D 
The lysosomal/endosomal system comprises a series of intracellular 
compartments responsible for many different functions in cells [24]. Their main function 
is the processing (e.g. digestion, post-processing) of extracellular materials and cellular 
proteins, lipids and carbohydrates which is accomplished by having a highly acidic (pH 
of 4.5) environment and containing many different catabolic (digestive) enzymes [41]. 
There are more than 40 lysosomal storage diseases, which are usually caused by the 
absence of a critical enzyme, many of which can lead to dementia and eventually death 
[24]. Specifically, the endosomal/lysosomal system has been shown to play a role in Aβ 
production and clearance and this system has been shown to be up-regulated (increase in 
the size and number of lysosomal bodies and the expression of lysosomal enzymes) in 
AD [42-45]. Lysosomes are highly enriched in APP and γ-secretase proteins (e.g 
presenilin) with the capacity for γ-secretase activity [46].  Several experiments where 
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APP on the cell surface was labeled with a fluorescent tag have shown the APP gets 
internalized within lysosomes, cleaved into Aβ and then secreted or retained 
intracellularly by the endosomal/lysosomal system [24, 47]. Three pathways have been 
previously described. APP originating from the cell surface can either migrate into 
endosomes through endocytosis [48], directly from the cell surface to the lysosomes [49], 
or through autophagosome processing [50]. Furthermore, in a recent elegant set of 
experiments, a fourth newly recognized pathway of APP trafficking was identified that 
involved the direct passage of APP from the Golgi apparatus to the lysosome [51]. All 
four pathways are illustrated in Figure 1-2 (adapted from Tam et al. [51]). 
 
Figure 1-2. Overview of the endosomal/lysosomal and autophagy systems. APP is 
synthesized in the ER and transits to the Golgi, where it is glycosylated and exported to 
the cell surface or alternatively to internal structures and eventually the lysosome. From 
the cell surface the APP may be cleaved and/or endocytosed into early endosomes, then 
late endosome and finally to the lysosome. APP can also be transported directly from the 
cell surface to the lysosome. Compartments implicated in Aβ productions are marked 
with an asterisk (*), while those implicated in Aβ accumulation are coloured yellow. 
It has been suggested that PSEN1 may be a unifying gene factor in AD as it may 
be the connection between the lysosomal system and APP. PSEN1 mutations are 
responsible for producing toxic Aβ species from APP and blocking autophagy (a form of 
a regulated cellular components destruction), impairing the cell’s ability to clear toxic Aβ 
species or aggregates and other toxic features (e.g. abnormal Tau). Additionally, PSEN1 
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is necessary for the clearance of proteins from the endosomes [52] and trafficking 
through the endosomal/lysosomal system [53]. Therefore, PSEN1 mutations reveal 
impaired lysosomal function [54], which implies FAD (and maybe AD in general) could 
be considered a lysosomal storage disease [24].  
One of the many (>80) lysosomal enzymes, an aspartyl protease (protein cleaning 
enzyme) called Cathepsin D (CatD) is known to be involved in tissue homeostasis 
including tissue renewal, remodeling, regulation of aging and programmed cell death 
under normal physiological conditions and base-line expression [55]. CatD has also been 
associated with the processing of the amyloid precursor protein [56], Tau protein [57] and 
apolipoprotein E [58] – all of which are considered important factors of AD pathology 
[59]. Other studies indicated an alternatively positive role for CatD in the degradation of 
toxic Aβ42 and Tau aggregations [60]. Moreover, increased expression and activity of 
CatD within the brain is shown to precede known histopathological features of AD 
including neurodegeneration [41-43]. Additional connections between CatD activity and 
AD pathogenesis have been made. Specifically, it has been shown that the CatD gene and 
its genetic polymorphism are associated with a higher risk for developing sporadic AD 
[61, 62]. Cerebral Spinal Fluid (CSF) collected from AD patients indicates that increased 
levels of CatD are released into the extracellular space, which is an active ongoing 
process in the AD brain. Furthermore, a recent study demonstrated that neural-derived 
plasma exosomal (membrane vesicles originating from endosomes) levels of CatD were 
significantly higher [63]. Considering the progressive state of AD involves cell death, it 
is no surprise that CatD has also been implicated, speculatively, in neurodegenerative 
apoptotic pathways [64] potentially by increasing the activity of caspases, increasing 
Reactive Oxygen Species (ROS), and decreasing mitochondrial function [65-68], but may 
be a failed attempt of lysosomes to deal with increased levels of amyloid accumulation in 
vulnerable neurons [42].  
The involvement of CatD in AD makes it a potentially useful biological marker of 
disease progression [44]. In fact, the targeting of CatD for AD imaging is unique, because 
it is a marker of biochemical function rather than just protein or peptide accumulation.  It 
is hoped that targeting CatD may provide a means to diagnose AD earlier than current 
 11 
 
clinical tools [69].  However, to first test the CatD targeting concept and the use of CatD 
to differentiate between AD and normal controls, experiments in non-human subjects 
must be used for initial validation. The goals of such studies include determining the best 
route of administration, and optimal concentration of the agent used to target CatD. These 
optimization studies are commonly performed in mice that mimic human pathologies 
most often by the use of genetic modification.  
1.2.3 Pre-Clinical Models of Alzheimer’s disease 
Some species such as monkeys, dogs and cats [70-72] develop age related 
cognitive impairment and Aβ plaques. However animals (almost all including mice) do 
not naturally develop AD; in order to develop AD animal models, human genes for 
Familial AD (human APP and PS1 bearing FAD mutations, further discussed later) must 
be introduced. The easiest and most commonly used animal models for studying AD 
pathology are genetically engineered transgenic (Tg) mouse models, the more recently 
available Tg rat models [73], the sparingly used non-human primates [74] and some 
invertebrate models [75, 76]. Animal models have been created and studied extensively 
to help researchers understand the etiology and pathophysiology of human 
neurodegenerative diseases and to develop and test new diagnostic techniques. Animal 
models are an essential component in the generation of therapeutic assessments [77]. 
While invertebrate models such as Drosophila melanogaster [75] and Caenorhabditis 
elegans [76] might offer the advantage of cost, sample size and short life spans over 
mouse models, they are evolutionarily more distant from humans than rodent models and 
caution must be taken when drawing conclusions from these models. Mice are the most 
commonly used model for AD studies. This over-representation of animal studies in mice 
is largely due to the ease of genomic manipulation capability, benefits of cost (e.g. less 
expensive than rats), ease of handling and relatively short life-span allowing a thorough 
pathogenesis investigation over the life-time of the animal. However, due to very small 
brain size, mouse models pose additional technical challenges (e.g. resolution, signal-to-
noise ratio, scan durations, partial volume effect) for any research using, testing or 
developing new imaging techniques.  
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1.2.3.1 Murine Models 
Transgenic mouse AD models advanced from the contentious discovery of FAD 
mutations, allowing these models to be developed based on the amyloid hypothesis. AD 
mouse models have contributed widely to the understanding of the pathophysiology of 
the disease as well as the development and testing of new imaging modalities/ techniques 
[77]. The discovery of the FAD mutations in APP as was described above, provided the 
opportunity to investigate AD pathogenesis more rigorously via the generation of AD 
mouse models carrying these mutations. One of the first AD mouse models 
overexpressed the Indiana mutation and was shown to exhibit an 18-fold increase in APP 
levels leading to age-dependent increase in senile plaque deposition [78]. Since then, the 
Tg2576 mouse, which expresses the Swedish mutation, has become one of the most 
widely studied models and has shown plaque pathology development at 9-12 months of 
age [79]. Other FAD mutations (e.g PSEN1) have been generated in mice to drive early 
AD pathology with increased Aβ42 levels [80] but also require a human APP transgene, 
usually with an FAD mutation to develop overt plaque deposition [81].  Previously, many 
of the available AD mouse models were hampered by the lack of NFTs and neuron loss. 
NFTs were recently achieved by either the incorporation of Frontotemporal lobe 
dementia Tau mutation into APP Tg mice, as in the 3XTg strain [82], or by the 
incorporation of wild-type human Tau gene into APP Tg mice [83]. The latter discovery 
further supported the hypothesis that Tau pathology develops downstream from Aβ. 
Neuronal cell death has been recently detected in more progressive Tg mouse models 
such as the 5XFAD where multiple mutations are expressed [84]. 
Currently there is no consensus on any particular gene(s) that can be used for 
creating an animal model representing the sporadic (most common) form of AD. An 
alternative has been suggested utilizing transduction of rat pup-brains with human genes 
that code for proteins that are downstream from another lysosomal enzyme activity, 
asparaginyl endopeptidase, leading to neurodegeneration as well as Tau and Aβ 
pathology. However, while animal models of sporadic AD do exist, they usually require 
extended periods of time to develop and pathological features of both sporadic and 
familial human AD are similar [85]. Thus, any Tg mouse model of AD is a compromise 
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and should be chosen to answer the specific question addressed by the study. In general, 
all AD Tg mouse models face some criticism due to the overexpression of one or more 
FAD mutations unlike humans and yet have provided invaluable insight into AD 
pathogenesis and therapeutic strategies. Although AD mice recapitulate few 
characteristics of the pathology (e.g. depending on the transgene incorporated, these mice 
may develop amyloid plaques or NFT), caveats must be considered when interpreting the 
data [84] especially considering only the 5XFAD mice present neuronal loss [86]. The 
following three AD mouse model strains were selected from Jackson Laboratories (Bar 
Harbor, ME, USA) for this work. Figure 1-3 summarizes the life-span reported 
pathological features of AD in these specific strains, which will be described in the next 
sections, based on several studies [40, 84, 87-94]. 
 
Figure 1-3. AD pathology progression with time in three Tg mice models. Colour 
markers are used to indicate the time of discovery and are not suggestive of quantitative 
measurement and pathological burden. Adapted from [86, 104, 105]. 
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1.2.3.1.1 APP/Ps1dE9 
The APPswe/PS1dE9 or B6C3-Tg(APPswe,PSEN1dE9) is a hemizygote double 
transgenic mouse strain (2X) on the parent background lines of B6C3F1/J and C57BL/6J 
strains. This model expresses a chimeric mouse/human amyloid precursor protein 
(Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-delta-exon 9) protein both 
controlled by independent mouse prion protein (PrP) promoter elements directed to 
neurons [95]. The overexpression of the transgene APP with the Swedish 
(K595N/M596L; also called K670N/M671L) mutation of APP, together with PS1 deleted 
in exon 9 leads to the overproduction of APP and PS1 splice variants. There is a 
concomitant increase in Aβ load with double the amount of toxic Aβ42 deposited 
compared to the less toxic Aβ40 [90]. Consequently, plaques are abundant in the 
hippocampus and cortex by 9 months of age with occasional deposits found in mice as 
young as 6 months of age [90, 93]. In addition, in the hippocampus, activated microglia 
and astrocytes, signs of inflammation/gliosis, surround the deposits [93]. Furthermore, at 
13 months of age and above, Tg mice weigh less than controls, exhibit a reduced ability 
to maintain balance on a rotarod and commit more errors in the water maze than controls. 
At 7 months of age, both groups test similarly [93]. Even though these mice do not 
exhibit neuronal loss, they do display a variety of other clinically relevant AD-like 
symptoms; for example, mild neuritic abnormalities [96], transient long-term potentiation 
(LTP/LTD)[93] and increased mortality [97].  These mice present with cognitive decline 
that correlates with soluble Aβ, accumulation of senile plaques, and neuroinflammation 
(gliosis), offering a valuable tool in AD studies [98]. 
1.2.3.1.2 3xTg  
The 3xTg or B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L) is a triple transgenic 
homozygous mouse strain (3X) on the parental background lines of 129S1/Sv, 
129X1/SvJ, and C57BL/6. This model was created in a unique way [99] where single-cell 
embryos from mice bearing the presenilin PS1M146V knock-in mutation on a mixed 
C7BL/6;129X1/SvJ;129S1/Sv genetic background (B6;129-Psen1tm1Mpm) were co-
injected with two independent mutant human transgenes: human amyloid beta precursor 
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protein (Swedish mutation KM670/671NL) and microtubule-associated protein Tau 
(tauP30IL). Both transgenes are integrated at the same locus and are under the control of 
the mouse Thy1.2 regulatory element [95]. Consequently, Aβ oligomers extracellularly 
and intraneuronally, begin to accumulate before 6 months of age, and continue with age-
dependent increases observed between 12 and 20 months [100]. In addition, Tau 
pathology including NFT is detected by 6 months of age with advanced NFT burden by 
20 months [100]. At age 6.5 months 3xTg mice display learning and memory deficits in 
the Barnes maze; however, compared to the 2xTg, 3xTg perform better on the Rotarod 
and water maze tests [101, 102]. Similar to the 2xTg, even though these mice do not 
exhibit neuronal loss, they do display a variety of other clinically relevant AD-like 
symptoms such as Aβ42 plaque and abnormal Tau accumulation. These mice have 
progressive accumulation of senile plaques, tangle pathology, and are associated with 
synaptic dysfunction leading to cognitive decline offering another valuable tool in AD 
studies. 
1.2.3.1.3 5XFAD Tg6799 
The 5XFAD or B6SJL-Tg(APPSwFlLon, PSEN1*M146L*L286V) 
6799Vas/Mmjax is a double transgenic hemizygote mouse strain model of AD with five 
FAD mutations (5X) maintained on a c57Bl/6 x SJL parental background. This strain 
overexpresses mutant human APP(695) containing the Swedish (K670N, M671L), 
Florida (I716V) and London (V717I) Familial Alzheimer's Disease (FAD) mutations 
along with human PS1 gene harboring two FAD mutations M146L and L286V. Both 
transgenes are regulated by the mouse Thy1 promoter to drive overexpression in the 
brain. The model was generated by introducing APP (Swedish, Florida and London 
mutations), and PS1 (M146L and L286V mutations) into APP (695) and PS1 cDNA 
sequences followed by insertion into exon 2 of the mouse Thy-1 promoter gene which 
was finally injected into pronuclei of the single-cell embryos. The presence of the 
Swedish mutation results in higher levels of total Aβ, whereas Florida, London, M146L 
and L286V mutations increase the production of Aβ42 specifically [84]. Consequentially, 
this abundance of FAD mutations is reflected by an early onset of plaque deposition, 
astrocytosis and microgliosis, age-dependent synaptic degeneration, working memory 
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impairments in Y-maze (~5 months) and neuronal loss at ~9 months [84]. In addition, 
certain presynaptic terminals and fine axonal processes undergo a process of swelling 
followed by dystrophy and are associated with the emergence and deposition of 
extracellular Aβ [103]. Similar to the 2xTg and the 3xTg, these mice preferentially 
produce toxic Aβ42 and form plaques aggressively. Unlike the 3xTg (but similarly to the 
2xTg) the 5XFAD model does not demonstrate Tau pathology. However, the 5XFAD 
mice do demonstrate neuronal cell death, which is unlike the 2xTg and 3xTg and many 
other AD mouse models. The 5XFAD mice therefore recapitulate many major features of 
Alzheimer's disease amyloid pathology and may be a useful model of intraneuronal 
Abeta-42 induced neurodegeneration, amyloid plaque formation, synaptic disruption and 
loss, and resultant cognitive impairments. This mouse model was selected despite having 
very aggressive genetically-driven brain changes that are accelerated compared to the 
typical human presentation. However, it is among the very few models that display 
neuronal loss with increased Cathepsin D activity, and can be rapidly examined for AD-
like pathology. 
1.2.4 Evaluation and Diagnosis of Alzheimer’s disease 
Alzheimer’s disease is a clinical diagnosis.  However, conclusive diagnosis of AD 
can only be achieved by the gold standard examination of postmortem tissue for the 
hallmark pathologies described above: amyloid plaques and NFTs [106]. However, as 
much as 20-40% of non-demented individuals have enough plaques and tangles to 
warrant a neuropathological AD diagnosis [107]. A non-invasive diagnosis of probable 
AD is possible by taking into consideration different individual/familial history and 
cognitive tests accompanied by limited imaging (see next section). Less than ~30% of 
patients with probable AD diagnosed have pure (not mixed) AD pathology [108]. 
However the aforementioned studies concentrated on patients with advanced age and 
disease and the findings of mix dementia could be incidental. 
With the advent of biomarkers, a modification to the criteria and guidelines for 
standardized diagnosis of AD has recently been proposed. The modified guidelines bared 
two notable changes: 1. There should be a distinction between three stages of AD: 
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preclinical AD, MCI due to AD, and dementia due to AD. 2. There should be an 
incorporated biomarker test agreed upon that provides measurements of certain biological 
factors that can be used to indicate the presence of disease [5]. However, the most 
effective test or combination of tests may differ depending on the stage of the disease and 
the type of dementia [109].  
1.2.4.1 Clinic 
Currently, a diagnosis of AD in the clinic is made by an individual’s primary care 
physician who obtains a medical, family and psychiatric history as well as a history of 
cognitive and behavioral changes [5]. While the patient’s medical history obtained 
directly from the patient and corroborated by a seperate informant is a basic practice in 
the diagnosis, the neurological and physical examinations serve as important parts of the 
differential diagnosis of dementia detecting memory impairments in early stages of the 
disease [110]. One such test is the Mini Mental State Exam, or MMSE [111]. Blood tests 
are necessary to identify secondary causes of dementia and coexisting disorders [112] 
that are common in elderly people (e.g. thyroid-function and serum vitamin B12).  
Unfortunately, the diagnostic accuracy is still relatively low, with a sensitivity and 
specificity of around 80% and 70% respectively [112]. To improve the diagnostic 
accuracy, the physician may request the patient to undergo Magnetic Resonance Imaging 
(MRI) to test for any obvious brain changes (e.g. tumour or stroke) [5]. More recently, 
the application of other imaging tools targeting AD pathology have been FDA approved 
and are slowly becoming more common in the clinic to assist in the discrimination of 
different types of dementia [5]. These consist of different diagnostic techniques that are 
in use, including but not limited to Magnetic Resonance Imaging (MRI), positron 
emission tomography (PET) and Cerebral Spinal Fluid (CSF) biomarkers.  
MRI has mainly been used to exclude alternative causes of dementia such as 
stroke, brain tumors, normal pressure hydrocephalus, and subdural hematoma [110]. 
However, additional research in the field holds promise to place MRI as a diagnostic tool 
for MCI/AD by measuring atrophy or other volumetric changes in the temporal lobe, 
entorhinal cortex, ventricles and hippocampus [113]. Blood flow and metabolism using 
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arterial spin-labeling perfusion magnetic resonance imaging [114] and functional 
magnetic resonance imaging [115] have also provided valuable information. 
PET offers the highest sensitivity for the detection of targeted molecular imaging 
contrast agents (further details provide in Chapter 1.3). In addition to glucose utilization, 
PET studies have focused on the hallmark pathologies namely Aβ plaques and NFT as 
well as others such as the neurotransmitter systems and inflammatory cells involvement 
[116, 117]. FDG is a glucose analogue [117]. FDG PET detects the amount of 18F FDG-
6P accumulated in the brain cells where the amount of radioactivity is used to provide an 
estimate of the brain’s glucose-consumption rate which indicates the level of synaptic 
activity [118]. Specific brain regions displaying reduced signal, interpreted as 
hypometabolism (reduced metabolism), identified by FDG in PET could be used to 
differentiate AD patients from cognitively normal elderly people with high sensitivity 
and with a good specificity to other dementias [119]. Aβ Plaques imaging was first made 
possible by the use of the 11C-labelled Pittsburgh compound B (PiB) and three new Aβ 
plaque-targeting CA have recently been FDA approved with the purpose of confirming 
Aβ pathology. Caution must be taken using brain amyloid (and associated imaging 
thereof) as a biomarker of AD because of the large number of clinically normal healthy 
older adults presenting Aβ positive imaging test results. This argument applies equally to 
CAs that targets the NFT (discussed next) as NFT are predominantly believed to be 
downstream from amyloid pathology, and in fact, CAs can have reduced specificity to 
AD due to non-AD tauopathies such as frontotemporal lobe dementia. 
Only very recently, there have been several tauopathy-targeting CAs developed. 
Some promising results have already been reported [120]. However, some challenges to 
tauopathy imaging include the much lower levels of Tau aggregates in the brain, relative 
to β-amyloid and the multiple structural conformations and differential distribution 
within neuronal subpopulations [120]. Because increasing Tau deposition with age is a 
normal part of aging, this increase must be addressed and standardized to provide a 
reliable threshold value of the normal deposition in order to avoid false positive detection 
[120]. Finally, while Tau pathology burden correlates very well with synaptic disruption 
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and cognitive decline, it may still not be an early diagnostic tool as Tau is downstream 
from Aβ synthesis. 
1.2.4.1.1.1 Other Imaging Targets 
Other important targeting features of AD include the main neurotransmitter systems 
and neuroinflammation. Both fields have gained smaller popularity, in part, because of 
limited findings. The cholinergic, dopaminergic and serotonergic systems are all impaired 
in AD [117]. PET imaging showed in-vivo clinical imaging of the neurotransmitter 
system altered function can be detected in AD by targeting features of the cholinergic 
system [121, 122], dopaminergic system [123, 124] and serotonergic system [125]. In 
addition, inflammatory features of AD have been argued to be both part cause and part an 
effect of AD pathology [116]. Thus, targeting activated inflammatory cells may help shed 
light on the disease progression (e.g. response to therapy). While preliminary work was 
able to detect differences between severe AD and normal controls by detecting different 
levels of inflammatory cells [126], other research has found no significant differences in 
mild AD and MCI or normal controls [127]. 
1.2.4.1.2 Cerebral Spinal Fluid Biomarkers 
Cerebral spinal fluid (CSF) biomarkers such as reduced Aβ42, increased total Tau  
(T-Tau) and phosphorylated tau (P-Tau) have been investigated as diagnostic biomarkers 
for AD [128]. Generally, CSF T-Tau has been shown to increase to approximately 300% 
and CSF-Aβ42 reduced to 50% of the control concentration in AD. These changes lead to 
an increase in specificity to above 80% for differentiating AD from other dementias 
[112]. 
1.2.4.2 Pre-clinical Studies of AD 
There are countless studies published on AD as a result of the many AD animal 
models (mostly mice) [129]. There are many benefits to the use of pre-clinical AD 
models. Broadly, the animals provide a uniform system that develops disease rapidly and 
reliably in a well characterized time frame. In addition, mice present a model that allows 
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the use of more invasive or dangerous procedures. Additionally, AD animal models can 
help in the discovery of new biomarkers that can be translated to human patients in the 
clinic.  Crucial information can be gathered, in parallel, using longitudinal in vivo 
neuroimaging of hypothetical and established biomarkers to better understand the disease 
progression allowing multiple tests elucidating the connection between imaging, 
pathophysiology, cognitive capacity and behavior. Finally, the preclinical biomarkers can 
be used to test the safety, performance, pharmacokinetics and pharmacodynamics of new 
drugs as well as studying the disease progression following drug administration. 
1.2.5 Treatment of Alzheimer’s disease 
Treatment regiments can be divided into pharmacologic and nonpharmacologic. 
The former are treatments in which the drugs are designed to slow or stop the disease or 
alleviate its symptoms. None of the treatments available today for AD slow or stop the 
malfunction and death of neurons in the brain that cause AD symptoms [5]. There have 
been at least five FDA approved drugs that temporarily improve symptoms of AD by 
increasing the amount of chemicals called neurotransmitters in the brain.  Studies 
consistently indicate that active management of AD can improve the quality of life [130]. 
The management includes the application of drugs, coordination of care, participation in 
activities and/or adults day care programs, being in support groups and utilizing support 
services. Nonpharmacologic therapies include physical therapy, cognitive training and/or 
stimulation as well as training in daily activities. These may alter the rate of disease 
progression. The most successful nonpharmacologic interventions were found to be 
multicomponent; tailored to the needs of each patient [131]. There are many drugs in 
clinical trials, and a plethora in pre-clinical development, all of which are aimed at 
treating the symptoms, the underlying disease, or both. None of the drugs developed to 
date have been successful at curing or stopping the disease progression, reverse clinical 
signs, or consistently improve quality of life long-term.  
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1.2.6 Importance of Early Detection of Alzheimer’s Disease 
Clinical trials of treatments have been disappointing with cholinergic function 
targeting drugs being the most consistent at alleviating symptoms temporarily, however, 
showing only modest clinical effect in late-phase trials [132]. It is possible that the lack 
of success is due to the progressive state of the disease by the time diagnosis is made, and 
therefore, the time delay from onset of disease to attempted therapy trials. In a study of 
anti-inflammatory drugs (NSAIDs) it was noted that drugs might be protective only if 
given during mid-life but will not reverse the degenerative process in patients with 
established pathology and therefore an on-going clinical trial of NSAIDs has been started 
to test whether they can be protective in patients with MCI [133]. Furthermore, in a failed 
study of Aβ immunotherapy it was estimated that antibodies targeting Aβ in the brain 
may provide the greatest efficacy when given before the development of clinical AD 
symptoms, i.e. during a period before substantial cognitive loss [134]. It is therefore 
imperative that an earlier method of detecting the disease in patients is found. Such a 
method would allow researchers to have access to a whole new cohort of patients that 
could be better suited to evaluate new and previously tested potential treatments. Drugs 
that had no beneficial effect in AD patients at late-stage could be re-tested in those with 
early-stage disease, only if there was a reliable diagnostic test to detect patients at the 
early stages of the disease.  
1.3 Molecular Imaging 
The in-vivo characterization and measurement of biologic processes at the cellular 
and molecular levels has been defined as the quintessential molecular imaging purpose 
[135]. Despite being a relatively new multidisciplinary field, being utilized more 
increasingly in the past 15-20 years, it aims to provide unequivocal pertinent disease-
related information [136] that can be used for the diagnosis or to direct the treatment of 
underlying pathologies. To do this successfully four key features are required [135, 136]: 
1. Identifying a disease-specific molecular target. 2. Identifying an affinity ligand (e.g a 
peptide, antibody) for the molecular target. 3. Choosing an appropriate imaging modality 
that provides adequate spatial resolution, sensitivity, and depth penetration. 4. 
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Successfully synthesizing a non-toxic, stable CA that can detect the molecular target 
using the chosen modality.  
Molecular imaging utilizes an arsenal of innovative methods that span the fields 
of engineering, physics, chemistry, biochemistry, molecular biology and others.  These 
methods have allowed non-invasive pre-clinical and clinical investigations of a variety of 
pathologies [135-137]. A general approach (adapted from James ML et al. [138]) for a 
successful molecular imaging investigation targeting any pathology is described next. 
The first step (Step 1) requires the identification of the pathology of interest and the 
associated biochemical processes involved. Next, a potential molecular target implicated 
in the latter is chosen and a targeting moiety could either be investigated or decided upon 
from literature (2). An imaging modality is then carefully selected (3). More than one 
modality can be utilized with the benefit of having multiple methods of visualization and 
localization of the targeting agent without the need of modification. Thus, an agent could 
be designed to have both optical, and MRI properties. Now, the synthesis of the probe 
may begin (4). Next, a series of in-vitro tests should be utilized to check for the probe 
specificity to its target, stability and safety when cultured with cells (5). At this point, any 
optimization necessary could be performed going back a step and repeating the process 
until successful preliminary data are obtained. Often, in-vitro results are not sufficient as 
these may not recapitulate in-vivo conditions and molecular outcomes (e.g. [139]). 
Sometimes, ex-vivo studies (6) will follow for assays that are too invasive (e.g. histology) 
or not practical for in-vivo studies (e.g. extremely long scans providing high imaging 
resolution [140]) but are necessary as a proof of principle prior to in-vivo attempts (e.g. 
due to associated costs). If the results are promising, addressing the in-vivo performance 
of the agent becomes of prime concern, and it is generally tested in small animals (e.g. 
mice) to test again for safety, and specificity to the target (7). Important information 
regarding the probe elimination and metabolism could be sought during these pre-clinical 
studies to better predict the pharmacokinetics and pharmacodynamics of the probes in 
humans. Finally, after successful pre-clinical performance the probe could be considered 
to move forward for clinical trials (8). 
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 There are several imaging modalities that are commonly used for molecular 
imaging.  Each has strengths and weaknesses (illustrated in Figure 1-4; strength in black, 
weakness in white) with respect to their utilization for imaging anatomical, physiological, 
or molecular processes details [137]. CT, US and MRI are commonly utilized for 
anatomic imaging purposes, even though all have the capacity to be used to varying 
degrees, for physiologic assessments. MRI has a stronger capability for molecular 
imaging assessments compared to CT and US. Where PET and optical imaging provide 
relatively less anatomic information, they can provide very sensitive molecular and, to a 
lesser degree, physiologic imaging information. 
 
Figure 1-4. Different imaging modalities comparison. Adapted from Hoffman et al. 
[137]. Strength of a modality is congruent with darker loci.  
1.3.1 Blood Brain Barrier Delivery  
The brain is a very delicate organ and therefore its estimated surface area of 12 m2 
of capillaries is safely guarded from many toxic substances by the blood brain barrier 
(BBB). The impermeability of the BBB is due to the tight junctions connecting adjacent 
endothelial cells composing the vasculature system and highly regulated transport 
systems which only permit transport of select molecules [141]. The BBB is practically 
inaccessible for lipid-insoluble compounds such as polar molecules and small ions. 
However, small hydrophilic molecules essential for the survival of brain cells, such as 
amino acids, glucose, and other molecules employ specialized transporters to allow their 
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transport across the BBB. Larger essential molecules such as hormones, transferrin for 
iron, insulin, and lipoproteins utilize specific receptors to transport across the BBB. In 
contrast, small lipophilic molecules can diffuse passively across the BBB into the brain, 
but they are exposed to efflux pumps.  
Different strategies to deliver therapeutics and imaging agents have been 
described previously [142]. Drug delivery approaches to the brain must be safe as well as 
effective and many are being intensively explored for either diagnostic or therapeutic 
purposes [141]. For example, in a novel approach using the ligand angiopep-2, it was 
demonstrated high BBB crossing capability and parenchymal accumulation may be 
mediated by the low-density lipoprotein receptor-related protein-1 [143]. On the other 
hand, lipid nanoparticles (NPs), having potentially lower cytotoxicity and higher drug 
loading capacity [144], and have been employed for targeting brain tumors [145]. In 
another example, recent advances in bispecific-antibody design (two different antibodies 
for two different targets conjugated together) show promising results. For example, 
targeting transferrin first to cross the BBB was used to deliver a β-secretase antibody into 
the brain to shift processing of APP in a Tg AD mouse model away from toxic Aβ [146]. 
Delivering diagnostic, therapeutic, or theranostic compounds across the BBB 
remains the rate-limiting step in brain-targeted diagnostic/therapeutic compound 
development. Several tools have been developed to permeate the BBB where the two 
most common approaches are described next. Mannitol (a type of sugar) is responsible 
for producing a transient hyperosmotic disruption of the BBB to facilitate its increased 
permeability. However, mannitol may preferentially permeate healthy BBB, thereby 
potentially increasing neurotoxicity and introducing bias in drug or diagnostic CA 
delivery [147].  Focused ultrasound (an oscillating sound pressure wave) for the transport 
of drugs across the BBB, is achieved by disruption of cell membranes. This procedure is 
considered safe for human use though some evidence does also suggest that damage may 
occur but is limited to minor hemorrhage [148] as well as notable but limited neuronal 
apoptosis [149]. In contrast, another approach supports a process that conjugates the 
cargo of interest (drug or diagnostic property) to a chaperon/ligand in order to deliver the 
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cargo across the BBB to its target.  The following sections describe a special family of 
BBB penetrating molecules to allow drug/CA delivery across the BBB. 
1.3.1.1 Cell Penetrating Peptides 
Cell Penetrating Peptides (CPP) may be able to successfully deliver a large cargo 
(drug or imaging probe) across the intact BBB and into cells [150-152]. CPPs are 
classified into three classes: protein derived CPPs (e.g. Penetratin, Tat), model peptides 
(e.g. MAP) and designed CPPs (e.g. Transportan). Very generally, CPPs are short 
peptides of less than 30 amino acids that are able to translocate different cargos across the 
BBB by mechanisms that require no energy and may or may not be receptor mediated 
[153]. The mechanisms of internalization of CPPs have not yet been resolved. The only 
two features in common for all CPPs are positive charge at physiological pH, and 
amphipathicity (having both polar and non-polar portions; with polyarginines as 
exceptions to this rule) [153]. While the role of endocytosis isn’t negligible for some CPP 
and may in fact be their exclusive form of internalization [154], efficient translocation 
was observed at low temperatures (0-4°C) with many different inhibitors of endocytosis 
[155].  
The rate of internalization of CPP is a relatively fast process (at 37°C). The 
maximal concentration of internalized peptide is achieved after less than 1 hour of 
incubation with cells. Small cargos do not affect the rate of internalization, while larger 
hydrophilic cargoes such as proteins get internalized more slowly [153]. Following 
internalization into cells, some CPP may undergo degradation. This was demonstrated, 
for example, for Transportan in vitro [156] where it is likely the disulphide bridge that is 
used to couple the CPP to cargo which dissociates quickly in the cell [153]. With respect 
to toxicity, most CPP are not considered very toxic [153]. However, MAP has been 
associated with adopting an α-helical structure causing pore formation in the cell 
membrane [157] exerting toxic effects at concentrations over 1 μM in vitro [158]. In 
contrast, Transportan showed less toxicity starting at 5 μM, Penetratin showed even 
lower toxicity and Tat appeared to cause practically no harm to the cell membranes [153]. 
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The Tat peptide (YGRKKRRQRRR) of the HIV-1 virus, which allows transport both 
into and out of the brain [150], is of particular interest. It is believed that hydrophilic 
arginine-rich CPPs such as HIV-1 Tat may be transported across membranes by direct 
penetration at high concentrations and by endocytosis at lower concentrations, with 
heparin sulfate as the binding site candidate [159-162]. In addition, Tat shows no toxicity 
at concentrations as high as 20 μM (highest tested) and produces no cell membrane 
leakage [163]. Furthermore, Tat displays a relatively long half-live in human serum (8.8 
hours compared to 1.2 for Penetratin) considering the number of available enzymes in 
serum able to digest the peptides [164]. 
In vivo utilization of some of the CPPs mentioned has shown promise for 
transporting molecules to their targets within the CNS across the BBB, particularly Tat 
and Penetratin peptides. For example, Penetratin was successfully detected in rat brain 
and spinal cord cells after intravenous administration [165]; D-JNKI1 peptide 
(conjugated to HIV transporter sequence) was shown to be a potent neuroprotectant 
against both transient and permanent ischemia [166]; PSD-95-TAT-NR2B9c (conjugated 
to Tat) attenuated brain injury in epilepsy as well as chronic pain inflammation [167]; 
TAT-NBD (conjugated to Tat) peptide prevented p53 upregulation and as a result 
reduced (>80%) brain damage in a model of neonatal cerebral hypoxia-ischemia [168]; 
and finally, TAT-Bcl-xL (conjugated to Tat) peptide protected neurons from death in a 
Parkinson’s disease model [169]. All together, these provide some evidence that CPPs 
could be used in models of neurodegenerative diseases for diagnostics and therapeutics. 
1.4 Fluorescence and Bright Field Imaging 
One of the most informative and oldest medical diagnostic and basic research 
tools utilizes light. The term light usually refers to a “packet” of photons of a specific 
energy range. It’s a portion of the electromagnetic wave spectrum that consists of wave 
lengths ranging from ~300 (ultraviolet) to about 800 (far red) nm with corresponding 
range of frequencies described by the following relationship: 
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     ( 1-1 ) 
Where c is the speed of light in vacuum, ν is the frequency of the wave (1/seconds) and λ 
(meters) is the wavelength. The energy (E) of each photon is given by (in Joules): 
     ( 1-2 ) 
Where h is known as Planck’s constant (Joule seconds) and ν is the frequency 
(1/seconds). Considering the wave-particle duality, the relationship between the 
wavelength of a wave and its energy is often written as: 
        ( 1-3 ) 
Photons traveling into, within and out of tissue experience absorption (the process by 
which energy of light is transferred to a medium), attenuation (the progressive loss of 
intensity through a particular medium), scatter (the diversion of particles from their 
original trajectory) and transmission (the process by which particles pass through a 
medium without being scattered or absorbed). 
Since the construction of the first microscope in 1674 by Anton van Leeuwenhoek 
the field of microscopy has expanded to include bright field, confocal, dark field and 
differential interference contrast [170]. Furthermore, the introduction of fluorescence 
microscopy has revolutionized the field of cellular biology by facilitating the 
visualization of cellular and molecular processes in living cells in real time [170, 171].  
The process of fluorescence can be described as a three-stage process that occurs in 
certain molecules (generally polyaromatic hydrocarbons or heterocycles). The process is 
demonstrated in Figure 1-5 illustrating the simple electronic-state Jablonski diagram. 
First, (1; Fig. 1-5), a photon of energy      originating from an external source (e.g. 
laser, incandescent lamp) becomes absorbed by a molecule, altering the state of an 
electron which was originally in state (S0) and now enters an excited electronic singlet 
state (S1’)[172, 173]. Next, (2; Fig. 1-5), while the excited electron state is short lived (1-
10 nanoseconds), several interactions (e.g. low frequency vibrational relaxation or 
solvent reorganization) between the molecule and its environment can occur, leading to 
some energy loss which puts the electron in a lower energy singlet excited state (S1). 
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Finally, (3; Fig. 1-5) a photon of energy      is emitted when the excited electron 
returns to its ground state S0. Due to the energy loss during the excited-state lifetime, the 
energy of the emitted photon is lower and therefore has a longer wavelength than the 
excitation photon. The energy (and wavelength) difference between the excited versus 
emitted photon is referred to as the stoke shift [173]. 
 
Figure 1-5. Jablonski diagram. Illustrating the processes involved in the creation of an 
excited electronic singlet state by optical absorption and subsequent emission of 
fluorescence. Adapted from  [172] 
For polyatomic molecules in solution, the discrete electronic transitions are 
replaced by broad energy spectra called the fluorescence excitation spectrum and 
fluorescence emission spectrum. For each fluorophore (a molecule producing 
fluorescence), the excitation spectrum is achieved by measuring the emission intensity at 
one wavelength while changing the excitation wavelength, while the emission spectrum 
is achieved by measuring the emission intensity at different wavelengths for a single 
excitation wavelength. The fluorescence emission spectrum is independent of the 
excitation wavelength due to the partial dissipation of excitation energy during the 
excited-state lifetime (Fig. 1-5 above) and the emission intensity is proportional to the 
amplitude of the fluorescence excitation spectrum at the excitation wavelength [173]. For 
example, if at excitation wavelength ‘A’, within the excitation spectrum, the intensity 
was double of that at another excitation wavelength ‘B’, the emission intensity following 
an excitation with wavelength ‘A’ would be double that of the resulting emission 
intensity following an excitation with wavelength ‘B’.  
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A loss of fluorescence can occur due to the short-range interactions between the 
fluorophore and a specific local molecular environment. This loss of energy could also be 
the result of other fluorophores (self-quenching) [174] or the use of specific quenching 
molecules [175]. While the possibility of self-quenching or un-predicted environmental 
reduction in fluorescence presents some challenges to the design of CAs in general; it can 
be utilized beneficially for the functionalization of a CA for the purpose of making them 
“activatable” following separation of the quencher and fluorophore by a cellular process 
(e.g. enzymatic activity) of interest [176]. Furthermore, absorption of light by 
hemoglobin and other molecules (such as water) may reduce fluorescent signals by a 
factor of ~10 per centimeter of tissue [138]. This absorption of light by hemoglobin is in 
part why organs such as the liver and spleen with high vascular content and more 
importantly blood pooling capacity have the lowest transmission. Skin and muscle on the 
other hand, have a higher transmission of light. 
Background fluorescence may originate from endogenous sample constituents 
(referred to as autofluorescence) or from unbound or nonspecifically bound probes. When 
utilizing fluorophores in vivo, replacing animals’ food temporarily with an alfalfa-free 
diet reduces the amount of tissue autofluorescence substantially especially, from the 
gastro-intestinal region [177].  By selecting probes that absorb and emit photons at longer 
wavelengths (>500 nm), specifically in the near infrared (NIR), not only is there less light 
scattering by dense media such as tissue but the absorbance by hemoglobin and water is 
lowest [177]. Altogether choosing to image in the NIR results in greater penetration of 
the excitation light and better signal detection [178]. 
A number of macroscopic optical imaging modalities have emerged, enabling 
noninvasive, repetitive, whole body imaging of living small animals. Two examples of 
such macroscopic optical techniques are fluorescence optical imaging and 
bioluminescence imaging [138]. The former is discussed next in further detail. 
1.4.1 In-vivo Fluorescence Optical Imaging 
In order to detect the location of fluorophores (attached to cargo or targeted 
against molecules of interest), there are a few essential elements that are required and 
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should be optimized separately and in combination: an excitation light source; a 
fluorophore; wavelength filters to isolate emission photons from excitation photons; and, 
finally a detector (e.g. a charge-coupled device camera) that registers emission photons 
and produces a recordable output. This infrastructure for optical fluorescence is relatively 
inexpensive and easy to setup resulting in imaging sensitivities as low as picomolar to 
femtomolar concentrations. Because optical imaging involves the detection of low-energy 
photons, unlike higher-energy radiation (e.g. PET), it is considered very safe. However, 
lower energy also means that the depth of penetration is limited to only a few centimeters 
of tissue with NIR [178] which cannot be overcome by using higher intensity as this 
energy deposition would result in overheating the tissue/sample [179]. Considering the 
size of small animals used for research (e.g. rats, mice) optical imaging employing 
fluorophores in the NIR range enables visualization of internal organs making the 
modality very practical and more affordable compared to other imaging such as MRI, 
CT, PET. Generally, for in-vivo optical imaging, the following steps are required and 
parallel the list described previously for molecular imaging (See section 1.3) [138]. First, 
the selection of a fluorescent entity with suitable optical and chemical properties is 
required (e.g. emission and excitation spectra, toxicity). Next the conjugation of the 
chosen fluorescence entity to a targeting moiety (peptide/aptamer/antibody/nanoparticle) 
is performed. The targeting moiety is a priori chosen or designed to specifically target the 
protein or molecular pathway of interest. Finally, the selection of an appropriate animal 
model is required to test the CA, using an appropriate optical imaging device.  
In conventional optical imaging the whole animal is illuminated with a broad 
beam of light tuned to the excitation wavelength of the fluorophore. Emitted fluorescent 
light is detected by a highly sensitive and low noise charged-coupled device (CCD) using 
an appropriate emission filter. Despite its popularity, this approach has inherent 
limitations with respect to the fluorescent probe localization, quantification and depth of 
detection. One main limitation is the inability to decouple the separate effects that 
fluorophore depth and concentration have on the detected signal [180]. The newer 
generations of optical imaging devices have multiple designs. Detailed description of 
their differences and relative performance is described elsewhere [180-183]. Three main 
classes of tomographic-capable optical imaging devices can be either continuous wave 
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(CW), time domain (TD) or frequency domain (FD) but are not discussed further, as they 
are not utilized for the purpose of the remaining integral chapters [184]. 
1.4.1.1 GE/ART eXplore Optix Pre-clinical Scanner 
The following information was made available from the supplier [185]. However, 
the GE/ART eXplore Optix made by Advanced Research Technologies Inc. and 
distributed by GE is no longer available. The eXplore Optix device was designed to 
measure, quantify and visualize fluorescence intensity and lifetime for multiple molecular 
imaging applications in small laboratory animals. Research using this system is varied, 
from imaging brain amyloid accumulation in mice [186], liver repopulation following 
hepatocyte transplantation [187] and pharmacokinetics in a human monoclonal single 
chain fragment antibody for cancer targeting [188]. To scan animals, the illumination 
source and detector point(s) of the acquisition system of the eXplore Optix device are 
scanned over the region of interest using galvanometer mirrors (see Figure. 1-6). The 
pulsed laser source wavelength can be customized to the desired fluorescence excitation 
wavelength, while the detector is sensitive to the spectral band of 450 - 900 nm.  In 
addition to top and side digital cameras (to capture visible images of the animal) a 
profilometer camera is incorporated into the system to obtain the shape of the animal. 
Figure 1-6 is a schematic of the acquisition system. The eXplore Optix system comes 
with an illumination system consisting of an 80 MHZ pulsed laser diode and pulse width 
(FWHM) under 100 ps. The excitation wavelength ranges from 900 to 1600 nm with an 
illumination diameter of 1 mm on imaging plane. The detection system comes with a 
time correlated single photon counting system that includes a detector photomultiplier 
tube (PMT) providing a temporal resolution of 250 ps, a depth sensitivity of over 10 mm 
at 700 nm and detection wavelengths ranging from 450 to 900 nm. The detection spot is 1 
mm in diameter anywhere within the scanning area of 20 x 8.5 cm. The spatial resolution 
ranges from 0.5 to 3 mm and is defined by the user. The animal plate is removable, 
adjustable (height) and can be heated to any temperature in the range of 26 to 42°C. 
Raster scanning with longitudinal linear translation of the animal plate is used to obtain 
spatial information.  
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Figure 1-6. eXplore Optix system schematic. The animal is positioned on the animal 
table and a region of interest is selected using a top and side live camera. The animal is 
then translated into the imaging section of the system where the optics are housed. The 
entire system is light tight. TCSPC = time correlated single photon counting; PMT = 
photon multiplier tube 
1.4.2 TissueScope 
A fully- integrated high throughput system for brightfield, fluorescence and 
confocal imaging has been developed to allow large fields of view imaging at high 
resolution without the requirement for “tiling” of individual smaller field of view images. 
This system is called the TISSUEscope (Huron Technologies Inc. previously Biomedical 
Photometrics, Waterloo, ON) [189, 190].  Using the panoramic, patented, and widefield 
MACROscope technology, the TISSUEscope can produce high-resolution images of an 
entire tissue specimen in a single scan.  This system will allow images of slide-based 
tissue specimens common to pathology, cytology, hematology and related laboratory 
medicine fields to be scanned in a timely manner. Specifications of the scanner are up to 
40x magnification for the brightfield and confocal fluorescence imaging. Scanning can 
accomodate multiple slides or several sizes (maximum 6”x8”) and provide an optical 
resolution of 0.60NA (0.25 μm/pixels at 40x). 
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1.5 Positron Emission Tomography 
Tomography (Greek - tomós a slice, a section; graphos drawn) is a type of 
imaging that can acquire multiple two dimensional slices (images) of a three dimensional 
object. One of the main tomographic radionuclide-based molecular imaging techniques 
(see also 1.2) that enable evaluation of biochemical changes and levels of molecular 
targets within a living subject is positron emission tomography (PET). PET scanners 
detect γ rays (high energy packet of electromagnetic photons) indirectly resulting from 
the decay of specific radioisotopes. It is has a limitless depth of penetration which 
enables whole body imaging of molecular targets/processes with very high sensitivity 
[136]. This chapter briefly describes several aspects of PET image acquisition as may be 
required to understand the contents of this thesis. The explanations include aspects of 
physics, detection system, signal corrections as well as the algorithms used to reconstruct 
PET data. 
1.5.1 Physics 
Three main physical aspects are involved in PET imaging and will be explained in 
this section in more detail. One is the generation of short-lived radioisotopes used for 
PET imaging [191]. Second, the β+ decay of the radioisotopes which indirectly results in 
the production of δ rays. Lastly, different interactions are possible by the emitted δ rays 
with matter that are then detected for the formation of a PET image. The reader is 
referred to a thorough and easy to follow review by Cherry et al. [192]. 
1.5.1.1 Radioisotopes for PET 
The most common PET radioisotope tracers are produced in a cyclotron which 
necessitates clinics and research centers interested in using a PET scanner to be in close 
proximity to facilities able to transport the radioisotopes within a short period of time. 
The close proximity of a cyclotron to a clinic or research center allows synthesis and 
preparation to take place while retaining adequate activity for detection following 
administration to the patient/subject. In short, proton or deuteron beams irradiate targets 
filled with the raw material for radionuclide production (e.g. 18O enriched water for the 
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production of 18F) [193]. In cyclotrons, charged particles follow a spiral trajectory due to 
a constant perpendicular (to their movement) magnetic field as they are accelerated using 
an electric field (perpendicular to both their movement and magnetic field). Once the 
accelerated charged particles reach a selective exit “hole” they hit the designated target 
with a known energy and can produce a variety of predicted and desired unstable 
radioisotopes. In contrast, there are other radioisotopes like 82Rb and 68Ga which are 
obtained from long-life mother radioisotopes generators. These produce the desired 
isotopes as a result of their own slow decay process and in turn are separated from the 
mother nuclei by a chemical process.  
  Choosing the appropriate radionuclide depends on the experimental requirements 
(e.g. duration of scan), the isotope availability (e.g. cyclotron nearby) and its physical and 
chemical characteristics (e.g. radioactive half-life and metal/non-metal designation) 
[194]. Table 1.2 lists some frequently used positron emitting radioisotopes and their 
characteristics. It should be noted that an increase in positron energy, results in an 
increase in the positron range in water, and therefore a decrease in the optimum PET 
image resolution possible. 
Table 1-2. Radioisotopes for PET imaging and characteristics.  
Adapted from Cherry et al and Bailey et al. [192, 195]: 
Radioisotopes Half-life (min) Source 
Max. Range in 
water (mm)* 
Max. Emission 
energy (MeV) 
15O 2.04 Cyclotron 7.3 1.738 
11C 20.4 Cyclotron 4.1 0.959 
68Ga 68.3 Generator 8.9 1.899 
18F 109.8 Cyclotron 2.4 0.633 
* In reality, the range traveled by positrons is much shorter (explained below) 
1.5.1.2 Beta decay 
Nuclei that undergo either β+ or β- decay (weak interaction mediated) have an 
excess of protons or neutrons respectively making them unstable. This instability is 
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rectified by transforming a proton into a neutron ( ), a positron (  ; antimatter 
counterpart of electrons) also referred to as a beta particle – hence the name, and a 
neutrino (  ; electrically neutral, weakly interacting elementary subatomic particle) 
[196]:  
𝑷  𝒏  𝒆   𝒆 ( 1-4 ) 
This process only occurs with protons in nuclei (not free) when it is energetically 
possible, resulting in a daughter nucleus having an atomic number decreased by one unit 
[196] (e.g   
   transforms to   
   with the latter being a stable isotope of oxygen). Other 
processes (e.g. β- decay and electron capture) are mediated by the weak interaction force 
as well, but do not contribute to the PET signal, and therefore, no further explanation is 
provided. 
The short-lived positron is ejected from the nucleus being repelled by the positive 
nuclei with varying degree of energy (having a continuous energy spectrum because the 
available energy in the decay is shared in a variable fashion between the β particle and 
the neutrino) [196]. Due to the inelastic interactions with electrons in surrounding tissue, 
the positron follow a tortuous path in tissue, rapidly losing kinetic energy causing it to 
slow down and collide with an electron; an event known as annihilation [192]. This 
process annihilates both the positron and electron (hence the name) but releases two 
photons. Each photon has an energy of 511 keV (due to the conservation laws of energy 
and momentum, the combined mass of the positron and electron is converted into two 
photons with equal energy) traveling at roughly opposite directions (~180° apart) to one 
another. Any residual kinetic energy prior to annihilation is converted to angular 
momentum, and therefore, the exact photons direction is not exactly 180°; a deviation 
from colinearity, which impacts resolution [197]. 
The distance from the emission point to the annihilation point is one of the main 
limiting factors to the spatial resolution of PET [192] and is known as the positron range 
(See figure 1-7).  
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Figure 1-7. Positron annihilation schematic. From emission, the positron (β+) travels 
an erratic path (green line) until it combines with an electron to form two high energy 
photons traveling in opposite directions (red lines). The blurring effect (blue line) is 
smaller than the positron range (pink line), which in turn is smaller than the complete 
positron path (green line) completed prior to annihilation. 
The latter follows a non-Gaussian distribution as previously described [192, 198] 
because positrons are emitted with a range of energy and follow an indirect path. A 
higher energy positron will be more likely to exhibit a longer traveled distance to 
annihilation, and an environment having a higher electron density will result in a shorter 
range. The perpendicular distance between the site of positron emission and line of 
response (LOR) of annihilation products (photons directions) is the positron range 
blurring (directly affecting image resolution).  
1.5.1.3 Gamma (γ) radiation interaction with matter 
When the gamma rays (photons), produced in positron-electron annihilation, pass 
through matter (e.g. tissue, bone) with intensity I0, some photons will be attenuated 
(removed out of the incident beam) by absorption after traveling distance x. The type of 
interaction between photons and matter depends on the atomic number Z and the energy 
E. However, only two types of interactions are relevant for PET imaging due to the 
energy produced (511 keV). Namely, the  photoelectric absorption, and the Compton 
effects [192]. Collectively, the total absorption coefficient results from these two 
absorption coefficients, as well as pair production. However, the latter is not considered 
here due to negligible contribution to PET and the total absorption coefficient is 
calculated as: 
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       ( 1-5 ) 
Where the photoelectric absorption (τ), and the Compton effects (σ) are added linearly to 
give the total absorption coefficient (μ). And therefore the attenuated remaining intensity 
can be described by: 
𝑰  𝑰𝟎𝒆
  𝒙 ( 1-6 ) 
Where the attenuated intensity of the beam (I) is calculated by an exponential decay 
process dependent on the incident intensity (I0), the thickness (x) of medium propagated 
through. In short, during photoelectric absorption, the incident gamma ray is absorbed by 
an atom resulting in an ejection of an electron from the electron shell of this atom. The 
resulting hole in the electron shell is then filled by other remaining electrons or any free 
electrons from the surrounding medium. When a gamma ray interacts with a shell 
electron by the Compton scattering effect, it is deflected from its incident direction, loses 
energy according to the conservation of momentum, and may result in the release of a 
recoiling electron [196]. 
1.5.2 Localization of Positron Annihilation Event 
PET detectors traditionally take the form of a closed circular ring or rings of 
detectors around a bore large enough for the subject (humans or animals) to be imaged 
comfortably as well as accommodate the depth of interaction effect (DOI). DOI is the 
term used to describe the degradation of resolution due to the thickness of detectors and 
radioactive sources off-center. DOI becomes smaller with a larger detector ring diameter. 
Each ring is designed to detect the gamma rays from annihilation events (using multiple 
scintillator detectors coupled to photomultiplier tubes). Using coincidence logic, the 
resulting electrical signals are converted into sinograms that can be used to reconstruct 
tomographic images [195]. The individual components and processes are explained in 
details by Cherry et al. [192]. 
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1.5.2.1 Annihilation coincidence detection and event classification 
Near-simultaneous detection of two annihilation photons by two separate 
detectors within a given time constraint allows PET to localize the origin of beta decay 
along an annihilation coincidence (ACD) detection line. The ability to define spatial 
location without the use of absorptive collimators has gained PET an indisputable 
advantage over single photon emission computed tomography (SPECT) by having much 
higher sensitivity. Coincidence logic is used to analyze the signal attained by the 
detectors and is accomplished by time stamping each event (gamma ray detection) 
registered by any detector. A coincidence event is assumed to have occurred when a pair 
of events is recorded within a specific coincidence timing window (normally 6-12 nsec in 
a clinical scanner) by two separate detectors. The use of the timing window permits other 
types of events (e.g. scattered, random and multiple coincidences) to be interpreted as 
taking place “in coincidence” - which negatively affects resolution and SNR. Three that 
are not discarded by the system are summarized in figure 1-8 [192].  
 
Figure 1-8. Types of coincidences in PET signal detection. True coincidence is when 
two gamma rays originating from the same e+e− annihilation site are detected as 
coincidence. Scatter events are registered like a true event, only one or both gamma rays 
scatter within matter. Random event happens when two separate unrelated events occur 
close enough in time that they are detected as one single event. Only True coincidence 
will contribute positively to the SNR. 
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1.5.3 Corrections 
For the PET system to provide users with quantitative and artifact-free images, a 
few corrections to the acquired data must be incorporated. These include, but are not 
limited to the time activity curves (TAC) exponential decay, attenuation of photons 
passing through matter [199], variations in detector-specific efficiency and performance 
with respect to other detectors in the scanner, the loss of detection of more than one event 
within the detection coincidence window (dead-time and pile-up effects). 
1.6 Magnetic Resonance Imaging 
This sophisticated imaging technique has evolved considerably since 1974 when 
it was published to the public and has become an invaluable clinical and research tool 
[200]. Unlike other anatomical tomographic imaging devices such as Computer 
Tomography (CT), positron emission tomography (PET) and Single-Photon Emission 
Computed Tomography (SPECT), the non-invasive MRI does not utilize ionizing 
radiation.  
1.6.1 CEST, paraCEST and OPARACHEE Imaging 
Chemical exchange saturation transfer (CEST) MRI is a relatively new imaging 
approach that allows the indirect measurement of exogenous or endogenous molecules 
that go through exchange of target protons with bulk water. As a result of this, the 
method has been used to provide special insight using MRI including pH, temperature, 
metabolite detection, imaging of mobile proteins/ peptides and more[201]. Briefly, 
exchangeable protons become saturated (Mz is destroyed) using radio frequency (RF) 
energy tuned to the frequency of the exchanging spins when bound to the solute (the 
minor component in a solution, e.g. urea in water). Next, due to the exchange of protons 
water (pool a) with solute protons (pool b), the water magnetization (and therefore the 
signal) becomes slightly diminished and protons that leave this pool of protons with   
specific magnetization exchange with solute protons with no magnetization while spin-
lattice relaxation is at work returning z-magnetization of pool a to equilibrium according 
to the longitudinal relaxation time. This effect is amplified if the exchange rate is 
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sufficiently fast (to quickly allow the exchange of more saturated solute protons with 
those of bulk water) and the saturation time is sufficiently long (to adequately destroy 
Mz). However the exchange rate should also be sufficiently slow as to allow the two 
exchanging pools to obey the slow exchange condition. As a result, low concentration 
solutes can be visualized indirectly by the reduced water signal. This detection 
amplification means that CEST may be a suitable candidate for molecular and cellular 
imaging. It is possible to increase the chemical shift by incorporating paramagnetic 
species (PARACEST) into exogenous CEST agents allowing much higher exchange rates 
to be used while still adhering to the slow-intermediate MR exchange regime. Clinical 
application requires careful considerations for the possible toxicity of the agents, scan 
time limits, the need to scan whole organs and specific absorption rate (SAR). Using 
higher field strength increases spectral resolution and separation between bulk and solute 
water resonance frequencies, but the higher frequency RF excitation is also associated 
with higher power deposition [201]. An alternative approach to detect the effects of a 
PARACEST agent is based on RF manipulation of the free water peak [202]. This is 
referred to as On-Resonance Paramagnetic Chemical Exchange Effect (OPARACHEE) 
and its use in  mice in vivo was first described by Vinogradov et al. [203] showing that 
the method is sensitive to as little as micromolar concentrations of the paraCEST agent. 
Most CEST/ParaCEST studies have employed either continuous or pulsed selective off-
resonance saturation of the solute protons exchanging with water-protons [201]. For 
OPARACHEE contrast, the water signal is excited directly (hence the name “on 
resonance” [202]) by applying 360° rotations using a low power RF WALTZ [203] pulse 
train to compensated for B1- inhomogeneity. Using this approach, protons that exchange 
between water and the paraCEST agent do not experience the full 360° refocusing pulse 
and therefore after several series of such pulses, water signal is reduced due to 
magnetization exchanging from bulk water to the CA [202]. OPARACHEE was shown to 
be able to provide an indirect measure of the exchanging protons having high sensitivity 
for the detection of paraCEST CA requiring relatively low RF power deposition. The 
exact chemical shift position of the exchanging proton does not need to be known a priori 
[204]. However, one clear disadvantage of OPARACHEE is that it cannot distinguish 
between different agents or chemically different protons, but it may be the most suitable 
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and sensitive approach for detecting single agents. Finally due to the lower SAR 
requirements of this technique clinical translation may be more likely. Preliminary work 
using a paraCEST CatD targeting CA was pursued to a limited extent. Exciting data was 
acquired, and received positive response in international conferences (e.g. ISMRI 2013; 
awarded the Magna Cum Laude Merit award). However more work outside the scope of 
my studies was required to validate the in-vivo utilization. The limited results are shown 
in Appendix 1. 
1.7 Molecular Biology Assays 
1.7.1 Western Blots 
Western blotting (WB) is a well-accepted assay that identifies (using specific 
antibodies) proteins that have been separated from one another according to their size by 
gel electrophoresis. Briefly, the process begins with preparation of tissue lysates, making 
all proteins available for separation and detection. The preparation is accomplished by 
first the introduction of tissue to lysis buffer and protease inhibitors which allows all 
intracellular proteins to become available. The tissue is homogenized (crushed and mixed 
thoroughly), agitated (mixed for two hours at 4°C) and sonicated (further breaks up tissue 
and cellular membranes) prior to being spun down for 20 min at 12000 rpm at 4°C in a 
microcentrifuge and finally kept at -80°C until ready to use. Antibodies typically 
recognize a small portion (epitope) of the protein which may reside within the 3D 
conformation of the protein. In order to unfold the 3D conformation and enable access of 
the antibodies to these epitopes, it is necessary to denature (unfold) the proteins. 
Therefore, the second step which can be done briefly before running the assay, is 
denaturing of the proteins which is accomplished by 60°C heat bath for 20 minutes with a 
dye and β-mercaptoethanol (to reduce disulphide bridges in proteins). The separation 
process takes place within a gel by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  When SDS is used with proteins, all of the proteins 
become negatively charged by their attachment to the SDS anions and sos SDS denatures 
proteins by “wrapping around” the polypeptide backbone as well as provide them all with 
a negative charge. An application of an electrical current induces the proteins in the gel to 
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move through it and become separated by their weight. So in effect, the gel acts as a 
filter, a molecular sieve of sort, and it holds the separated proteins in place once the 
current has stopped. The blot (hence the name) is a membrane, almost always of 
nitrocellulose or polyvinylidene fluoride (PVDF) to which the proteins have been 
transferred to from the original gel used for protein separation. The membrane is a replica 
of the gel’s protein pattern and is subsequently (after being blocked with 5% milk to 
avoid non-specific antibody binding) stained with primary antibodies targeting different 
proteins of interest at a time. After washing off unbound primary antibodies with tris-
glycine buffered tween-20 (TBST) secondary antibodies are incubated to target the 
primary set. The secondary antibodies are bound to a reagent that reacts with a chemical 
solution to provide a chemiluminescent signal that can be detected using a designated 
sensitive camera. The ability to extract and study individual proteins provides valuable 
information. For the purpose of this work, the primary use of WB was to explore the 
CatD expression with reference to that of α-tubulin (α-T) within the same sample. This 
relative expression (CatD to α-T ratio) is indicative of the amount of target protein 
available within the sample explored.  
1.7.2 Histology and Immunohistochemistry 
Histology is the study of tissue structure at the microscopic level, including the 
cellular and molecular components. It extends from the level of sub-cellular 
compartments to individual cells to collection of tissue systems, organs and organ 
systems. Immunohistochemistry (IHC) is the application of antibodies to target specific 
features (e.g. enzymes, receptors etc). These antibodies in turn are detected using 
secondary antibodies that can interact with chemical processing creating a stain. 
Alternatively some secondary antibodies may be “tagged” with fluorescent dye that can 
allow beautiful multiple channel (colours) producing complex microscopic views of a 
several features at the same time. The principle behind immunohistochemistry is very 
similar to that of the WB in the sense one is targeting a specific feature (e.g. pathogenic 
protein) by the use of an antibody (hence ‘immuno’) that has high specificity and affinity 
to this target of interest. Rather than using chemiluminescence like WB, IHC commonly 
utilizes a colorimetric detection using nickel 3,3’-diaminobenzidine (DAB). As well as 
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Hematoxylin and Eosin counter staining. This provides 3 main visible colours on a slide: 
1. Brown stain for localization of the secondary, and therefore primary antibodies, which 
indicates the target. 2. Blue stain localizing the nuclei due to hematoxylin, and 3. Pink 
stain binds to many different intracellular and extracellular proteins due to Eosin. In order 
to separate the three colours for quantification of the amount of DAB staining (relating to 
the amount of target proteins) we used ImageJ (v. 1.46r, http://rsbweb.nih.gov/ij/). Color 
deconvolution plugin written by Dr. Gabriel Landini was used (available via the 
aforementioned website) and quantified using the ImageJ built-in threshold tool (triangle 
thresholding with seldom minor manual adjustments if deemed necessary by the primary 
observer JAS).  
1.8 Thesis Overview 
The following provides a brief description of each chapter to follow. Combined, the 
individual studies that are described next provide the proof of concept of an intelligent 
design of a functionalized molecular imaging contrast agent with multi-modality 
capabilities for the diagnosis Alzheimer’s disease (AD). 
Chapter 2 presents the work inspired by the findings nearly 25 years ago of the lysosomal 
system involvement in AD. Because our lab has developed a novel contrast agent (CA) 
that targets Cathepsin D (CatD), a lysosomal aspartyl protease, it was necessary to find an 
appropriate animal AD model that not only presents AD-like pathology but also displays 
over-expression or increased levels of our target CatD enzyme. Therefore Chapter 2 
presents the in-depth longitudinal examination of three different transgenic (Tg) mice 
strains compared with wild type (WT) controls. We examined the well accepted AD-like 
pathology of amyloid plaques (Aβ42) as well as CatD by means of Western blots (WB) 
and immunohistochemistry (IHC) analysis. In this study, we found that 5XFAD mice 
were the best AD model mouse strain for the purpose of testing out our CA. This work is 
in preparation for submission. 
Next, in Chapter 3, we present the preliminary, first in-vivo application of our CA, 
following a modification to include a Near Infra-red (NIR) dye. The study reports the 
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preliminary testing of our CA using the eXplore Optix system (GE Healthcare, 
Milwaukee, Wisconsin) in the 5XFAD mice at 5 and 12 months of age showing 
remarkable difference between these mice and age-matched WT controls. Furthermore, 
we synthesized two separate control CAs; one that lacked the CPP, and another that 
lacked the CatD targeting moiety. There were no significant differences in washout 
dynamic between the Tg and WT mice when using the control agents, only when using 
the complete CatD targeted CA. This work was accepted for publication in the Journal of 
Alzheimer’s Disease (JAD) in May 2015. 
In Chapter 4 we present a more translatable preclinical examination of our CA 
performance by using a radioactive 68Ga chelated version of the CatD targeted CA. The 
Inveon microPET scanner (Siemens Medical Solutions, Knoxville TN, USA) was used. 
We imaged the 5XFAD mice as well as non-Tg controls at 2, 6 and 9 months of age with 
the administration of the 68Ga CatD targeted CA intravenously (dynamic list-mode scan). 
The relative standard uptake values (SUVr) were calculated by analyzing the signal from 
the forebrain (including the cortex), dividing it by the signal from the hindbrain 
(including the cerebellum). Remarkably, significant differences were found for the rate of 
change of SUVr in mice aged 2, 6 and 9 months. Additionally, averaging the signal over 
the course of the last 30 minutes of the scans provided significantly higher SUVr values 
in the 5XFAD mice compared with the age-matched non-transgenic littermates. This 
work is in preparation for submission. 
 In conclusion, together, the three chapters provide evidence that our novel CatD 
targeted CA has the capacity to differentiate between the 5XFAD mouse model and age-
matched normal controls using both optical NIR imaging techniques and microPET 
imaging. Future directions will focus on moving this CA closer to clinical trials and are 
described in more detail in Chapter 5 of the thesis. 
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2.1 Introduction 
Alzheimer’s disease (AD) is an insidiously debilitating and lethal condition 
affecting tens of millions of people over the world [1]. Currently the diagnosis of AD is 
primarily on clinical grounds. Because AD has a prodromal period estimated to be 
decades, by the time a patient develops cognitive complaints, permanent neurological 
damage is already underway.  To develop an effective treatment, we must diagnose AD 
in the early or presymptomatic stage. 
 An important aspect of AD research focuses on recognizing and the evaluating 
biomarkers for prodromal AD diagnosis. The hallmark pathologies involved in AD 
include amyloid beta plaques (Aβ) and neurofibrillary tangles (NFT). The expression 
levels of Cathepsin D (CatD), a lysosomal aspartyl protease, has also been correlated 
with AD pathology and was suggested to be a biomarker for AD [2-5]. In AD patients 
there is a several fold increase in CatD in the Cerebral Spinal Fluid (CSF) compared to 
age-matched controls [3]. Furthermore, a recent study demonstrated that neural-derived 
plasma exosomal levels of CatD were significantly higher in AD patients reflecting AD 
pathology up to 10 years before clinical onset [69].  The exact role CatD plays has yet to 
be elucidated, however, since its activity has been shown to increase early in AD brains 
[2] it is a potential biomarker for early AD diagnosis. 
Characterizing early signs of the disease development in humans is inherently 
difficult because post-mortem confirmation of the associated pathology is required for an 
accurate diagnosis. Genetically engineered transgenic (Tg) rodent models (mostly mice) 
recapitulate at least the initial phases of AD pathology within a relatively short period of 
time, offering a window into the development of AD [6]. Because mice do not develop 
AD naturally, mouse models require the introduction of the human gene for APP; for 
robust amyloid plaque formation, mice typically rely on the introduction of human APP 
and Presenilin genes bearing mutations that cause familial Alzheimer’s disease. In 
addition, Tau gene (MAPT) mutations in frontotemporal and related tauopathies cause 
NFT’s to develop in mouse models [6].  The presence of multiple different models of AD 
makes possible the correlation of biomarkers across disease severity, but also opens the 
question of how to choose the model best suited for the study at hand [7].  
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 One of the first successful AD mouse models overexpressed a human APP 
bearing a Familial Alzheimer’s disease causing mutation and was shown to exhibit an 
age-dependent increase in senile plaque deposition [8]. Since then, many mouse models 
have been developed incorporating human genes with Familial Alzheimer’s disease 
(FAD) mutations (e.g in the PSEN1 gene) to increase Aβ42 levels [9] and deposition [10]. 
For example, double mutation (2X) of both APP and PSEN1 is used in the 
Tg(APPswe,PSEN1dE9) mouse. This model expresses a chimeric mouse/human amyloid 
precursor protein with a Swedish mutation and a mutant human presenilin 1 with exon 9 
deleted (PSEN1-dE9;) both controlled by independent mouse prion protein (PrP) 
promoter elements [12]. Consequently, plaques are abundant in the hippocampus and 
cortex by 9 months of age with occasional deposits found in mice as young as 6 months 
of age [13, 14]. This mouse model leads to the accumulation of senile plaques and 
cognitive decline offering a valuable tool in AD studies [15].   
Previously, many of the available AD mouse models were hampered by the lack 
of neurofibrillary tangles and neuron loss. NFT were recently achieved by the 
incorporation of a human Tau gene containing mutations associated with Frontotemporal 
lobe dementia into AD Tg mice, as is the case of the triple transgenic (3X) mouse strain 
[16]. The 3xTg or B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L) is a triple transgenic 
homozygous mouse strain combining the presenilin PS1M146V mutation (increases the 
ratio of Aβ42/Aβ40) as well as the amyloid beta precursor protein (Swedish mutation 
KM670/671NL) and microtubule-associated protein Tau mutation (tauP30IL). Both 
transgenes integrate at the same locus and are under the control of the mouse Thy1.2 
regulatory element [12]. In this model, Aβ plaques begin to accumulate before 6 months 
of age, and continue with age-dependent increases observed between 12 and 20 months 
[17]. In addition, Tau pathology including NFTs is detected by 6 months of age with 
advanced NFT burden by 20 months [17].  
Despite AD model mice displaying cognitive decline, synaptic loss, and increased 
mortality - most models seldom present neuronal cell death. However, the latter has been 
recently detected in more aggressive Tg mouse models such as the 5XFAD where 
multiple mutations are expressed [18]. The 5XFAD strain, overexpresses a human APP 
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gene bearing 3 mutations (the Swedish (K670N, M671L), Florida (I716V) and London 
(V717I) mutations) along with human PSEN1 with two human FAD-causing mutations 
(M146L and L286V). Consequentially, the 5XFAD presents early (<2 months) onset of 
plaque deposition, age-dependent synaptic degeneration, working memory impairments 
and neuronal loss [18]. 
We have previously developed a contrast agent (CA) to detect CatD activity in-
vivo, consisting of a magnetic resonance imaging/fluorescent moiety linked to a cell 
penetrating peptide (CPP) by means of a CatD cleavage site. The objective of this study 
was to verify that CatD is over expressed in multiple AD mouse models, to characterize 
the onset of these changes compared to AD pathology, and to select an appropriate model 
to provide proof of concept for a novel working CatD-targeting CA. To do this, we 
mapped the levels of CatD as well as Aβ and Tau accumulation across several brain 
regions and over the age of the mice useing immunohistochemistry (IHC) and Western 
blot (WB) analysis.  We found that CatD expression increased over time in normal mice, 
and was greatly increased in proportion to Aβ pathology.  These findings validate the 
idea of CatD as a biomarker for Alzheimer’s disease. 
2.2 Materials and Methods 
2.2.1 Animals 
All animal studies were conducted in accordance with the guidelines of the 
Subcommittee on Animal Care at the University of Western Ontario, and conformed to 
the Canadian Council on Animal Care guide for the care and use of laboratory animals. 
The required documentation is attached in Appendix 5. All mice were received from 
Jackson Laboratories (Bar Harbor, ME, USA). Three Tg mouse models of AD were 
selected. In the current study, a total of three female mice per time point (age) per strain 
were used (N=63) in total; eighteen controls, fifteen 5X (5XFAD), fifteen 2X 
(APPswe/PS1dE9) and fifteen 3X (3xTg) mice. All animals, which were used up to 
twelve months of age, were housed with a 12-h light/12-h dark photoperiod and received 
food and water ad libitum. 
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2.2.2 Preliminary tissue processing 
At each time point (age group), mice were placed into a surgical plane by 
induction chamber CO2 inhalation followed by severing the diaphragm, left ventricle 
heparin injection (2 ml/kg), right atrium cut and ice-cold phosphate buffered saline (PBS) 
perfusion (at least 10 ml) via the left ventricle catheter and lastly decapitation. Brains 
were rapidly removed and dissected while kept on ice. One hemisphere was removed and 
immersed in 10% neutral buffered formalin NBF immersion for at least another 48 hours 
prior to additional processing. The other hemisphere (contralateral) was dissected further 
to separate the hippocampus, cortex, and striatum and then stored at -80°C.   Tissue 
collection was performed at 5, 16, 32, 44 and 60 weeks of age for the 2X and 3X mice, 5, 
8, 16, 28 and 60 weeks of age for the 5X mice; and finally 5, 8, 16, 32, 44, 60 weeks of 
age for the WT mice. 
2.2.3 Western Blotting 
Frozen tissue samples were combined in ice cold lysis buffer [20mM Tris–HCl 
(pH 8), 150 mM NaCl, 0.1% SDS, 1mM EDTA, 1% Igepal CA-630, 50mM] with 
protease cocktail inhibitors with pepstatin A (Roche, Mississauga, Ontario, Canada) and 
homogenized using a Pestle Grinder System (Thermo Fisher Scientific, Massachusetts, 
USA) and frozen at -80°C. Lanes were run with 20 μg of protein on a 12% SDS–
polyacrylamide gel and the resolved proteins were transferred to a nitrocellulose 
membrane (all from Bio-Rad, Mississauga, Ontario, Canada) using a Trans-Blot Semi-
Dry Electrophoretic Transfer Cell (Bio-Rad, Mississauga, Ontario, Canada). The 
membrane was blocked with 5% nonfat milk (w/v) dissolved in Tris buffered saline with 
0.05% Tween-20 (TBST). Blots were probed using Anti-Cat-D antibody at 1:300 dilution 
factor (chosen to ensure a linear response across a several fold increase in the 
concentration of target protein) overnight (C-20- sc6486; Santa Cruz Biotechnology, 
Santa Cruz, CA, USA), and detected using rabbit-anti-goat antibody coupled to 
horseradish peroxidase using enhanced chemiluminescence reagents (ECL;).  Blots were 
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imaged digitally using the Gel Doc XR+ System (BIORAD; California, USA). Blots 
were then washed 3 times in TBST and re-probed with anti-α-tubulin at 1:50k dilution 
factor overnight (Sigma Aldrich, St Louis, MO, USA) as a loading control and imaged 
the following day. Since immature Cat-D is also the active form and performs the same 
enzymatic functions as the mature form, both forms were grouped into a total CatD 
expression {Benes, 2008, Cathepsin D--many functions of one aspartic protease}. Images 
were analyzed using ImageJ (http://rsbweb.nih.gov/ij/). CatD chemiluminescent bands 
were evaluated relative to the loading control measurement of α-tubulin as follows using 
Equation (2-1): 
   
 𝑰    
 𝑰        𝒏
      (2-1) 
Where ψ is the ratio of CatD compared to α-tubulin. The SICatD or SIα_tubulin are the 
densitometric “signals” measured from the blot for either CatD or α-tubulin respectively, 
i = 1..3 are the number of animals used. Next, in order to normalize all data across all 
strains, brain regions and ages - all ψ (of any strain, age, or mouse) were normalized to 
the ψ of a single five week old WT mouse cortex based on the relative CatD expression 
previously measured using a separate WB analysis for all 5 week old WT tissues (9 
samples: 3 mice, 3 brain regions). This process was completed for each mouse, at each 
time point, for each brain region (striatum, hippocampus and cortex). 
 
2.2.4 Immunohistochemistry Processing and Analysis of 
Transgenic and Wild Type Mice 
All brains were allowed to fix over time in 10% NBF before switching to 70% 
ethanol and embedded in paraffin. Five (5) µm thick sections were cut in a coronal 
orientation to expose the hippocampus, striatum, cortex, as well as the thalamus. All 
sections were stained (for each primary antibody) at the same time for standardization 
purposes. In addition, any potential variability in staining between the sections, animals 
and time points was minimized by using an automatic threshold as described in more 
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detail below. Endogenous peroxidase activity was inhibited by using hydrogen peroxide 
(3%) followed by antigen retrieval using formic acid (70%, 2 minutes) and sections were 
immunolabeled with either an antibody against CatD (1:200 dilution factor; C-20 sc-6486 
from Santa Cruz Biotechnology; Santa Cruz, CA, USA) or against Aβ42 (1:200 dilution 
factor; custom made).  The dilution factors were chosen after performing serial dilutions 
of different concentration.  A dilution was chosen that did not produce excessive staining 
of CatD in the younger mice (as well as a linear response in Western blots). In addition, 
dilution factor was chosen for the Aβ42 antibody to produce no staining of note in the 
older WT mice (non-zero values measured in WT mice set base-line for thresholding/ 
colour deconvolution).  This antibody was detected using an anti-rabbit secondary 
antibody conjugated to horseradish peroxidase, prior to colorimetric detection using 
nickel 3,3’-diaminobenzidine (DAB; 0.15 mg/ml in 0.03% H2O2; Sigma-Aldrich, 
Oakville,ON, Canada) with the Vectastain ABC kit (Dako, Burlington, ON, Canada) and 
counterstaining with Hematoxylin and Eosin (H&E; Leica Microsystems Inc.  Concord, 
Ontario, Canada). Negative control (no primary antibody) did not produce any notable 
staining. Sections were imaged and digitized using a TISSUEscope CF slide scanner 
(Huron Technologies, Waterloo, ON) at a 0.5 µm resolution using bright field imaging 
(at 40X). Slides were measured for positively stained areas in four brain regions (each 
covering >200,000 µm2) per mouse, in each of three mice per age group using ImageJ (v. 
1.46r, http://rsbweb.nih.gov/ij/). Staining was identified using the color deconvolution 
plugin written by Dr. Gabriel Landini (available via the aforementioned website) and 
quantified using the ImageJ built-in threshold tool (triangle thresholding with seldom 
minor manual adjustments if deemed necessary by the primary observer JAS). To assess 
intra-observer variability, a subset of the data (Aβ42) was analyzed by a second blinded 
observer (blinded to strain, age, and tissue type). 
2.2.5 Statistical analysis 
Two-tailed, unequal variance Student’s t-test was used to test for significant 
differences correcting for multiple comparisons using the Sidak-Bonferroni method using 
Prism5 (GraphPad software, Inc. La Jolla, CA, USA) comparing the amount of DAB 
staining detected in the different brain regions via both Western blots and 
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histopathological examination. Additionally, a two-way ANOVA with Tukey’s 
correction for multiple comparisons was used to examine the influence and statistical 
differences as a result of having AD mutations (strain factor) and aging (age factor). For 
ANOVA, when comparing WT mice with 2X or 3X, the missing 32-week old WT mice 
data assumed the values of the available 28-week old data. Finally, a Pearson correlation 
test as well as Student’s t-test was used to check for intra-observer variability and 
correlation of the measurements performed for CatD and Aβ42 staining. 
2.3 Results 
2.3.1 Immunohistochemistry 
As expected, all cells expressed CatD in a punctate pattern consistent with 
lysosomal/organellar expression. We examined CatD and Aβ42 staining across the 
lifespan in WT, 2X 3X and 5X experimental animals. CatD (Fig. 2-1) as well as Aβ42 
(Fig. 2-2) staining was most pronounced in 12 months old Tg mouse brains both 
intracellularly (Figures open arrow) as well as extracellularly in senile plaque-like 
morphology (close arrow). WT mice also demonstrated increasing CatD staining with 
age, but did not show any Aβ deposition.The staining was least in the WT mice, and 
increased progressively in the age-matched 3X, 2X, and 5X strains. The staining was 
observed most notibly in the cortex (left pane is zoomed into layers II-III and IV-V) and 
hippocampus. Within the hippocampal formation of the 2X and 5X mice, the dentate 
gyrus polymorph layer as well as the CA1, CA3 and dorsal part of the subiculum 
pyramidal cell layers presented heavy staining in the Tg mice. The thalamus and striatum 
presented far less positive staining for CatD in the 2X and 3X mice compared to the 5X 
line, whereas the 3X presented the least amount of the plaque-like extracellular staining.   
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Figure 2-1. CatD staining in older Tg and control WT mice (60 weeks). Progressive 
CatD positive staining appears throughout the Tg mouse brains in the cortex (COR), 
hippocampus (HIP), the hippocampal CA1 region (HIP-CA1), striatum (STR) and 
thalamus (THL) as noted above for the 2X, 3X, 5X and WT as noted on the left, both 
intracellularly (open arrow) as well as extracellularly in senile plaque-like morphology 
(close arrow). Different regions of the brain are indicated above for the different AD 
mouse models indicated on the left (2X, 3X and 5X versus WT controls). Scale bar is 100 
μm (for the HIP-CA1 the scale bar is 10μm).  
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Figure 2-2 Aβ42 staining in older Tg and control WT mice (60 weeks). Progressive 
Aβ42 positive staining appears throughout the Tg mouse brains in the cortex (COR), 
hippocampus (HIP), the hippocampal CA1 region (HIP-CA1), striatum (STR) and 
thalamus (THL) as noted above for the 2X, 3X, 5X and WT as noted on the left, both 
intracellularly (open arrow) as well as extracellularly in senile plaque-like morphology 
(close arrow). Different regions of the brain are indicated above for the different AD 
mouse models indicated on the left (2X, 3X and 5X versus WT controls). Scale bar is 100 
μm (for the HIP-CA1 the scale bar is 10μm). 
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We used ImageJ to calculate the percent area occupied by DAB stain with respect to a 
region of interest within the Cortex (Cor) Striatum (Str), Hippocampus (Hip) and 
Thalamus (Thl).  These results are shown in Figure 2-3 plotted over time for all mouse 
ages and strains.   
2.3.1.1 Aβ42 Staining Quantification 
All measured Aβ42 DAB staining is reported in Table 2-1 and plotted in Fig. 2-3. 
2.3.1.1.1 2X vs. WT 
The amount of 2X cortex Aβ42 staining was significantly (p < 0.05) higher at 44 
(4.48 ± 0.94 vs 1.34 ± 0.16%) and 60 (7.21 ± 1.67 vs 0.85 ± 0.25 %) weeks of age 
compared to age-matched controls. Both age [F (4, 19) = 6.539, p = .0017, η2 = 0.232] 
and strain [F (1, 19) = 32.09, p < .0001, η2 = 0.284] factors contributed to the significant 
differences. In the hippocampus, there was significantly (p < 0.05) more positive staining 
for Aβ42 at 44 (4.20 ± 0.69 vs 1.19 ± 0.17 %) and 60 (5.82 ± 0 .63 vs 1.12 ± 0.38 %) 
week of age in 2X mice where both strain [F (1, 18) = 42.67, p < .0001, η2 = 0.403] and 
age [F (4, 18) = 5.274, p = .0054, η2 = 0.199] contributed to the significant differences. 
However, in the striatum, only the 60-week old 2X mice had significantly higher staining 
for Aβ42 (3.00 ± 0.88 vs 0.43 ± 0.04 %; p < 0.05). Finally, the thalamus presented only 
strain dependent differences in staining [F (1, 16) = 5.587, p = .0311, η2 = 0.199]. 
2.3.1.1.2 3X vs. WT 
The 3X mice presented with little pathology in the cortex, with most plaques 
observed in the hippocampus (primarily in the SUBd region) and thalamus regions near 
the lateral ventricles. There were no significant differences in staining in the cortex and 
striatum, but the hippocampus presented significantly higher staining dependent on age 
[F (1, 18) = 14.6, p = .0013, η2 = 0.362] and strain [F (1, 18) = 7.386, p = .0141, η2 = 
0.244]. 
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Table 2-1. Aβ42 DAB staining measurements over time (weeks) for all strains. 
 Αβ42 
Cortex WT 2X 3X 5X 
5 1.19 ± 0.36 1.53 ±  0.25 0.96 ± 0.37 2.73 ± 0.87 
8 1.53 ± 0.11 NA 5.18 ± 0.1α 
16 1.45 ± 0.77 2.41 ± 0.74δ 1.6 ± 0.44δ 8.36 ± 1.14αβγ 
28/32 1.17 ± 0.08 1.68 ± 0.19δ 2.68 ± 1.72δ 10.69 ± 0.76αβγ 
44 1.34 ± 0.16 4.48 ± 0.94α 2.23 ± 0.5 NA 
60 0.85 ± 0.25 7.21 ± 1.67αδ 3.10 ± 0.89δ 19.44 ± 1.62αβγ 
Hippocampus 
    
5 0.97 ± 0.34 1.79±0.73 1.63 ± 0.19 3.54 ± 1.35α 
8 1.41 ± 0.03 NA 5.81 ± 3.32 
16 1.14 ± 0.32 2.40 ± 0.60δ 2.33 ± 0.75δ 6.54 ± 3.37βγ 
28/32 1.29 ± 0.02 2.37 ± 0.46δ 2.86 ± 1.20δ 10.15 ± 3.17α βγ 
44 1.19 ± 0.17 4.20 ± 0.69α 3.65 ± 0.72 NA 
60 1.12 ± 0.38 5.82 ± 0 .63αδ 3.88 ± 1.15δ 13.35 ± 1.44αβγ 
Striatum 
    
5 1.07 ± 0 0.81 ± 0.07 0.88 ± 0.28 1.32 ± 0.14 
8 0.63 ± 0.1 NA 1.72 ± 0.14 
16 0.92 ± 0.4 1.01 ± 0.69 0.89 ± 0.37 δ 2.07 ± 0.43γ 
28/32 0.74 ±  0.04 0.48 ± 0.21δ 0.32 ± 0.05 δ 3.71 ± 1.41β γ 
44 0.28 ± 0.05 1.63 ± 0.19 0.70 ± 0.16 NA 
60 0.43 ± 0.04 3.00 ± 0.88αδ 1.46 ± 1.22δ 10.26 ± 0.76 αβγ 
Thalamus 
    
5 1.3 ± 0.22 2.21 ± 0.26 1.87 ± 0.15 2.5 ± 0.47α 
8 1.12 ± 0.09 NA 5.79 ± 0.80α 
16 1.34 ± 0.17 1.49 ± 0.13 1.87 ± 0.15 6.23 ± 1.30α 
28/32 1.80 ± 0.18 2.34 ± 0.76δ 1.88 ± 0.21δ 8.03 ± 1.44 αβγ 
44 1.4 ± 0.15 2.61 ± 0.99 2.62 ± 0.22 NA 
60 1.39 ± 0.18 1.63 ± 0.19δ 2.13 ± 0.93δ 16.60 ± 0.88 αβγ 
Significance (p < 0.05) of data points are bolded and designated according to what they 
are compared to: Vs. WT – α; Vs. 2X – β; Vs. 3X – γ; Vs. 5X – δ. Data is mean ± 
standard error (N=3). 
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2.3.1.1.3 5X vs. WT 
The 5X mice presented the most progressive amount of pathology.  There was a 
significant (p < 0.01) amount of positive area staining for Aβ42 in the cortex compared to 
WT as early as at 8 (5.18 ± 0.1 vs. 1.53 ± 0.11%) followed by 16 (8.36 ± 1.14 vs 1.45 ± 
0.77 %), 28 (10.69 ± 0.76 vs 1.17 ± 0.08 %) and 60 (19.44 ± 1.62 vs 0.85 ± 0.25 %) 
weeks of age. Overall both strain [F (1, 20) = 347.2, p < .0001, η2 = 0.481] and age [F (4, 
20) = 42.06, p < .0001, η2 = 0.233] factors contributed significantly to the differences. 
The 5X hippocampal Aβ42 staining was significantly higher at 5 (3.54 ± 1.35 vs 0.97 ± 
0.34 %), 16 (6.54 ± 3.37 vs 1.14 ± 0.32), 28 (10.15 ± 3.17 vs 1.29 ± 0.02 %) and 60 
(13.35 ± 1.44 vs 1.12 ± 0.38 %) week time points (p < 0.01). Strain [F (1, 20) = 46.98, p 
< .0001, η2 = 0.518] but less so age [F (4, 20) = 2.974, p = 0.0444 η2 = 0.13.11] both 
contributed to the significant amount of staining (ηstrain
2> ηage
2). 5X striatum Aβ42 staining 
was significant (p < .01), but only at 60 weeks of age (10.26 ± 0.76 vs 0.43 ± 0.04 %) but 
both strain [F (1, 17) = 53.47, p < .0001, η2 = 0.224] and age [F (4, 18) = 16.98, p < 
.0001, η2 = 0.285] contributed to the overall significant Aβ42 staining noted across the 
data. Finally, there was a significant (p < 0.01) amount of positive staining for Aβ42 in the 
thalamus compared to WT as early as 5 (2.5 ± 0.47vs 1.3 ± 0.22 %), and 8 (5.79 ± 0.80 
vs 1.12 ± 0.09) weeks of age, followed by 16 (6.23 ± 1.30 vs 1.34 ± 0.17 %), 28 (8.03 ± 
1.44 vs 1.80 ± 0.18 %) and 60 (16.60 ± 0.88 vs 1.39 ± 0.18 %) weeks of age. Both strain 
[F (1, 17) = 238.5, p < .0001, η2 = 0.428] and age [F (4, 17) = 35.44, p < .0001, η2 = 
0.254] contributed to the variation in the thalamus DAB stain data. 
2.3.1.1.4 Tg vs. other Tg differences 
There were no significant differences between the Aβ42 staining in all Tg mice at 
5 weeks, but at 16 weeks the 5X cortex and hippocampus stained area was larger than 2X 
and the 3X. At 28/32 weeks, The 5X cortex, striatum, hippocampus and thalamus stained 
areas were larger than those measured for 2X and 3X. At 60 weeks, the 5X’s cortex, 
hippocampus, striatum and thalamus stained areas were all larger compared to 2X and 
3X. At no point was the 2X significantly different than the 3X. 
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2.3.1.1.5 Inter-observer variability 
To test observer variability, a blinded (unaware of the age, the strain, or brain 
region segmented for calculation of % DAB) observer was tasked with quantifying the 
Aβ42 staining. Measurements were compared to those made by the primary observer 
(JAS). There were no significant differences (paired two-tailed Student’s t-test) and the 
measurements were highly correlated (Pearson coefficient r >0.8) for the 2X mice (paired 
Student’s t-test p = 0.065), 3X mice (paired Student’s t-test p = 0.0638) and the 5X mice 
(paired Student’s t-test p = 0.2619).  
2.3.1.1.6 Aβ42 levels at different ages 
The levels of DAB staining are shown in Fig. 2-3 over time. In Fig. 2-4, pseudo 
colour maps are used to show the lease-square linear fitting associated slopes indicating 
the “rate of change” in positive DAB staining in different brain regions over the age of 
the mouse (% DAB stain/ week of aging). Of note, are the stark differences between the 
WT mice and all Tg mice. The linear fit slopes for the 2X cortex, hippocampus and 
striatum Aβ42 data were all significantly different than those of the WT mice (excluding 
the thalamus) as can be seen in Figure 2-4. The 3X hippocampus and cortex presented 
significantly higher slopes (p < 0.05) than WT mice and only the cortex of the 3X was 
significantly different (p < 0.05) than that of the 2X. The 5X cortex, hippocampus, 
thalamus and striatum had significantly higher (p < 0.01) slopes than those of the 2X 
(excluding the 2X hippocampus which was not significantly different), 3X and WT 
corresponding brain regions. It is important to note that none of the WT brain regions 
showed significant differences with each other (p = 0.06) and none of the WT Aβ42 slopes 
significantly deviated from zero. 
2.3.1.2 Cathepsin D Staining Quantification 
The amount of CatD staining was most notable in the 5X, followed by the 2X, 
then 3X and finally WT mice. All measured CatD DAB staining is reported in Table 2-2 
and shown in Fig. 2-3.  
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Table 2-2. CatD DAB staining measurements over time (weeks) for all strains. 
 CatD 
Cortex WT 2X 3X 5X 
5 2.01 ± 0.74 2.28 ± 1.44 1.92 ± 0.19 3.01 ± 0.55 
8 2.04 ± 0.31 NA 5.26 ± 1.01α 
16 3.18 ± 0.63 3.39 ± 0.71 2.54 ± 0.49δ 7.07 ± 1.23αβγ 
28/32 3.44 ± 0.11 4.25 ± 0.43δ 2.8 ± 0.61δ 10.13 ± 1.34 αβγ 
44 2.96 ± 0.66 5.62 ± 0.43αγ 2.60 ± 0.52β NA 
60 3.58 ± 0.98 8.64 ± 0.71αγδ 2.67 ± 0.58βδ 15.77 ± 1.96 αβγ 
Hippocampus 
    
5 2.58 ± 0.61 2.44 ± 0.94 1.88 ± 0.52 3.13 ± 0.98 
8 3.5 ± 0.71 NA 4.64 ± 0.52 
16 3.89 ± 0.22 4.74 ± 0.61 1.74 ± 0.72δ 7.32 ± 2.07βγ 
28/32 3.29 ± 0.68 5.81 ± 0.98 3.11 ± 0.10δ 12.30 ± 1.09αβγ 
44 3.80 ± 0.81 8.15 ± 1.15α 3.79 ± 0.15 NA 
60 3.66 ± 0.46 9.80 ± 1.52α 4.79 ± 0.14δ 17.62 ± 1.90αβγ 
Striatum 
    
5 0.8 ± 0.20 0.66 ± 0 1.16 ± 0.21 0.87 ± 0.22 
8 1.01 0.50 NA 0.75 ± 0.16 
16 1.50 ± 0.33 0.76 ± 0.14δ 0.67 ± 0.25δ 1.95 ± 0.32βγ 
28/32 1.48 ± 0.32 0.87 ± 0.30δ 0.78 ± 0.40δ 3.72 ± 0.75βγ 
44 1.40 ± 0.07 1.57 ± 0.27 1.52 ± 0.42 NA 
60 1.54 ± 0.90 1.59 ± 0.04δ 1.04 ± 0.50δ 15.63 ± 1.26αβγ 
Thalamus 
    
5 1.79 ± 0.34 1.46 ± 0.14 3.19 ± 1.06 2.22 ± 0.27 
8 1.59 ± 0.03 NA 4.10 ± 1.15α 
16 2.37 ± 0.48 1.74 ± 0.42δ 2.40 ± 0.68δ 6.32 ± 0.61 αβγ 
28/32 1.48 ± 0.15 1.9 ± 0.24 2.68 ± 1.06 3.31 ± 0.51α 
44 1.92 ± 0.34 1.79 ± 0.21 1.95 ± 0.29 NA 
60 2.13 ± 0.28 2.48 ± 0.69δ 1.85 ± 0.25δ 9.89 ± 0.49 αβγ 
Significance (p < 0.05) of data points are bolded and designated according to what they 
are compared to: Vs. WT – α; Vs. 2X – β; Vs. 3X – γ; Vs. 5X – δ. Data is mean ± 
standard error. 
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2.3.1.2.1 2X vs. WT 
When comparing 2X mice with WT, cortex CatD expression was only 
significantly higher in 2X mice at 44 and 60 weeks of age (5.62 ± 0.43 vs 2.96 ± 0.66 and 
8.64 ± 0.71 vs 3.58 ± 0.98 %; p < 0.05). Two-way ANOVA indicated that both strain [F 
(1, 19) = 16.68, p = .0006, η2 = 0.186] and age [F (4, 19) = 8.450, p = .0004, η2 = 0.377] 
factors contributed to significant differences. Next, only at 44 (8.15 ± 1.15 vs 3.80 ± 0.81 
%; p < 0.01) and 60 weeks of age (9.80 ± 1.52 vs 3.66 ± 0.46 %; p < 0.01) was the 2X 
hippocampal CatD staining significantly higher than WT with both strain [F (1, 18) = 
23.00, p = .0001, η2 = 0.268] and age [F (4, 18) = 6.397, p = .0022, η2 = 0.299] effects 
contributing. In contrast, no significant differences were noted for the striatum or 
thalamus. 
2.3.1.2.2 3X vs. WT 
In 3X mice, only age-dependent difference were observed [F (4, 18) = 1.717, p < 
.0033, η2 = 0.422] but no significant differences were measured compared to WT.  
2.3.1.2.3 5X vs. WT 
The 5X mice presented with a significantly higher amount of staining for CatD 
throughout the brain. Specifically, a considerable amount of staining was observed in the 
cortex at 8 (5.26 ± 1.01 vs 2.04 ± 0.31 %), 16 (7.07 ± 1.23 vs 3.39 ± 0.71 %), 28 (10.13 ± 
1.34 vs 2.95 ± 0.81 %), and 60 (15.77 ± 1.96 vs 3.58 ± 0.98 %) weeks of age with strain 
factor [F (1, 18) = 92.39, p < .0001, η2 = 0.548] and age factor [F (4, 18) = 17.68, p < 
.0001, η2 = 0.420] contributing.  Similarly, the hippocampus CatD expression values at 
28 weeks (12.30 ± 0.56 vs 3.29 ± 0.68; p < 0.05) and 60 (3.66 ± 0.46 vs 17.62 ± 1.90; p < 
0.05) were significantly higher with strain factor [F (1, 17) = 67.16, p < .0001, η2 = 
0.443] and age factor [F (4, 17) = 14.06, p < .0001, η2 = 0.371] contributing. The striatum 
had a significantly higher value in the 5X mice at 60 weeks of age (15.63 ± 1.26 vs. 1.54 
± 1.10) with strain [F (1, 15) = 83.12, p < .0001, η2 = 0.279] and age [F (4, 15) = 47.01, p 
< .0001, η2 = 0.632] factors contributing to the differences between the groups. Lastly, 
the 5X thalamus was found stain significantly higher (6.40 ± 1.06 vs. 2.37 ± 0.83; p < 
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0.05) at as early as 16 weeks, 28 weeks (3.31 ± 0.51vs 1.48 ± 0.15) and 60 weeks (9.89 ± 
0.49 vs 2.13 ± 0.28) with strain [F (1, 17) = 74.16, p < .0001, η2 = 0.545] and age factors 
[F (4, 17) = 12.68, p < .0001, η2 = 0.372] contributing significantly. 
2.3.1.2.4 Tg vs. Tg 
There were no significant differences between the CatD staining for any of the Tg 
mice at 5 weeks, but at 16 weeks the 5X cortex, striatum and thalamus had significantly 
more CatD staining than the 3X and the 2X, whereas only the 5X hippocampus region 
presented with more CatD staining than the 3X hippocampus. At 28 weeks, the 5X 
cortex, hippocampus and striatum DAB stain area was larger than those measured for 2X 
and 3X. At 60 weeks, the 5X cortex, hippocampus, striatum and thalamus stained areas 
were all larger compared to 2X and 3X. At this age, the 2X also presented significantly 
larger staining area in the cortex and hippocampus compared with the 3X.   
2.3.1.2.5 CatD levels at different ages 
The levels of DAB staining are shown in Fig. 2-3 over time.  In Fig. 2-4, pseudo 
colour maps are used to show the lease-square linear fitting associated slopes indicating 
the “rate of change” in positive DAB staining in different brain regions over the age of 
the mouse (% DAB stain/ week of aging).  In 2X mice, only the cortex and hippocampus 
presented significantly higher slopes than WT.  In 3X, only the hippocampal CatD 
expression was significantly higher than that of WT mice. But both the hippocampal and 
cortex presented with significantly lower slopes than those calculated for 2X. Finally, all 
of 5X brain regions tested presented with significantly higher slopes than those of the 
corresponding 2X, 3X and WT brain regions. An interesting observation is that the 2X 
hippocampal and cortex slopes for CatD expression were higher than that for the Aβ42 
stain in the same brain region. Similarly, the 5X hippocampal slope for CatD expression 
was higher than the corresponding brain region Aβ42 stain slope. 
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Figure 2-3 CatD and Aβ42 positive Immunohistochemistry assessment in aging Tg 
and control WT mice levels at different ages (5-60 weeks). The average ± standard 
error of the mean is shown for N=3 mice for the indicated brain regions on the left, with 
the associated positive DAB staining for the respective antibody on top. Mice strains are 
indicated on the right (2X, yellow upright tringle; 3X brown upside-down trianglel 5X, 
red circle, and WT in black box).  
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Figure 2-4 Estimated rate of change of DAB staining levels for all mice strains. 
Colour bar represents the slope of a least squares linear fit to the data in Fig. 2-3. Brain 
regions have been grossly countored and represent a broad generalization of the change 
in Aβ42 and CatD expression within the associated brain regions. Brain regions are 
depicted in the top image, with indicated mouse strains on the left and antibody of 
interest at the top. 
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2.3.1.2.6 Cathepsin D Correlates With Aβ42 
When testing the correlation between the CatD staining and Aβ42, we found the 
2X cortex (p = 0.011; Pearson r = 0.957) as well as the hippocampus (p= 0.015; Pearson r 
= 0.947) were highly correlated. Only the hippocampus of the 3X mice presented a 
similar correlation (p = 0.019; Pearson r = 0.936). However, the 5X mice presented high 
correlation between CatD and Aβ42 staining in the cortex (p < 0.001; Pearson r = 0.997), 
hippocampus (p = 0.001; Pearson r = 0.992), striatum (p < 0.001; Pearson r =0.997) and 
thalamus (p = 0.044; Pearson r =0.888). 
2.3.2 Western Blots 
Representative WB images are shown in Fig. 2-5 together with the associated 
plots showing longitudinal data for the three strains and three brain regions. Similar to the 
IHC analysis, the 5X mice consistently exhibited the highest level of expression of CatD 
compared to the other two Tg strains as well as the control WT mice at all time points. 
Examining values for the 2X mice compared to age matched WT, no significant 
differences were noted in the cortex. In contrast, striatum 2X CatD expression was 
significantly higher and dependent on AD mutations [F (1, 20) = 21.38, p = .0002, η2 = 
0.315] as well as age [F (4, 20) = 3.274, p = .0322, η2 = 0.193]. Lastly, hippocampal 
CatD expression was only significantly higher in 2X mice due to strain factor differences 
[F (1, 20) = 6.395, p = .02, η2 = 0.191] since no age-based differences were observed. For 
specific ages, hippocampal CatD expression was not found to be significantly different 
between the 2X and the WT controls. 
Examining the 3X mice, there were no significant differences with the WT mice 
at any specific time points when comparing cortex, striatum or hippocampus CatD 
expression. Overall though, the 3X striatum had significantly higher expression [F (1, 20) 
= 5.534, p = .029, η2 = 0.099] with older mice having more CatD than younger ones [F 
(4, 20) = 3.327, p = .030, η2 = 0.238]. Hippocampal CatD expression was also 
significantly higher in 3X mice [F (1, 20) = 7.472, p = .0128, η2 = 0.154], with age 
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contributing significantly to the variability in CatD expression [F (4, 20) = 3.873, p = 
.0173, η2 = 0.319].  
Finally, 5X mice presented a consistent increase in CatD expression across all 
brain regions with age. Cortex CatD expression was significantly higher (p < 0.05) as 
measured in 5X mice compared to age-matched WT at 8 weeks (2.68 ± 0.88 vs 1.10 ± 
0.13 AU) and 28 weeks (5.29 ± 1.74 vs 1.76 ± 0.53 AU). Two-way ANOVA indicated 
that strain factor was significant [F (1, 48) = 49.83, p < .0001, η2 = 0.255] with 5X 
having overall higher CatD levels compared to WT age-matched controls. Age factor was 
also significant with older mice having higher CatD expressions [F (3, 48) = 19.91, p < 
.0001, η2 = 0.306] compared to younger mice. The interaction of age and AD mutations 
was also significant [F (3, 48) = 12.58, p < .0001, η2 = 0.193]. Similarly, CatD expression 
in the striatum was significantly higher with 5X older age; however only at 28 weeks did 
the 5X mice present with significantly higher CatD expression in the striatum (9.35 ± 
5.83 vs 0.85 ± 0.46 AU; p < .05). Using two-way ANOVA, the 5X striatum is considered 
to have significantly higher CatD expression [F (1, 16) = 137.3, p < .0001, η2 = 0.240] 
compared with WT age-matched controls. In addition, older mice presented significantly 
higher CatD expressions [F (3, 16) = 55.85, p < .0001, η2 = 0.293] compared to younger 
mice. The interaction of age and AD mutations was also significant [F (3, 16) = 83.66, p 
< .0001, η2 = 0.439]. Lastly, hippocampal CatD expression was significantly (p <0.01) 
higher at 16 (8.47 ± 1.67 vs 4.10 ± 1.17 AU) and 28 (8.44 ± 1.42 vs 3.88 ± 0.95 AU) 
weeks of age compared to age-matched WT controls with strain factor, not age, being the 
only significant contributor to the significant differences [F (1, 24) = 33.63, p < .0001, η2 
= 0.532]. 
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Figure 2-5 Western Blots analysis. Analysis of the amount of CatD protein expression 
in the three main associated regions of the Cortex, Hippocampus and Striatum is shown 
for the 2X, 3X, 5X and WT controls. Representative blots of N=3 are shown where both 
Tg and WT lanes are on the same blot with the CatD showing on top, and the loading 
control on the bottom. The 2X and 3X shared all common age time points but only 2 with 
the 5XFAD as shown. The associated change in protein quantification is plotted on the 
right handside with respective graphs for the three brain regions. Data is mean±standard 
error of the mean (N=3). 
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2.4 Discussion 
In this study, we compare the levels of amyloid pathology across three different 
Tg strains of AD mice and WT mice, and compared these with the level of CatD. AD 
models as well as WT control were investigated at ages ranging from just over a month to 
one year after birth. The 2X, 3X and 5X Tg mouse models that were selected for this 
study have been investigated extensively to study the various aspects of early onset AD 
[18, 20, 21]. However, the pattern of progressive CatD expression over the age of mice 
has not been previously described across different strains. Here, we report for the first 
time, the quantitative analysis of CatD expression both by IHC and WB alongside the 
evaluation of Aβ42 plaque burden in three main brain regions.  
The three AD mice strains were selected because they show a range of pathology, 
with the 5XAD mice expected to show amyloid deposition more rapidly and more 
aggressively than the 2X mice, while the 3X mice were added to examine if Tau 
expression altered CatD expression. Unlike both the 2xTg and 3xTg, the 5XFAD mice do 
exhibit neuronal cell death by 9 months [18] and CatD over expression at a month 
younger age. The choice of C57Bl/6 as the control mouse strain was a compromise for 
the lack of better control (non-transgenic littermates) since all three Tg mice were 
established at least partially using this commonly used parental background mouse strain. 
These control mice are not known to develop AD pathology naturally; although they have 
been reported to develop age dependent hippocampal granular deposits similar to Tau 
pathology which were immunoreactive to Tau protein and alpha synuclein, but not to Aβ  
[23]. In addition, Lipofuscin can often be found in the hippocampus of these aging mice 
[24] but we did not suspect this to be a problem for our study.  
Through the work presented herein, we showed that the levels of CatD expressed 
in several brain regions of Tg mice were significantly enhanced with age above the levels 
measured in younger mice, as well as above the levels of the age-matched wildtype 
controls (C57Bl/6). Furthermore, the 5X mouse model presented the highest levels of 
CatD expression, followed by the 2X, then the 3X and finally the lowest in WT controls. 
Three regions were examined for protein quantification using Western blots analysis 
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including the cerebral cortex, striatum, and hippocampus. The same three regions as well 
as the thalamus were also quantified by measuring the percent DAB staining by means of 
IHC.  In addition to investigating the lysosomal enzymatic expression, measurements of 
the hallmark pathology of AD, namely Aβ42, were also performed by IHC analysis. The 
dual-assay approach allowed us to uncover data undetected by the WB analysis as well as 
provide spatial understanding of the AD-like pathology developed in the Tg mice studied. 
The time course of plaque deposition and Cathepsin D staining in the mice is required to 
allow an optimized selection of the appropriate animal model for the purposes of testing 
CatD targeting contrast agents that may help with early diagnosis of AD.  
Although there have been a number of observations of lysosomal upregulation in 
human AD brains [2-5, 25], it was not clear if lysosomal upregulation would be a 
uniform feature in mouse models. A few, previous studies have made the observation of 
lysosomal enzymes upregulation in the 5X mouse model [22, 26] which were in 
agreement with the human AD brains pathology. Enhancement of CatD expression has 
been argued to be the result of an enhanced neuronal expression, activated glial cells, or 
neuritic plaques [22].   But it remains unclear whether these changes in CatD expression 
are the cause of, or simply correlated to AD pathology as well as other neuropathological 
conditions where upregulation of lysosomal system activity (e.g. CatD expression) has 
been observed [5]. The lysosomal system (including CatD) has been shown to be 
involved in the production and degradation of Aβ42 peptides [27-29]. But the 
enhancement of intracellular CatD in AD brains could be indicative of not only neurons 
involved in the production of the pathogenic Aβ42 peptides [2, 5, 30] but also certain 
activated microglia that are involved in the deposition and/ or removal of the pathogenic 
peptides by phagocytic pathways [31-33]. These activated microglia as well as reactive 
astrocytes involved in modulation of toxicity and Aβ degradation, have been shown to be 
located around neuritic plaques [35, 36]. In addition, some microglia surrounding the 
neuritic plaques have shown to be positive for CatD expression [22]. The observation of 
elevated lysosomal enzymes in skin fibroblast from AD patients [34] suggests that 
lysosomal defects might be systemic in AD.  Alternatively, a recent study suggests the 
accumulation of CatD in neurons first, followed by microglia and astrocytes, is associated 
both spatially and temporally with intracellular cholesterol accumulation and 
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neurodegeneration as was shown in a non-AD mouse model [37]. As for extracellular 
lysosomal enzymes, the origin of these in plaques remains unsettled. No loss of neurons 
has been reported in either 3X or 2X Tg mice lines used and so the measured CatD 
activity above base-line levels may likely be extracellular deposition of the lysosomal 
enzymes due to their release from intact cells or from vulnerable neurons  attempting to 
regulate their environment [4]. In contrast, the 5X Tg mice used in this study have been 
shown to present neurodegeneration and neuronal loss [18] and therefore may have 
supplemental CatD staining originating from lysed neurons burdened with excessive 
intracellular Aβ42 pathology, releasing their cytoplasmic contents into the extracellular 
space to form neuritic plaques [38].  
On analyzing the Aβ42 staining, there was a clear propensity for the 5X to stain 
positive compared with all other Tg mice as was seen by the early and progressive 
accumulation of plaques and intracellular accumulation of Aβ42 in the hippocampus, 
cortex and thalamus over time. While the 3X mice presented with very limited 
extracellular Aβ42 and plaque formation until the very last two time points (aged 44 and 
60 weeks) this was in agreement with another longitudinal study of this strain showing 
progressive accumulation of extracellular Aβ42 in plaques only at and after 12 months of 
age [39]. Our observation that CatD expression correlates with severity of AD pathology 
in the 5X mice (i.e. heavy lysosomal system involvement with heavy Aβ42 positive 
plaques) is supported considering the 5X mice present a very aggressive pathology as 
well as CatD overexpression compared with 2X and 3X Tg mice. This coincides with 
previous observation that lysosomal receptors/ enzymes levels were enhanced profoundly 
in Tg mice, which exhibit high Aβ42 levels and deposition [22]. Interestingly, and 
potentially important for future trials of CatD investigation as an AD biomarker, was the 
faster increase of CatD expression in the hippocampus of both 2X and 5X models as well 
as the cortex of 2X compared to the increase in Aβ42 synthesis measured over the age of 
the mice. 
 A potential weakness of the study was the difference between antigen retrieval in 
IHC and protein processing in WB. Specifically, no formic acid was used in the tissue 
preparation for WB, and therefore it is likely that some CatD not solubilized and trapped 
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in insoluble plaque formations within the homogenized tissue lysates. This means the 
WB analysis could have a bias for under-estimating the amount of CatD available. 
Alternatively, while the pretreatment of AD tissues using formic acid for IHC enhances 
the immunological detection of extracellular plaques, it might have an opposing effect on 
intracellular Aβ peptides [40]. In addition, the different Tg mice express different 
mutations, and therefore could have produced different formation of oligomers and 
consequentially differently formed plaques that as consequence could require separate 
optimization for staining using the same Aβ42 antibody. Finally, considering the report of 
3X mice developing plaques as early as 6 months, the location of our IHC investigation 
was concentrated on a more posterior region that allowed the visualization of the striatum 
(caudoputamen), the thalamus, the cortex (isocortex) and the hippocampal formation. It is 
therefore possible that the earlier pathology reported by others [16, 21, 41] was missed.   
 In summary, we report a significantly progressive accumulation of CatD in both 
intracellular compartments as well as extracellular plaques in the 5X mouse model 
correlated to an aggressive Aβ42 pathology. This was mirrored but to a lesser extent in our 
findings from the 2X mouse model. The 3X mouse model presented a smaller distribution 
of plaques within the examined areas and reduced CatD expression compared with the 
age-matched 5X and 2X counterparts. Overall, CatD expression depended on both AD 
mutations load and age.  These studies demonstrate that CatD lysosomal enzyme 
expression correlates with AD pathology, showing that CatD may be a suitable biomarker 
for following AD progression. 
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3.1 Introduction 
An estimated 115 million people will have dementia by 2050 worldwide with 
Alzheimer’s disease (AD) being the most common cause [1]. The first description of AD 
over a century ago highlighted neurofibrillary tangle (NFT) and amyloid plaque 
accumulation [2] as two pathological changes associated with the disease. These have 
remained central to the post mortem confirmation and definitive diagnosis of AD to this 
day; however, the development of AD involves many subcellular and morphological 
features associated with loss of synapses [3], mitochondrial dysfunction and oxidative 
stress [4] and neuro-vasculature disruption [5, 6]. Currently, diagnosis of AD is based 
upon clinical assessment and although biomarkers have been proposed, these are not 
uniformly recommended for clinical use.  This problem has taken on urgency, as several 
promising clinical trials may have failed, because treatment was initiated too late in the 
disease, when irreversible synaptic and neuronal loss had already occurred [7-11]. 
The development of imaging biomarkers provides a means to non-invasively 
detect brain changes associated with AD to monitor disease progression and the effects of 
treatment. Imaging biomarkers include brain structural changes [12], blood flow [13, 14], 
function [15], and glucose utilization [16, 17]. Recently, positron emission tomography 
(PET) imaging with the 11C-labelled Pittsburgh compound B, or PIB [18] has provided 
insight into the accumulation of amyloid pathology in the brain. PIB binding correlates 
with cerebral atrophy [19], it inversely correlates with cerebral glucose metabolism [20], 
and it strongly relates to the degree of memory impairment [21]. However, some studies 
have also shown PIB uptake in a significant proportion of non-demented elderly controls 
[22].  Moreover, many anti-amyloid treatments have failed in clinical trials and therefore 
interest in NFT pathology has intensified [23]. Imaging this biomarker, an aggregate of 
hyperphosphorylated Tau protein, could provide important information about the course 
of the disease [24]. Novel ligands targeting NFT have shown promise in murine models 
of AD [25, 26] and more recently in humans [27, 28]. Currently, however, the 
aforementioned biomarkers are hampered by variability and are frequently positive in 
normal older patients [7, 23, 29] sometimes more than 15 years before clinical symptoms 
[30]. 
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One possible novel biomarker for AD is Cathepsin D (CatD). CatD is a lysosomal 
aspartic endopeptidase (EC 3.4.23.5) involved in normal protein turnover associated with 
tissue homeostasis including tissue renewal, remodeling, and regulation of aging and 
programmed cell death [31]. However, CatD is elevated within brain parenchyma and the 
cerebrospinal fluid of AD patients and active CatD is present at high levels in amyloid 
plaques [32-34].  In addition, increased expression of CatD has been proposed to be the 
earliest histopathological feature of AD [33]. Therefore, there is increasing interest in 
developing molecular imaging techniques targeting CatD for the early diagnosis of AD 
[35]. 
Animal models provide a consistent platform for testing early diagnostic 
techniques and can provide insight into the etiology and pathophysiology of human 
neurodegenerative diseases [36]. Transgenic (Tg) mice are the most common model of 
AD, while very few rat [37], and even fewer non-human primate models exist [37-39]. 
Although many different Tg mouse strains are available, the 5XFAD model [40] has 
several key features requisite for AD modeling. These mice rapidly accumulate cerebral 
pathogenic amyloid protein (Aβ) that begins at two months and reaches a very large 
burden by nine months.  They are also characterized by hippocampal synaptic 
dysfunction as early as six months [41], and impaired memory as well as neuronal loss 
and synaptic degeneration by nine months that worsens by 12 months [40]. Furthermore, 
previous work using this strain showed co-localization of the CatD enzyme with intra-
lysosomal Aβ aggregates at one month of age [42] and increased CatD expression 
compared to non-transgenic controls at 3.5 months [43]. The latter suggests that this 
strain is an appropriate platform for investigating contrast agents (CA) targeting CatD.  
The passage of molecules from the circulation across the blood brain barrier 
(BBB) into the brain is highly selective, making drug delivery difficult [44-47].  Most 
CAs do not normally cross the BBB unless it is damaged.  One strategy to deliver 
contrast agents into the brain is to use cell penetrating peptides (CPP) [48]. One CPP is 
derived from Tat peptide (YGRKKRRQRRR) of the HIV-1 virus, which allows transport 
both into and out of the brain [48]. This CPP has been explored for drug delivery [49] as 
well as cellular delivery of CAs [50].  It is believed that hydrophilic arginine-rich CPPs 
 95 
 
such as HIV-1 Tat may be transported across membranes by direct penetration at high 
concentrations [51], and by endocytosis at lower concentrations [52], although there is no 
consensus on the mechanism of uptake and maintenance of functionality of cargos after 
delivery [53].  
We have previously described a dual modality (MRI and fluorescence) CatD 
targeted CA consisting of an imaging moiety conjugated to a peptide composed of a CatD 
cleavage site and a CPP [54, 55]. The CPP allows transport across membranes 
bidirectionally.  In regions with increased CatD activity, cleavage at the CatD site 
removes the CPP, causing prolonged retention of the imaging moiety. Because each CatD 
enzyme molecule can cleave many substrate CA molecules, this strategy potentially 
offers amplification compared to contrast agents that depend on target binding. We have 
shown that this CA is taken up preferentially by cultured cells overexpressing CatD [54]. 
In addition, it exhibited a distinct difference in uptake and retention over a two-hour 
period post administration in an APPswe, PSEN1dE9 Tg mouse model compared to wild-
type mice in ex-vivo studies [55]. In the current study, we have conjugated this agent with 
IRDye800, a near infra-red (NIR) fluorescent dye that can be detected though several 
centimeters of tissue [56] and exhibits a much higher fluorescence than the commonly 
used NIR dye indocyanine green [57].  This fluorophore has increased stability in blood 
[58] and is non-toxic at doses up to ~428 nmol [59].  As little as 5 pmol [58, 60] of this 
dye is required for detection in rodents.  This new agent is suited for in-vivo, non-
invasive optical imaging to examine CA washout kinetics following intravenous (IV.) 
administration in small animals as a proof of concept, but will naturally fall short in its 
applicability in the clinic due to the significantly thicker human skull. 
 The objective of this study was to evaluate the uptake and washout kinetics of the 
newly modified CA in vivo in 5XFAD transgenic AD and wild-type (WT) control mice 
using NIR optical imaging. We hypothesized that the agent would be preferentially 
retained in the brain of 5XFAD Tg mice compared to WT mice. To better understand the 
mechanism of uptake of this agent we compared washout kinetics for three similar CAs 
in 12 month old 5XFAD and WT mice: 1) a diagnostic CatD Targeted agent having an 
imaging moiety, a CatD cleavage site and a CPP, 2) a control Non-Penetrating agent 
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having an imaging moiety, an incomplete CatD cleavage site lacking the CPP, and 3) a 
control Non-Targeted agent having only an imaging moiety and a CPP but no CatD 
cleavage site. Here we show that the cell penetrating CatD Targeted CA is taken up and 
retained more efficiently in the brain than the Non-Penetrating and Non-Targeted agents, 
and that this agent can distinguish AD mice from wild type mice at 5 months and 12 
months of age. 
3.2 Materials and Methods 
3.2.1 CA synthesis and characterization 
The IRDye800 from LI-COR Biosciences (Lincoln, NE, USA) was chosen for 
NIR detection (part of the detection probe along with the chelated Gd3+ lanthanide metal). 
Peptide sequences were assembled on a Wang resin using a standard solid phase peptide 
synthesis protocol (59).  Conjugation of DOTA-derived terminal monomer and 
subsequent HPLC purification of peptides 1a-c was performed as previously described 
[54, 55] (Fig. 3-1).  In separate reaction vessels (Falcon tubes) peptides 1a (4.2 mg, 1.2 × 
10−6 mol), 1b (0.7 mg, 3.0 × 10−7 mol) and 1c (2.7 mg, 1.5 × 10−6 mol) were treated with 
the solution of IRDye 800CW maleimide (2; 1.4 mg, 1.2 × 10−6 mol, peptide 1a; 0.4 mg, 
3.0 × 10−7 mol, peptide 1b; 1.8 mg, 1.5 × 10−6 mol, peptide 1c) in acetonitrile (200 μL, 
peptide 1a; 100 μL, peptide 1b; 400 μL, peptide 1c) and water (1 mL, peptide 1a; 400 
μL, peptide 1b; 1.6 mL, peptide 1c).  The tubes were set aside for 48 h at room 
temperature in the dark (wrapped in the Al foil).  The solvents were removed by 
lyophilization, the residues were dissolved in acetonitrile (200 μL, peptide 1a; 50 μL, 
peptide 1b; 300 μL, peptide 1c) and water (1 mL, peptide 1a; 100 μL, peptide 1b; 300 
μL, peptide 1c) and 0.1 M solution of GdCl3 · 6H2O (38 μL, 3.8 × 10
−6 mol, peptide 1a; 
10 μL, 1.0 × 10−6 mol, peptide 1b; 30 μL, 3.0 × 10−6 mol, peptide 1c) was added.  The 
tubes were set aside for another 48 h at room temperature in the dark (wrapped in Al 
foil).  The solvents were removed by lyophilization, the residues were dissolved in water 
and were purified by dialysis (for 5 days) using a membrane with a molecular weight cut-
off of 500 Da.  The solutions were lyophilized to produce the desired peptides 3a-c as  
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Figure 3-1. Synthesis of the different CAs. CatD Targeted (3a), Non-Targeted (3b) and 
Non-Penetrating (3c) conjugates used in this study 
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green solids.  The conjugates were characterized by high resolution electrospray 
ionisation mass spectrometry (HR-ESI-MS) as follows: 
Conjugate 3a (1.9 mg, 35%), HRMS (ESI) m/z: found 4512.0560 [M-2H]+ 
(4512.0456 calculated for C194H299N56O49S5Gd). 
Conjugate 3b (0.9 mg, 90%), HRMS (ESI) m/z: found 3387.3570 [M-2H]+ 
(3387.3615 calculated for C137H210N42O39S5Gd). 
Conjugate 3c (4.2 mg, 78%), HRMS (ESI) m/z: found 2584.8555 (formic acid 
adduct) [M-2H]+ (2584.8543 calculated for C110H152N18O34S5Gd).  
The three conjugates were named according to their functional characteristics: Conjugate 
3a (Fig. 3-1) was dubbed the CatD Targeted or diagnostic CA (having a CatD cleavage 
site and a CPP), conjugate 3b (Fig. 3-1) was dubbed the Non-Targeted CA (having only a 
CPP), and conjugate 3c (Fig. 3-1) was dubbed the Non-Penetrating CA (having only a 
partial CatD cleavage site, similar to what remains following cleavage by an active CatD 
enzyme). 
3.2.2 CA optical properties 
Optical properties were characterized using a SpectraMax M5 spectorphotometer 
plate reader (Molecular Dynamics Devices, Sunnyvale, CA USA). The optimal excitation 
wavelength of our CA was determined for emission at 845 nm using excitation between 
600 to 820 nm (no cut-off filter, high precision reading, and 2 nm step size).  The optimal 
emission wavelength was made at wavelengths ranging from 790 to 850 nm following 
excitation at 780 nm. To control for backscatter and lamp light contamination, the 
purified milli-Q water fluorescence values were subtracted from all other measurements. 
Furthermore, to measure CA fluorescence following cleavage with the targeted enzyme 
(C3138-10UN; Sigma-Aldrich Canada Co. Oakville, Ontario), 25 µM solutions of either 
CatD targeted, non-penetrating, or non-targeted CA were maintained at 37°C and a low 
pH (~4.5) to replicate in-vivo lysosomal conditions.  Six wells were used to test each 
CatD targeted CA but three wells also included the CatD enzyme (0.7 µM) incubated 
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with the CA for ~30 minutes.  Additionally, the fluorescent signal from each sample was 
measured as a function of time using the eXplore Optix system (GE Healthcare, 
Milwaukee, Wisconsin). The fluorescence signal was examined in both the eXplore 
Optix system and the SpectraMax M5 Molecular Devices plate reader by measuring the 
signal from 1.35, 2.75, 5.5 and 11µM concentrations of the CA corresponding to 0.27, 
0.55, 1.1 and 2.2 nmol respectively.  These solutions were placed in a black solid Costar 
96-well plate (Corning Life Science, Tewksbury MA USA). 
3.2.3 Animals 
All animal studies were conducted in accordance with the guidelines of the 
Subcommittee on Animal Care at Western University, conformed to the Canadian 
Council on Animal Care guide for the care and use of laboratory animals as well as the 
ARRIVE guidelines. B6SJL-Tg (APPSwFlLon, PSEN1*M146L*L286V) 6799 
Vas/Mmjax transgenic mice, commonly known as the 5XFAD line Tg6799 of a C57Bl/6 
and B6SJL hybrid background and age-matched wild type C57Bl/6 (both from Jackson 
Laboratories, Bar Harbor, ME, USA) were used for this study. The 5XFAD mice 
overexpress human APP(695) with the Swedish (K670N, M671L), Florida (I716V), and 
London (V717I) Familial Alzheimer's Disease (FAD) mutations and the human PS1 gene 
harboring two FAD mutations, namely, M146L and L286V [43].  
There was no significant difference in average mouse weight (5XFAD: 23.1 ± 
1.6g; WT: 23.5 ± 2.5g) between the groups at five months, however at 12 months, the 
body weight of the 5XFAD mice (23 ± 1.5g) was significantly lower (p<0.05) than the 
WT mice (31 ± 1.9g). 
3.2.4 Experimental Design 
To examine whether the CatD Targeted diagnostic CA could be used to 
differentiate between old 5XFAD mice having progressive disease pathology and old yet 
healthy control mice, six (N=6) 5XFAD and six (N=6) age-matched WT (C57Bl/6) 
control mice were studied at 12 months of age. To determine whether observed 
differences could be attributed to the targeting and BBB penetrating moieties attached to 
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the CA, the uptake and washout of the three different CA versions were compared. The 
ability of the CatD Targeted CA to differentiate between the 5XFAD and WT control 
mice at an earlier disease stage was also studied at five months of age. 
3.2.5 Optical Imaging 
Animals were kept warm (~37°C) using a latex glove containing warm water 
placed over the lower back and extremities.  The warm water was replaced every 10 
minutes. Two animals were scanned simultaneously using a Y-shape nose cone for 
isofluorane anesthesia with a scavenger system connected to a charcoal filter. Hair was 
removed from the scalp using an electric razor, and depilatory agent (e.g Nair; Brookvale 
Australia) prior to optical imaging. All mice received an intravenous injection of 5 nmol 
CA suspended in 200 µL PBS through a tail catheter. One (N=1) 5 month old 5XFAD 
mouse received a subcutaneous (sc) injection in the flank to examine the time delay for 
peak fluorescent signal. 
Optical imaging was performed using the eXplore Optix system (GE Healthcare, 
Milwaukee, Wisconsin); a reflectance-based, raster scanning, time domain optical 
imaging system with a 3 mm source–detector distance.  An 80 MHz, 780 nm pulsed 
diode laser (picoQuant, Berlin, Germany) was employed with a 10 nm FWHM bandpass 
excitation filter centered at 780 nm (Thorlabs, Newton, New Jersey).  Light was collected 
with a 55 nm FWHM bandpass excitation filter centered at 845 nm (Chroma Technology 
Corp., Bellows Falls, Vermont). The maximum power output of the laser at the surface of 
the sample or animal did not exceed 10 µW, and signal was collected with an integration 
time of 100 ms resulting in an image acquisition time of ~2 minutes. Images were 
acquired for a maximum duration of 4.5 hours (270 minutes), with a variable temporal 
step size depending on the magnitude of the observed signal changes.  The horizontal 
level of heads of both animals was manually adjusted to be of equal distance to the 
detector. Optimization was performed prior to execution of the experiment as well as 
considerations to utilize the time-domain imaging capacity of the scanner as is shown in 
Appendix 2. However, only the intensity of the light (amplitude) was considered for 
purposes of this preliminary work.  
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3.2.6 Optical Signal Analysis 
All optical signal data were recorded as photon counts per second for each pixel.  
Optical signal maps were analyzed using ImageJ 1.46r (National Institutes of Health 
U.S.A). Statistical analysis was performed using Prism 5 (GraphPad Software, Inc. CA 
USA). The average fluorescence signal (average pixel intensity ± standard deviation) 
time course from within a selected region of interest (ROI) was used for analysis.  Unless 
otherwise stated, the ROI was drawn around only the head region visualized under plain 
white light (WL).  The baseline signal amplitude was centered at zero by subtracting the 
background signal measured prior to the injection of agent.  To equalize the step sizes, a 
piecewise cubic Hermite interpolation was applied to the data and binned into 1 minute 
intervals using MATLAB (The MathWorks, Inc., Natick, Massachusetts, United States.). 
For all parameters excluding the absolute peak enhancement values, the CA signal was 
normalized to the maximum intensity. The CA washout following maximum peak 
enhancement was modeled and fitted using a least squares minimization method in Prism.  
The model function incorporated a constant maximum enhancement period followed by a 
one phase exponential decay [Eq 1] to determine the washout coefficient (λTotal) and 
asymptote (Plateau Total). 
Eq 1.    ( )  {
                                                                                                       
               (               ) 
       (    )         
 
The initial values of Y0 (Y-intercept) were set to 1 because the data were 
normalized. T0, the time delay from CA administration to washout was fitted by Prism to 
account for variability in the start time of observed CA washout, and the asymptote 
PlateauTotal was restricted to values greater than zero.  The latter constraint is reasonable 
because the CA will not clear from the body completely within the scan time allotted for 
the current study, however, we observed the signal return to baseline levels (N=2) within 
24 hours; data not shown. For statistical purposes, the extra sum-of-squares F-test was 
used to compare the parameters λTotal and PlateauTotal between groups with a p-value < 
0.05 required to achieve significance.   
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The time delay following maximum enhancement to signal washout (T0,), the absolute 
maximum peak signal intensity value (SImax), the linear slope (SI2hrs−SI1hrs) between the 
signal at one hour post injection (SI1) and the signal at two hours (SI2) post injection, and 
the attenuation coefficient for data collected during the first hour post peak enhancement 
(λ1hr) assuming a plateau of zero were measured in each animal. Both SI2hrs−SI1hrs and λ1hr 
were calculated to provide a straight-forward metric that could be easily applied in 
patients. A Student’s t-test was used to compare parameters between the different groups 
with a p-value < 0.05 required to achieve significance. Receiver Operating Characteristic 
(ROC) curve analysis was performed using the Prism 5 built-in analysis tool with 95% 
confidence level to determine whether CA washout parameters (T0, λ1hr, and SImax) could 
differentiate between the AD model to WT control mice. 
3.2.7 Cathepsin D Expression in Brain Tissue 
WT and 5XFAD mice (4 and 12 months old) were perfused with saline followed 
by 10% neutral buffered formalin (NBF). Brains were dissected and immersed in 10% 
NBF for 24 hours, embedded in paraffin, and 5 µm sections were cut. Antigen retrieval 
was performed using formic acid (70%, 2 minutes) and sections were immunolabeled 
with antibody against CatD (1:200; C-20 sc-6486 from Santa Cruz Biotechnology; Santa 
Cruz, CA, USA).  This antibody was detected using an anti-goat secondary antibody 
conjugated to horseradish peroxidase, prior to colorimetric detection using nickel 3,3’-
diaminobenzidine (DAB; 0.15 mg/ml in 0.03% H2O2; Sigma-Aldrich, Oakville,ON, 
Canada) with the Vectastain ABC kit (Dako, Burlington, ON, Canada) and 
counterstaining with Hematoxylin and Eosin (H&E; Leica Microsystems Inc.  Concord, 
Ontario, Canada). Sections were imaged and digitized using a TISSUEscope CF slide 
scanner (Huron Technologies, Waterloo, ON) at a 0.5 µm resolution using bright field 
imaging (at 40X). Staining area was measured in three regions (each covering >200,000 
µm2) of primary somatosensory cortex in each of three sections per mouse, in each of 
three mice per group using ImageJ (v. 1.46r, http://rsbweb.nih.gov/ij/) with staining 
identified using the color deconvolution plugin written by Dr. Gabriel Landini (available 
via the aforementioned website) and quantified using the ImageJ built-in threshold tool. 
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3.3 Results 
3.3.1 CA Optical Properties 
Measuring the fluorescence at 845 nm, each CA had an excitation peak at 780 nm 
(similarly to non-conjugated IRDye800). We then measured the emission intensity 
spectrum for all three CA variants using an excitation laser at 780 nm. The CatD 
Targeted (Fig. 3-2 A, blue triangles) and Non-Targeted (data not shown) agents had a 
similar peak emission centered at ~805 nm.  The Non-Penetrating CA (Fig. 3-2 A, green 
circles), lacking the CPP, produced higher peak at a slightly lower wavelength, which 
could not be fully measured because it overlapped with the excitation light source. The 
CatD Targeted CA incubated with the CatD enzyme (Fig. 3-2 A, red triangles) produced 
an intermediate curve with significantly higher fluorescence than the intact, CatD 
Targeted CA at wavelengths below 800 nm.  Furthermore, the Optix eXplore pre-clinical 
scanner measurements of the CatD Targeted CA after CatD enzyme addition showed a 
gradual increase in fluorescence over time, to about 1.5 times the original signal (Fig. 3-2 
B). The optical fluorescent signal changes detected using the M5 plate reader (Fig. 3-2 C) 
were linear with CA concentration (em/ex 780/845 nm; R2=.986) and correlated strongly 
(Pearson correlation R2=.97; p =0.01) with the optical signal measured using the Optix 
eXplore pre-clinical scanner measurements (Fig. 3-2 D) which were similarly linear with 
CA concentration (R2=0.997). 
3.3.2 Optical Signal Dynamics 
An example of the NIR imaging data acquired on the GE eXplore Optix scanner is shown 
in Figure 3-3. Following injection of the contrast agent, signal was acquired from the 
head (Fig. 3-3A; white rectangular ROI) to produce images. Signal changes from ROIs 
over the brain (Fig. 3-3A; red elliptical ROI) and from the skin and soft tissue over the 
neck (Fig. 3-3A; green ROI) were examined. Generally, optical signal increased rapidly 
following injection, reached a peak value, and then declined over time; a typical curve is 
shown in Figure 3-3B.  The signal from the skin/neck was more than 10 fold lower than 
the signal from the brain region.  
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Figure 3-2. Fluorescence characteristics of the CAs. A. Emission spectrum observed 
using the M5 plate reader at different wavelengths following excitation at 780 nm for the 
CatD Targeted CA (blue), the Non-Penetrating CA (green) and the CatD Targeted CA 
incubated with CatD (red). The CatD Targeted agent has a peak width of about 15 nm 
(FWHM) centered at ~805 nm, whereas the Non-Penetrating agent has a peak emission 
centered below 790 nm (Not shown). B. Relative fluorescence intensity of the CatD 
Targeted CA when interacting with a CatD enzyme measured using the GE Optix 
eXplore optical scanner. The fluorescent signal intensity, normalized to the signal 
intensity prior to enzyme addition (0.7 µM), increases to ~1.5 times the baseline level one 
hour after incubation with the enzyme at 37°C. The fluorescence measurements by both 
C. M5 plate reader (red) and D. eXplore optix (blue) for the same concentrations of CatD 
targeted CA in PBS are shown where regression lines for each set are plotted. 
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Figure 3-3. Uptake and washout of the CatD targeted CA in a 5XFAD mouse. The 
NIR signal is collected over time from an ROI (white outline in A) with associated 
pseudo color bar indicating photons/second (A). The brain signal is then analyzed from 
an elliptical ROI (red outline in A; red data in B) drawn over the brain region and a 
control region closer to the neck (green outline in A; green data in B). Representative 
images of signal intensity are shown (left to right; I to IV) that correspond to epochs 
designated by the assigned letters on the NIR intensity curve (B). Analyzed variables 
include (some are indicated in B): the time delay from CA administration to washout 
(T0), the peak signal intensity (SImax), the exponential signal decay coefficient for the 
duration of each scan (λTotal), the signal value at asymptote (plateauTotal), the exponential 
signal decay coefficient for 1 hour washout (λ1hr), the signal intensity at 1 hour and 2 
hours after injection (SI1and SI2 respectively) and their associated signal decay rate 
(SI2hrs−SI1hrs). 
More importantly, there were no significant differences observed in the uptake/washout 
kinetics of the CatD targeted CA between 5XFAD and WT mice in the skin/neck region 
(data not shown), therefore all subsequent analyses focus on the signal measured from the 
brain region only. The key features of the uptake and washout curve include the time 
delay to signal washout (T0), the peak signal intensity (SImax), the exponential signal 
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decay coefficient for the entire scan period (λTotal) or 1 hour washout (λ1hr) starting at peak 
value, the asymptotic signal (PlateauTotal), and lastly, the linear slope (SI2hrs−SI1hrs) 
between the signal measured at 1 and 2 hours post injection. The measured characteristics 
of these curves are summarized in Table 3-1 for the 12 month old mice and in Table 3-2 
for the 5 month old mice. 
3.3.3 Cathepsin D Targeted Contrast agent pharmacokinetics in 
12 month old mice 
The pharmacokinetics of the different contrast agents were compared in 12 month 
old WT mice (Fig. 3-4; Table 3-1).  As expected, the signal from the Non-Penetrating CA 
(green curve, Fig. 3-4) peaked very quickly following injection (T0 = 14.1 ± 2.3 
minutes;λ1hr = -1.42 ± 0.14 × 10
-2 minutes-1). The Non-Targeted CA (orange curve, Fig. 
3-4) had a slightly longer T0 (18.9 ± 3.5 minutes) with a 10% increase in signal at peak 
compared to initial measurements, and washed out more slowly (λ1hr = -1.25 ± 0.2 × 10
-2 
minutes-1).  Finally the CatD Targeted CA (blue curve, Fig. 3-4) exhibited the longest 
time delay to peak (T0 = 46.5 ± 8.2 minutes), and was cleared much more slowly (λ1hr = -
0.52 ± 0.03 × 10-2 minutes-1) than the control CAs demonstrating the prolonged retention 
of the Targeted agent requires both the CPP and the CatD cleavage site.   
The uptake and washout curves for each contrast agent were compared between 
12 month old WT and 5XFAD mice in Fig. 3-5, and the analyses of five different features 
is summarized for all groups in Table 3-1.  Following injection of the Targeted CA, the 
uptake and washout curves of the 5XFAD and WT animals are clearly separated 
throughout the experiment (Fig. 3-5 A).  Although the CatD Targeted agent shows a trend 
to take longer to reach maximum signal intensity in 5XFAD mice (72.2 ± 43.8 minutes) 
compared to controls (46.5 ± 8.2 minutes) this difference was not statistically significant. 
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Figure 3-4. CA mechanistic uptake and washout. Average optical imaging signal 
measurements for twelve-month-old WT mice injected with either the Non-Penetrating 
CA, Non-Targeted CA or CatD Targeted CA. Data were normalized to the first post CA 
administration measurement (mean ± SEM). 
The CatD Targeted agent reached a higher SImax in the 5XFAD mice (7.1 ± 0.8 × 
103 photons/s, Fig. 3-5 A) compared to the WT mice (4.6 ± 0.5 × 103 photons/s; p = 
0.019). The CatD Targeted agent washout coefficient fitted at one hour (λ1hr) for 5XFAD 
mice (-0.28 ± 0.08 × 10-2 Minutes-1) was significantly different than for the WT controls 
(-0.52 ± 0.03 × 10-2 Minutes-1; p < 0.05, Fig. 3-5 B, Table 3-1) as was the washout 
parameter λTotal (-3.68 ± 0.2 vs -0.68 ± .03 for 5XFAD and control respectively; p < 0.01, 
Fig. 3-5 B, Table 3-1). In addition, the asymptote (PlateauTotal ) was almost four times 
higher in the 5XFAD mice (82 ± 1%) compared to the control mice (23 ± 2 %, p < 0.01).  
Finally, there was a significant difference between SI2hrs−SI1hrs (-0.43 ± 0.02 vs -0.15 ± 
0.08 for 5XFAD and control respectively (Table 3-1, p < 0.01) in 5XFAD mice and WT 
controls. Taken together these results indicate that the contrast agent reached a 
significantly higher plateau in the 5XFAD mice compared to the WT mice and reached it 
faster.  
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To test whether the CatD targeted CA could differentiate between 5XFAD and 
WT mice, a receiver operating characteristic (ROC) analysis was performed 
incorporating three different parameters (T0, λ1hr, and SImax) (Null hypothesis: true area = 
0.5). For the 12 month old 5XFAD compared to WT mice, the area under the curve 
(AUC) was 0.78 (p = 0.11), 0.81 (p = 0.07) and 0.86 (p = 0.04), for T0 , λ1hour and SImax 
respectively. 
 
Figure 3-5. Uptake and washout in 12 months old WT and 5XFAD mice following 
CA administration. Non-normalized data for twelve month old mice injected with CatD 
targeted CA (A; 5XFAD in red, WT in blue), normalized shifted data for twelve month 
old mice injected with CatD Targeted CA (B; 5XFAD in red, WT in blue), mice injected 
with non-targeted CA (C; 5XFAD in red, WT in blue), and mice injected with Non-
Penetrating CA (D; 5XFAD in red, WT in blue) are shown. Data are the mean ± standard 
error of fluorescent signal as a function of time (N=6). 
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Table 3-1. Fluorescent Signal Intensity Curve Characteristics (12 months old mice). 
Data is average ± standard error (N=6) in 12 months old 5XFAD and WT mice 
following different CA injections. 
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3.3.4 Non-Targeted and Non-Penetrating Contrast Agents in 12 
month old mice 
When WT mice were injected with the Non-Targeted CA, it took significantly 
longer for the signal to reach peak enhancement (T0) compared to the 5XFAD mice 
(Table 3-1, p<0.01).  However, there was no difference between groups in the time to 
peak for the Non-Penetrating agent.  Most importantly, there were no significant 
differences between the parameters λTotal, plateauTotal, and λ1hr when comparing the 
5XFAD and WT mice after administration of either the Non-Targeted (Fig. 3-5 C) or 
Non-Penetrating (Fig. 3-5 D) CAs (Table 3-1). 
3.3.5 Cathepsin D Targeted Contrast agent pharmacokinetics in 5 
month old mice 
The uptake and washout of the CatD Targeted CA is shown in both five-month 
old 5XFAD and WT mice in Fig. 3-6 and the average fitted curve parameter values are 
provided in Table 3-2.   Although there was a trend for the T0 to be prolonged in the 
5XFAD mice vs control mice (64.1 ± 25.8 vs 39.2 ± 28.8 min), this difference was not 
significant. As with 12 month old mice, the clearance of the CatD Targeted agent at 1 
hour (λ1hr) was significantly slower in 5XFAD mice compared to WT mice (-0.62 ± 0.08 
×10-2 Minutes -1 vs. -0.92 ±0.08 ×10-2 Minutes -1; p<0.05) as was the overall clearance rate 
(λTotal ) (-1.02 ± 0.06 vs. -1.25 ± 0.03 ×10
-2 Minutes; p<0.05). However, the PlateauTotal, 
and SI2hrs−SI1hrs were not different between groups. The AUC for the ROC was evaluated 
for λ1hr (null hypothesis: true area = 0.5). For the 5 months old 5XFAD compared to WT 
mice, the AUC was significantly higher than the null hypothesis (0.89; p = 0.02) for λ1hr, 
demonstrating that this agent can successfully differentiate between WT and 5XFAD 
mice at 5 months of age.  
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Figure 3-6. CA washout in 5 months old WT and 5XFAD mice following CatD 
targeted CA administration. Non-normalized data for five month old mice injected with 
CatD targeted CA (A; 5XFAD in red, WT in blue, N=5), Normalized shifted data for 
twelve month old mice injected with CatD targeted CA (B; 5XFAD in red, WT in blue, 
N=6), Data shown is mean ± standard error of fluorescent signal as a function of time. 
 
Table 3-2. Fluorescent signal intensity curve characteristics (5 months old mice). 
Data are average ± standard error (N=6) in 5 months old 5XFAD and WT mice 
following injections of the CatD Targeted CA 
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3.3.6 CatD expression 
CatD expression was examined in primary somatosensory cortex of WT and 5XFAD 
mice at 4 and 12 months of age using histology.  Representative tissue sections are shown 
in Figure 3-7.  In these sections, CatD staining was visible intracellularly in WT mice at 
four months of age, and staining increased at twelve months of age.  The 5XFAD mice 
also showed intracellular CatD staining at both time points (Fig. 3-7; arrow heads) but 
also demonstrated CatD staining in large extracellular deposits resembling amyloid 
plaques at both ages (Fig. 3-7; arrows) In these sections, there appeared to be increase 
CatD staining in 5XFAD mice compared to wild type controls at both ages. 
The expression of CatD in these sections was quantified by measuring the area 
covered by CatD immunostaining using ImageJ (Figure 3-8). At 4 months of age, CatD 
staining covered 3.2 ± 0.3 % of the cortex in WT mice, and this increased to 16.2 ± 1.2 % 
in the 5XFAD mice  (p<0.01).  Similarly, at 12 months of age, CatD staining covered 5.8 
± 1.1 % of the cortex in WT mice, which increased to 29.5 ± 1.2 % in the 5XFAD mice 
(p<0.01).  Staining was increased with age in the 5XFAD mice (p<0.01) but not in WT 
controls. These results demonstrate that CatD expression is increased in 5XFAD mice, 
and that this difference increases with age.  
3.4 Discussion 
Here, we characterize the behavior of a novel contrast agent targeting CatD for 
the diagnosis of Alzheimer’s disease in the 5XFAD Tg Alzheimer mouse model.  The 
CA was composed of an MR/optical detection probe that incorporated a chelated 
lanthanide metal (Gd) and a NIR dye. The chelating DOTA structure allows clinically 
translatable tomographic imaging modalities to be pursued at a later time point (e.g. PET 
or MRI) without the need for any chemical structural changes. [55]. The NIR dye was 
conjugated to a known and validated [54] enzymatic hydrolysis site for CatD and a cell 
penetrating Tat peptide. The Tat peptide allows the agent to permeate the BBB and enter 
the brain in a bidirectional fashion [48].  The Tat peptide has previously been shown to 
enter into the hippocampus and portions of the cortex (known sites of heightened AD  
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Figure 3-7. Immunohistochemistry of CatD in WT and 5XFAD mice at 4 and 12 
months of age. Photomicrographs of the cortex in mice showing CatD staining (brown) 
with Hematoxylin counter staining of the nuclei (blue).  Enlarged views (×2) show the 
vicinity near the black framed rectangles. CatD staining is present intracellularly (e.g 
arrow heads) and in amyloid plaques (e.g. arrows). Scale bar 100µm. 
 
Figure 3-8 Quantification of CatD-specific DAB staining. The area covered by CatD 
staining shown in Fig.3-7 was quantitated using ImageJ software (mean ± standard error 
of the mean; N=3). Significant differences are noted with an asterisk for p ≤ 0.01. 
pathology) with at least 0.2% of the intravenous dose taken up per gram of brain [48]. 
Once inside the brain the cleavage at the CatD site removes the Tat peptide. This enables 
the diffusion of the Tat peptide out of the cell [54] while temporarily trapping the CA in 
the CNS compartment. 
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Comparing the uptake and washout between the 12-month 5XFAD mice and WT 
controls, the CatD Targeted agent demonstrated clearly different uptake and washout 
kinetics, with a higher SImax, a slower washout (λ1hr, λTotal, and SI1hr−SI2h) and a higher 
plateau.  In the five-month old the cell penetrating CatD Targeted CA exhibited a 
significantly lower rate of clearance (λ1hr, SI1hr−SI2hr) from the brain compared to age 
matched WT control mice resulting in higher CA retention.   
These results are consistent with our previous ex-vivo examination [55] of the 
uptake and washout of a similar CatD Targeted CA in 12 month old APP/PS1-dE9 
(APP/PS1) mice.  The previous study also demonstrated greater retention of the cell 
penetrating CatD Targeted agent in APP/PS1 mice compared to WT mice [55].  In the 
current study we were able to provide a more complete in-vivo evaluation of the CA 
washout kinetics with the inclusion of Non-Targeted and Non-Penetrating control agents.  
In the current study no differences in CA washout between 5XFAD and WT animals 
were observed when using the control CAs, suggesting that both the Tat peptide and the 
CatD cleavage site were required for the uptake and specificity of the agent. Additional 
control experiments with use of inhibitors targeting CatD activity would have helped 
proving the specificity of the cell penetrating CatD targeted CA. But we are unaware of 
inhibitors that have the required kinetics and ability to cross through the BBB. 
The 5XFAD mice also exhibited a significantly (p < 0.05) higher SImax compared 
to the WT control mice following administration of the Non-Penetrating CA (~35% 
higher signal in 5XFAD), Non-Targeted CA (~64% higher signal in 5XFAD) and CatD-
Targeted CA (~55% higher signal in 5XFAD). The significantly higher SImax of the 
5XFAD compared to the WT mice coincided with a significant 26% lower body weight 
(p < 0.05). Since the CA dose remained at 5 nmol/ injection regardless of weight, the 
SImax was likely higher in the 5XFAD mice as a result of an average 35% higher CA 
plasma concentration.  The fact that the Targeted and Non-Targeted agents had SImax that 
averaged 64% and 55% higher respectively implies increased uptake of the agents, and 
not merely increased plasma concentration. 
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Another possible source of increased signal in the 5XFAD mice is the change in 
structure of the contrast agent itself after interaction with Cathepsin D.  For example, the 
Non-Penetrating CA produced a higher emission intensity at a shorter wavelength 
compared to the CatD Targeted CA, while cleavage of the CatD Targeted CA by CatD 
produced an emission spectrum that was intermediate (Fig. 3-2A; red) as expected. The 
increased fluorescence of the cleaved agent compared to the intact CatD Targeted CA is 
likely due to quenching of the fluorophore by the longer amino acid peptide backbone in 
the CatD Targeted CA.  As a result, enzymatic cleavage of the CA could have 
contributed to the significant increase in fluorescence intensity in the 5XFAD mice 
compared to WT controls. 
There are several limitations that must be considered in the current study.  The 
first is that we did not asses the stability of the CA.  However, the the serum-based half-
lives of the CPP and IRDye800CW are ~8.8 hours [61] and ~8 days [62] respectively, so, 
it is unlikely that these components would degrade significantly in the 4 hour post-
injection window studied here.  We must also consider the mouse models studied.  
Although 5XFAD mice only recapitulate some aspects of the pathology observed in 
humans, this study used the 5XFAD because this model is known to have higher levels of 
Cathepsin D compared to controls [42, 43] as is the case in humans [32, 34]. Whether 
increased levels of CatD precedes amyloid pathology in 5XFAD mice similar to humans 
AD pathology [33] has yet to be shown; however, it is not a necessity for the preliminary 
investigation of our CA.  In addition, we used WT C57Bl/6 mice as the control group.  
Non-transgenic littermates would be preferred as they are a better genetic match to the 
experimental group, and further studies comparing Tg to non-Tg littermates are on-going. 
Moreover, although cerebral perfusion and vascular permeability were not measured in 
these animals, the lack of a significant difference in the washout kinetics of the Non-
Targeted and Non-Penetrating CAs between WT and 5XFAD mice suggests that these 
factors were not significantly different between these groups. Finally, due to the nature of 
the non-tomographic optical imaging used, the exact contribution of the CA accumulated 
within the brain, skull, vasculature, and skin to the detected signal is unknown. However, 
there were no significant differences in the skin signal kinetics between the 5XFAD and 
wild type animals when using the CatD targeted CA, no significant differences between 
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the 5XFAD and wild type animals when using the control CAs, and increased levels 
CatD in the brain of 5XFAD mice was validated. Therefore, we believe that the 
significant differences in observed signal kinetics between the 5XFAD and wild type 
animals are dominantly the result of preferential brain uptake in the 5XFAD mice. Future 
utilization of tomographic imaging techniques will provide further insight to the brain-
specific accumulation of the CA compared to other tissues. 
The major strengths of this study are the use of the engineered control CAs and 
the use of a NIR dye. The use of agents lacking a CPP or CatD cleavage site 
demonstrates that the uptake and retention of the CA are not non-specific, and depend on 
the CPP and the CatD cleavage. Although complicated light scattering of the NIR signal 
reduces resolution compared to Oregon Green fluorescence in our previous work, the 
NIR signal provides much higher signal-to-background contrast, and reduced auto-
fluorescence.  Furthermore, because NIR light can penetrate tissues for up to several 
centimeters, it allows imaging of the agents in live animals.  
In conclusion, we have developed a contrast agent that targets Cathepsin D and 
shows promise as a tool for the diagnosis of AD. Specifically, the measured λ1hr as well 
as λTotal with its associated PlateauTotal following administration of the cell-penetrating 
CatD Targeted CA may be used to differentiate between AD model mice and WT 
controls at 5 months and 12 months of age. At 12 months of age, SI1hr−SI2hr and 
PlateauTotal may also be used to differentiate between AD and WT mouse models. This 
study is the first to provide proof of principle for in-vivo detection of AD in an animal 
model with CatD overexpression, a unique yet validated human pathology associated 
with AD. Future studies will examine CatD expression over the lifespan of several animal 
models and correlate these findings with the development of AD pathology. 
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4.1 Introduction 
Alzheimer’s disease (AD) was first described over 100 years ago and today it is 
the most common type of dementia affecting over 750,000 Canadians, a number that will 
triple by 2050 [1]. There are two hallmark pathologies required for a conclusive post-
mortem diagnosis of the disease: the progressive accumulation of the protein fragment β-
amyloid (plaques) outside neurons in the brain and twisted strands of the protein Tau 
(tangles) inside neurons [1]. These pathological targets have been the subject of intense 
pre-clinical investigation to understand disease etiology, ongoing clinical trials [2-4] to 
delay disease progression, and FDA approved diagnostic agents (e.g. Florbetapir [5]) to 
detect the disease early. However, our inability to define the causative features of AD 
requires new non-invasive research tools. Currently, there are many techniques 
undergoing testing to detect features of AD in the clinic. These include the examination 
of the metabolic function of the brain [6], amyloid plaque (Aβ, [7]) and Tau burden [8], 
and neurotransmitter systems [9]. However, when targeting Aβ with imaging contrast 
agents (CA) the number of false positives remains high [10]; and when targeting Tau, one 
requires an accurate understanding of age-dependent normal accumulation of Tau [2, 8, 
11] and its involvement in the different forms of dementia such as frontotemporal 
dementia or other tauopathies [12]. Therefore to improve the differential diagnosis of AD 
early in the disease course, other biomarkers should be investigated to supplement 
existing tools. With no cure currently available and the most recent treatment options 
having a limited capacity for long-term symptomatic relief, it is believed an earlier and 
more specific diagnosis of AD could increase the effectiveness of new drugs or perhaps 
even drugs that have previously failed [13, 14].  
It has been suggested that brain changes caused by AD may begin as early as 20 
or more years before clinical signs [7]. In order to provide an early and specific diagnosis 
of AD it has been suggested that the lysosomal aspartyl protease, Cathepsin D (CatD), 
could serve as a potential biomarker [15-17]. Previously, we introduced a novel Contrast 
Agent (CA) that consisted of a cell penetrating peptide (CPP) derived from the Tat 
peptide of HIV-1, conjugated to a CatD cleavage sequence and an imaging moiety 
containing a fluorescent dye and a DOTA conjugate chelating gadolinium [18, 19]. The 
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cell penetrating peptide allowed the agent to bi-directionally cross the blood brain barrier.  
Once exposed to CatD, the recognition sequence was cleaved, resulting in separation of 
the CPP from the imaging probe, trapping the agent in the brain. We have demonstrated it 
to be preferentially taken up by CatD over-expressing cells, and able to transverse across 
the BBB (ex-vivo) [19]. We have also found significantly increased brain retention at five 
month and one year in a transgenic (Tg) mouse model of AD compared to age matched 
wild type (C57BL/6) controls using a near-infrared-labeled version of the CA [20]. In the 
same experiment we found no differences between mice in the uptake and washout of 
control CAs (lacking the CatD targeting moiety, or the CPP portion).  
In the current study, our primary objective was to produce and test a third 
generation CA labeled with the 68Ga isotope for imaging by PET. This modification 
resulted in a probe that allowed us to acquire tomographic images and gain 
pharmacokinetic information about the CA accumulation in the brain as well as study 
uptake and retention in different organs longitudinally. There are many different AD 
mouse models; with many that aim to reproduce amyloid pathology, Tau pathology, or 
both [21]. One particular strain, the 5XFAD, presents many AD-like characteristics such 
as amyloid pathology, cognitive decline, neuronal cell death, and synaptic disruption 
[22]. Interestingly, these mice have also shown increased levels of CatD [20, 23, 24], and 
therefore were used in the current study. The purpose of this work was to determine 
whether a CatD targeted contrast agent would show differential uptake and retention in 
5XFAD mice compared to controls using a 68Ga PET tracer. Based on previous studies, 
we hypothesized that increased retention would be evident in the 5XFAD mice.  
Additionally, considering the important role that 18F Fluorodeoxyglucose (FDG) plays in 
clinical evaluation of AD [9], the relative metabolic function of the forebrain compared to 
hindbrain was evaluated in Tg and non-Tg control mice at 10 months.   Here we 
demonstrate that our novel CatD targeting agent is preferentially retained in the brains of 
an AD mouse model. 
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4.2 Materials and Methods 
4.2.1 [
68
Ga] Cathepsin D targeted CA 
4.2.1.1 General Peptide synthesis and labeling protocol 
Reagents were commercially available and all solvents were HPLC or peptide 
synthesis grade except for water (18.2 MΩ cm-1 millipore water), aqueous solutions were 
lyophilized.  Peptides used in this study were assembled on a peptide synthesizer (CEM 
Liberty Blue) using a standard solid phase peptide synthesis (SPPS) protocol.  Rink 
Amide MBHA resin (100-200 mesh) was used, corresponding amino acid monomers 
were protected as follows: (R-Pbf, Q-Trt, K-Boc, Y-tBu, C-Trt, ‘N’ terminal-Fmoc).  
Ultra performance liquid chromatography (UPLC) was performed using a chromatograph 
(Waters Acquity) equipped with an autoinjector, HR-ESI-MS detector and a UV detector 
on a BEH C18 column (particle size 1.7μm; 1.0 id × 100 mm).  Mobile phase: Method A: 
100% H2O to 100% MeCN (both solvents containing 0.1% HCOOH) over 5 min, then 
100% MeCN over 2 min, linear gradient, flow rate 0.1 mL/min.  HPLC purification 
(Method B) was performed on a chromatograph (Waters Delta 600) equipped with an in-
line filter, an autoinjector, a fraction collector and a UV detector  using a Delta-Pak C18 
300 Ǻ column (particle size 15 μm; 8 × 100 mm Radial-Pak cartridge).  Mobile phase for 
Method B was 0 min, 99% H2O – 1% MeCN (both solvents containing 0.1% TFA) to 10 
min, 32% H2O – 68% MeCN, 3 mL/min.  Verification of radiolabeled conjugate purity 
was carried out on a chromatograph equipped with a radiodetector and a UV detector, on 
an analytical Sunfire C18 300 Ǻ column (particle size 15 μm; 8 × 100 mm). Mobile phase: 
Method C: 0 min, 70% H2O – 30% MeCN (both solvents containing 0.1% TFA) to 10 
min, 100% MeCN, 1 mL/min.  Mass spectra (MS) were obtained on a mass spectrometer 
(Micromass LCT Premier XE) using electrospray ionisation (ESI).  Radiolabeling was 
performed on a fully automated 68Ge/68Ga generator (type). 4-(2-Hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) buffer (1 M) used for radiolabeling was prepared 
by dissolving HEPES (23.8 g, 100 mmol) in water (100 mL), followed by adjusting the 
pH to 3.50. 
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4.2.1.2 Preparation of DOTA-peptide conjugate for radiolabeling 
Conjugation (Fig. 4-1A) of the DOTA terminal monomer with a peptide on the 
resin and subsequent labeling with Oregon Green (Fig. 4-1A; 2) was performed as 
described previously [18]. Crude conjugate 1 (Fig. 4-1A) was purified by semi-
preparative HPLC as described in General experimental protocols.  Pure conjugate 1 was 
obtained as 14 × CF3COO
- salt (4.1 mg, 5%, based on 0.05 mmol scale used for the 
SPPS), yellow solid, HPLC (Method B): tR 8.0 min; HRMS (ESI) m/z: found 3697.8918 
[M+H]+ (3697.9003 calcd for C166H252F2N53O40S). 
4.2.1.3 Metallation of DOTA-peptide conjugate 1 with “cold” GaCl3 
Conjugate 1 (1.8 mg, 3 × 10-7 mol) was dissolved in an acetate buffer (250 μL, pH 
3.5), followed by the addition of GaCl3 solution in water (0.002 M, 300 μL).  The 
mixture was incubated for 20 min at 80 ºC; the completion of the reaction was verified by 
mass spectrometry as described in General experimental protocols.  The mixture was 
transferred to a centrifuge tube, was frozen and was lyophilized.  The residue was used as 
a “cold” standard for radiotracer 3 (Fig. 4-1A) without further purification, HPLC 
(Method C): tR 2.52 min; HRMS (ESI) m/z: found 3764.7918 [M-2H]
+ (3764.7937 calcd 
for C166H248F2N53O40S
71Ga). 
4.2.1.4 Radiolabeling of conjugate 1 
A solution of conjugate 1 (0.1 mg, 1.9 × 10-8 mol) in water (190 μL) was added to 1 M 
HEPES buffer (700 μL) in a sterile vial.  A solution of 68GaCl3 in 0.1 M HCl was eluted 
into the vial to reach an average (± standard deviation of the mean) activity of 303.9 ± 
102.0 MBq as described in General experimental protocols.  The vial was incubated for 
10 min at 100 ºC, followed by solid phase extraction on Waters light tC18 Sep-pak 
cartridge, consecutively eluting with water (2 mL) and EtOH (2.5 mL).  Radiolabeled 
peptide 3 was obtained as a solution in EtOH (in a sterile vial), the activity of the peptide 
solution was 53.5 ± 14.5 MBq, at a radiochemical yield of 60.3 ± 3.5 with a specific 
activity of 2.0 ± 0.5 GBq/μmol.  EtOH was removed by a stream of N2 at 80 ºC; the 
residue was subsequently used for the animal studies as described below.   
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Figure 4-1. Contrast Agent Synthesis. A. Reaction of conjugate 1 with the Oregon 
Green (2) and subsequent radiolabeling with 68GaCl3 to produce peptide 3. B. HPLC 
chromatograms (Method C) of radiotracer 3 (top) and corresponding “cold” standard 
(bottom). 
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The purity of radiotracer 3 was verified by HPLC (General experimental protocols, 
Method C, tR 2.50 min), by comparison with the chromatograms corresponding to the 
“cold” standard described above (Fig. 4-1B). 
4.2.2 Fluorodeoxyglucose (18F) Radiotracer 
Fluorodeoxyglucose (18F-FDG; or simply FDG) was synthesized (Nordal 
Cyclotron & PET Radiochemistry Facility) in accordance to standard procedures. An 
average activity of ~500MBq was available as residual from earlier clinical use and was 
transferred for research purposes.  
4.2.3 Animals 
All animal studies were conducted in accordance with the ARRIVE guidelines as 
well as the Subcommittee on Animal Care at The University of Western Ontario, and 
conformed to the Canadian Council on Animal Care guide for the care and use of 
laboratory animals. B6SJL-Tg (APPSwFlLon, PSEN1*M146L*L286V) 6799 
Vas/Mmjax transgenic female only mice (Jackson Laboratories, Bar Harbor, ME, USA), 
commonly known as the 5XFAD line Tg6799 of a C57Bl/6 and B6SJL hybrid 
background and age-matched non-transgenic littermates were used for this study. The 
5XFAD mice overexpress human APP(695) with the Swedish (K670N, M671L), Florida 
(I716V), and London (V717I) Familial Alzheimer's Disease (FAD) mutations and the 
human PS1 gene harboring two FAD mutations, namely, M146L and L286V [24] known 
to develop significant Aβ plaques. Animals had access to food (2018 Teklad Global 18% 
Protein Rodent Diet, Harlan Laboratories) and water ad libitum and were kept in a 12 
hour light/dark cycle, housed in rooms with temperature and humidity controls, within 
standard mouse shoebox-type cages (maximum four, minimum two mice per cage) 
supplied with nestlets (Ancare) and Bed-o’Cobs® Combo bedding (The Andersons Lab 
Bedding). Using the resource equation [25], having two groups consisting of 5-7 mice 
each has an adequate probability of finding a significant result while minimizing the 
number of animals used. Specific details of the number of mice examined for each 
experiment, age and weight are recorded in Table 4-1.   
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Table 4-1: Experimental information of microPET study. 
 N Strain Age (months)  Weight (g) 
CatD targeted CA     
 1st TP 6 Tg 2 20 ± 1 
  5 Non-Tg 2 20 ± 2 
 2nd TP 7 Tg 6 23 ± 2 
  6 Non-Tg 6 23 ± 2 
 3rd TP 6 Tg 9  22 ± 1* 
  5 Non-Tg 9 26 ± 1 
FDG      
 3 Tg 10 21 ± 2* 
 3 Non-Tg 10 28 ± 2 
*denotes Tg value is significantly different from the non-Tg (P < 0.05); TP – time point. 
 
4.2.4 Aβ42 pathology in brain tissue 
5XFAD mice (~12 months old) were perfused with saline followed by 10% 
neutral buffered formalin (NBF). Brains were dissected and immersed in 10% NBF for 
24 h, embedded in paraffin, and 5 µm sections were cut. Antigen retrieval was performed 
using formic acid (70%, 2 min) and sections were immunolabeled with antibody against 
Aβ42 (1:200; made in-house). This antibody was detected using an anti-rabbit secondary 
antibody conjugated to horseradish peroxidase, prior to colorimetric detection using 
nickel 3,3’-diaminobenzidine (DAB; 0.15 mg/ml in 0.03% H2O2; Sigma-Aldrich, 
Oakville, ON, Canada) with the Vectastain ABC kit (Dako, Burlington, ON, Canada) and 
counterstaining with Hematoxylin and Eosin (H&E; Leica Microsystems Inc.  Concord, 
Ontario, Canada). Sections were imaged and digitized using a TISSUEscope CF slide 
scanner (Huron Technologies, Waterloo, ON, Canada) at a 0.5 µm resolution using bright 
field imaging (at 40X). 
4.2.5 microPET Imaging 
Imaging was performed using the Inveon preclinical PET system (Siemens 
Medical Solutions, Knoxville TN, USA) on transgenic and non-transgenic age-matched 
littermate mice using list mode scanning. Acquisition, histograms, and reconstructions 
were all performed using the Siemens Inveon acquisition and reconstruction software 
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supplied with the scanner.  An energy bandwidth of 350 to 650 keV was used for 
acquisition with a timing window of 3.432 nanoseconds. Decay correction and detector 
normalization were applied, excluding attenuation and scatter corrections due to the small 
size of the mouse body. Histograms were set using separate delay handling, global 
deadtime correction, and 79 ring difference for maximum sensitivity [26]. Reconstruction 
was accomplished using the Ordered-Subsets Expectation Maximization (OSEM3D) with 
ordinary Poisson Maximum a posteriori OP-MAP (2 OSEM3D iterations, 18 MAP 
iterations) algorithm to produce a 3D data set with a resolution of 128×128×159 and a 
voxel size of 0.78×0.78×0.80 millimeter in the x-, y- and z-directions. Animals were kept 
warm (~37°C) using a heat lamp before, during and immediately after the imaging 
session with body temperature monitored by rectal probe. Anesthesia was achieved using 
a nose cone to supply isofluorane (<1.5%) with a scavenger system connected to a 
charcoal filter. The mice head and body were “fixed” in position using medical tape and 
using heparinized saline for catheterization, a catheter (31G) was placed into either lateral 
tail veins for CA administration under anesthesia before scanning was initiated.  
4.2.6 CatD targeting CA 
Mice were studied at 2, 6 and 9 months of age. All mice received a slow 
intravenous injection of 11.2 ± 1.0 MBq 68Ga chelated CA suspended in ~200 µL 
heparinized saline (0.9% NaCl) through a tail vein catheter.  To reduce discomfort, the 
solution was adjusted to a nearly neutral pH ≈ 7 by titration with 1M NaOH prior to 
administration at 6 and 9 months of age. Imaging was initiated up to 1 minute before 
injection of contrast agent, and lasted for up to 4 hours (median 3 hours). Histograms 
were set to 5×30s, 5×60s, 5×300s and remaining time-steps set at 600s intervals. 
4.2.7 FDG study 
Mice were examined at ~10 months of age. All mice were examined using a static 
30 minutes long scan which was initiated 1 hour after injection of the FDG (12.4 ± 1.5 
MBq in a volume of 100-200 µL of physiological 0.9% NaCl) into the tail vein; after 
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which the mice were left safely without anesthesia. Static scan image reconstruction was 
achieved in the manner described above. Analysis is described below.  
4.2.8 Quantitative Analysis of PET Images 
The µPET image voxel intensities correspond to units of Bq/cc. Analysis was 
performed using AsiPro software (Concorde Microsystems, Knoxville, Tenn, USA) to 
view and analyze the microPET images as well as CarimasTM developed at the Turku 
PET Centre (Turku, Finland) for 3D rendering [27]. Measurements were made from 3D 
volumes of interest (VOI) that were drawn over the brain. Specifically, approximate 
segmentations of the hindbrain and forebrain were made using a magnetic resonance 
imaging data set to guide VOI selection.  The head of the animal was fixed and the brain 
clearly delineated making identification straightforward. The brain-periphery 
measurement was also uncomplicated and achieved by placing a VOI on the lateral and 
superior regions of the head excluding the brain cavity. In contrast, the delineation of the 
VOI for the other organs within a live, breathing animal was less accurate (in particular 
the liver and lungs) without the use of gating and image registration. For this preliminary 
study, organ VOI segmentation was guided solely by an anatomical reference image and 
activity (signal visualized in the PET image). This approach adds some uncertainty to the 
absolute activity measurements in the aforementioned organs but was considered 
insignificant for this preliminary investigation of the CA pharmacokinetics. The signal 
accumulation/washout of the radioisotope was observed in the axial, coronal and sagittal 
planes. The average ± standard deviation of the signal intensity was used for analysis.  
Due to the low signal within the brain, a moving average filter was used for 
analysis of CA dynamics as it is optimal for reducing random noise while retaining a 
sharp step response making it the premier filter for time domain encoded signals [28]. 
The standardized uptake values (SUV) were calculated using Equation 4-1: 
    ( )  
 ( )
𝑰 ( )  ⁄
     (4-1) 
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using the image derived radioactivity (in Bq/cc) concentrations C at time t measured 
pixel-wise or from a volume of interest (VOI) normalized to the injected dose (ID) 
measured prior to the scan (Bq) corrected for radioactive decay at time t normalized to 
the weight of the animal W (g). SUV could then be considered unit-less with the 
reasonable assumption that 1 cc = 1 g. The hindbrain was used for the calculation of the 
relative SUV (SUVR = SUVforebrain/SUVhindbrain) because it is mainly occupied by the 
cerebellum, which has been shown to be devoid of important AD pathology (Aβ plaques) 
in humans, and has only limited pathology in 5XFAD mice [22]. In addition, the 
cerebellum has been shown to have a significantly reduced pathologic burden in other 
AD model mice [29, 30]. The reduced pathology in the cerebellum was corroborated by 
histological examination in our lab (Figure 4-2). The time constants associated with the 
change of SUVR with time were obtained from least square line fitting (Prism; GraphPad 
Software, Inc. CA USA) of the SUVR data. The rate of relative contrast agent uptake 
(change of SUVR with time) was calculated starting at ~7 minutes post injection (p.i) to 
avoid signal from the first pass of the contrast agent through the brain.  Finally, 
considering the previous NIR CA data [20], differences between diseased and normal 
mice become more pronounced with time p.i, and therefore a weighted average of the 
dynamic SUVR was created for the last full hour of the scan to approximate a single 60 
minute static scan beginning at 120 minutes post injection. In this study, the primary 
experimental outcome assessed was the rate of change (linear slope) in activity measured 
over time in the forebrain relative to the hindbrain (SUVR). Secondary to the latter, the 
absolute SUVR measurements for the delayed static scan were compared between Tg and 
nonTg mice at different ages. No randomization procedures were taken when assessing 
results; however the VOI segmentations were defined purely based on anatomical 
reference. 
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Figure 4-2. Mouse brain Aβ42 DAB staining. Aβ plaques formations occupy large 
portions of the 5XFAD mouse brain at 12 month of age. Regions found in the cortex, 
hippocampus, thalamus and striatum displayed large plaque burden. In contrast, there 
were less Aβ42 positive staining plaques in areas of the cerebellum corresponding to the 
region selected as part of the hindbrain VOI. The sub-micrographs on the right 
correspond to an enlarged region as indicated on the left in black rectangles. All scale-bar 
are 100 μm. 
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4.2.9 Statistical Evaluation 
To test for statistical significance in the differences between Tg and non-Tg 
littermates the Student’s T-test (two-tailed, unequal variance) or extra sum-of-squares F-
test were performed using Prism 5 (GraphPad Software, Inc. CA USA) with an alpha-
level of P ≤ 0.05. To evaluate the effect of age and genotype, a two-way analysis of 
variance (ANOVA) was used to test the change in SUVR values (slopes) in mice that 
were either positive (Tg) or negative (non-Tg) for AD mutations, in the three different 
age groups. 
4.3 Results 
4.3.1 CatD Targeting Ca In Vivo Imaging 
PET data were successfully acquired in all animals. The dynamic-signal SUV and 
SUVR in the brain of one animal are presented in Figure 4-3. The 3D render of the mouse 
on the scanning bed (Fig. 4-3A), with a reference CT image showing the VOI for the 
forebrain (Fig. 4-3B; pink curve) and the hindbrain (Fig. 4-3B; green curve) used for 
measurements are shown. Due to the blurring caused by positron motion (root mean 
squared effective range of ~1.2 mm [31]) VOIs were drawn conservatively, avoiding 
signal from brain periphery. The dynamic signal from within the head is displayed over 
time in Fig 4-3C during sequential epochs marked with roman numerals (I-VIII) within 
the head. The associated forebrain and hindbrain dynamic SUV (correcting for subject 
weight and injected dose) as well as SUVR are shown in Fig 4-3D. The images and 
respective time activity curves (activity measured over time) displayed in Fig 4-3 present 
the fast perfusion  
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Figure 4-3. Brain signal dynamics - SUVR calculation. A 3D CT image showing the 
mouse on the scanning bed (A) with corresponding orienting red box around the head.   
The head is shown in more detail using a 2D cross sectional axial CT image with outlines 
of the hindbrain (green) and the forebrain (pink) contours (B). The sample CT image 
from B is fused with the dynamic PET images that are shown chronologically with roman 
numerals indicating order as displayed in C. The sample data is that of a single 12 month 
old Tg mouse following administration of our CatD CA. The corresponding data (TAC) 
for both the forebrain (pink) and hindbrain (green) regions SUV (D; left y-axis) are 
shown together with the calculated SUVR ratio of the two (D; right y-axis, black circles). 
The x- axis is shown with two segments to properly display the early signal kinetics. 2nd 
order smoothing (4 neighbors) was used to produce the TAC and SUVR curves for 
demonstration purposes only (pink, green and black curves respectively). 
of the CA following administration (under 3 minutes) and gradual changes in 
accumulation within the hindbrain (green) and the forebrain (pink) over the course of the 
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rest of the scan. The resultant ratio (forebrain over hindbrain; black) was observed to 
increase in value over time in this mouse. 
The average SUVR time courses in the brain of both animal groups are provided 
in Figure 4-4 at 2, 6, and 9 months of age. At 2 months of age there was a decrease in 
forebrain SUVR values over time for both Tg and non-Tg age matched controls (Figure 4-
4A). However, the non-Tg mice had a significantly greater negative slope (k = -0.070 ± 
0.011) compared to the Tg mice (k = -0.037 ± 0.011; P = 0.035; F(1, 197) = 4.507). In 
contrast, the forebrain SUVR in 6 and 9 month old mice (Figures 4-4B and 4-4C 
respectively) showed a slow increase in Tg mice but a decreasing trend in the non-Tg 
mice. This result is likely due to differences in CA kinetics (illustrated in Figure 4-3) in 
the forebrain and hindbrain between Tg and non-Tg mice. At six months of age (Fig. 4-
4B), the rate of change of Tg mice forebrain SUVR (slope) was k = 0.014 ± 0.010 and 
was different from the non-Tg mice k = -0.023 ± 0.008 (P = 0.0015; F(1, 40) = 11.579).  
Similarly, at 9 months of age, Tg mice (Fig. 4-4C) had a rate of change in forebrain 
SUVR k = 0.027± 0.014, which was significantly higher compared to the non-Tg mice k = 
-0.033 ± 0.010 (p ˂ 0.0001 ; F(1, 40) = 28.082). The forebrain SUVR slopes at 6 and 9 
months were significantly higher than at 2 months for both Tg and non-Tg mice. 
However, the slopes at 9 months were not significantly different from those at 6 months 
for both Tg and non-Tg mice. Using two-way ANOVA for all time points and mice 
groups, Tg mice, showed a significantly higher forebrain SUVR slope [F(1, 29) = 139.6, P < 
.0001, η2 = 0.403] compared to non-transgenic age-matched controls. Older mice 
presented significantly higher forebrain SUVR slopes [F(2, 29) = 83.80, P < .0001, η
2 = 
0.483] compared to younger mice. The interaction of age and AD mutations was also 
significant [F(2, 29) = 5.3, P = 0.011, η
2 = 0.031]. Finally, it was found that the SUVR 
values calculated for the approximated delayed static scan (60 min long) for the Tg 
compared to the non-Tg mice were significantly different at 6 and 9 months for scans at 
~2 hours p.i.  
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Figure 4-4. SUVR in transgenic and non-transgenic mice at 2, 6 and 9 months of age. 
Calculated SUVR from the TAC of forebrain and hindbrain is shown for both Tg (red) 
and non-Tg (blue) at 2 (A), 6 (B) and 9 (C) months with corresponding fitted slope 
coefficient displayed in D respectively. Vertical lines in A, B and C represent original 
SUVR data points and standard error (N=5-6) used for fitting, with symbols (circles) 
representing the corresponding smoothed average data (moving average). The linear least 
square fitting for data after ~6-7 minutes p.i is shown by thick horizontally oriented lines 
(Tg – Red, non-Tg – blue). Slopes were significantly different (P <0.01) for 2, 6 and 9 
month old mice (A B and C respectively) when comparing the Tg (red) with the non-Tg 
controls (blue). A summary of the slopes is shown in D. The static SUVR calculated at 
different ages is also shown in E. Statistical significance (P ≤ 0.05) is denoted with an 
asterisk (*). All data is mean ± standard error of the mean (N=5-7). 
Specifically, the average forebrain SUVR was significantly higher in the Tg mice 
at 6 months (0.926 ± 0.033 versus 0.835 ± 0.021; P = 0.024) as well as 9 months (1.003 ± 
0.057 versus 0.811 ± 0.034; P = 0.022) for an hour long scan starting at 2 hours p.i. 
A sample 3D render of a single 6 months old Tg mouse data are shown in Figure 
4-5 with activity displayed using different colours for signal observed during distinct 
epochs showing the head, heart, liver, lungs and bladder.  The activity emanating from 
areas including but not limited to the skull and adjacent muscle, skin and other tissues 
were higher than in the brain. There were no significant differences in the signal kinetics 
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(fitting) as well as absolute SUV values from tissues outside the brain as a function of age 
or strain (P >> 0.05). Overall there were no significant differences between the Tg and 
Non-Tg age matched littermates in the liver, spleen and bladder. While the liver and 
spleen had a rapid uptake at first, the absolute signal remained stable over time. Finally, 
the signal in the lungs decayed progressively after the first 30 minutes. The lungs 
exhibited a trichotomous behavior: at two months of age there was no significant 
difference between Tg and non-Tg lung SUVs, at six months of age the Tg mice 
presented a significantly higher lung SUV and at nine months of age they presented a 
significantly lower lung SUV (p < 0.01) compared to their age-matched non-Tg 
counterparts. However, the fitted decay coefficients were found to be the same at 2, 6 and 
9 months old mice. 
 
Figure 4-5. Mouse whole body PET.  A sample 3D render of PET data for a single 6 
months old Tg mouse injected with the CatD targeted CA is shown by overlaying semi-
transparent 3D images of the mouse body (outlined in white) with the activity displayed 
using different colours depending on the time frame: All activity detected, per voxel, 
under 2 minutes is shown in red; under 15 minutes in yellow, under 60 minutes in teal 
and over 60 minutes in green. The brain (Br), heart (Hrt), liver (Liv), lungs (Lun) and 
bladder (Bl) are noted. Pseudo-colour bars correspond to the range of SUV values 
displayed in each time point of the scan. 
 
4.3.2 FDG 
When administered FDG, mice (N=3 per group) presented heterogeneous 
metabolic function across the brain in both Tg and non-Tg mice. Examining individual 
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brain regions (forebrain versus hindbrain) and measuring the SUV, significantly reduced 
FDG signal (hypometabolism) was observed in the Tg mice compared to the non-Tg 
controls. Specifically, hypometabolism was noted in both the forebrain (1.560 ± 0.066 
(Tg) versus 1.851 ± 0.085 (non-Tg), P = 0.009) and the hindbrain (1.667 ± 0.100 (Tg) 
versus 1.905 ± 0.078 (non-Tg), P =0.031). As a result, no significant differences were 
observed in the forebrain SUVR between the Tg and the non-Tg mice. A sample image of 
both Tg and non-Tg mice is shown in Fig. 4-6 with the measured SUV. The image is 
showing the distribution of PET FDG signal overlaid a sample unrelated MRI of a mouse 
brain for anatomical reference purposes only. Gross VOI of the forebrain as well as the 
hind brain (including the cerebellum) were used for calculation of the SUVR values, 
which were not different between the different strains. It is important to note though that 
the absolute SUV values calculated in the Tg mice were significantly lower in several 
particular brain regions compared to the non-Tg age-matched controls.  
4.3.3 Biodistribution 
Methods, results and partial discussion for a limited (N=3) biodistribution study 
are available in Appendix 3. These data are not discussed further in the scope of this 
chapter.  
4.4 Discussion 
In this study, in agreement with our hypothesis, Tg 5XFAD mice could be 
differentiated from age matched non-Tg littermates at 2, 6 and 9 months of age by PET 
using a novel CatD targeted contrast agent. Supporting our primary objective, significant 
differences in the relative forebrain SUVR kinetics of the CatD targeted CA were 
measured in all age groups. In contrast to our CatD targeted CA SUVR analysis, FDG 
forebrain SUVR was not significantly different when comparing the 10 months old Tg 
mice to their age matched non-Tg littermates. However it is important to note that the  
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Figure 4-6. FDG analysis.  Representative coronal and transverse images corrected for 
injected dose and mouse weight (SUV) are shown of microPET data (A). Signal was 
obtained from a 30 min long static scan following intravenous administration of [18F]-
FDG and an hour-long uptake period. Characteristic qualitative differences between the 
strains could be distinguished especially in the midbrain, thalamus and hippocampus. 
Areas of interest are noted: Hip – Hippocampus, Str – Striatum, Cor – Cortex, Mid – 
Midbrain, Thal – Thalmus, Olf – Olfactory, CB – Cerebellum. B. SUV measurements 
were performed for the whole cerebrum and cerebellum (easier to correctly contour with 
smaller segmentation errors without individual registration to pre-PET scan MRI or CT 
acquisition catered to provide accurate anatomical reference). Both the cerebrum and 
cerebellum presented lower SUV in the Tg mice (red) compared to the nonTg 
counterparts (blue). The cerebrum and cerebellum were significantly different between 
the strains. * denotes a significant difference p value of P ≤ 0.05; similarly so ** denotes 
P ≤ 0.01. Data are mean ± standard error (N=3). 
activity measured was reduced across the brain compared to the controls, implying 
lowered metabolic demand in several brain regions in the Tg mouse brain. The SUVR is 
an important relative measurement that can eliminate some experimental differences 
unrelated to pathology that could contribute to differences between groups. 
The current study builds on a previous in vivo animal AD model examination of a 
CatD targeting CA using optical near-infrared imaging [20]. While the structure of the 
CA is slightly different in this study (different chelated metal and a different fluorescent 
dye) it shares similar characteristics and targeting design (same cleavage site, DOTA 
cage and cell penetrating peptide). This CA was designed to detect Alzheimer’s disease 
in patients by measuring the upregulation of the lysosomal system [15, 16] and CatD [16, 
17]. While our previous optical data were very promising, the drive toward translation to 
the clinic requires the use of tomographic imaging modalities.  To our knowledge this is 
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the first ever in-vivo PET imaging study using a CatD targeting CA for the detection of 
AD. Furthermore, unlike the more common targets used in CA development for AD 
diagnosis (e.g. Aβ and Tau), CatD activity is a unique biomarker that is a direct indicator 
of biochemical function in the brain rather than a marker of peptide/ protein 
accumulation. 
It is important to note that CatD activity as well as increased levels of the enzyme 
have been measured both intracellularly, as well as extracellularly in senile plaques. This 
may have implications on the kinetics of the contrast agent, but controlling for this effect 
would require an extra- or intracellularly sensitive probe to delineate the differential 
contribution of these compartments on the CA kinetics. Achieving such regional 
specificity is very challenging.  One approach would be to design a CatD inhibitor that 
penetrates the BBB but not the cellular membrane. 
With respect to the CA kinetics observed throughout the body, no significant 
differences in CA uptake and washout were identified in any organs except the brain 
using the CatD targeted CA. Substrates (e.g drugs) are commonly cleared from the blood 
circulation by the liver and kidneys, and so the relative contribution of the liver and 
kidney to the overall clearance of drugs may be important for pharmacological and 
toxicological considerations [32]. Therefore, considering their normal physiological 
function, the liver (hepatic clearance, drug metabolism), spleen (blood filtration) and the 
kidneys (renal clearance) are not surprisingly the primary organs of CA accumulation in 
our animals [33] consistent with previous attempts to use CPPs [34, 35]. However, the 
relatively smaller kidney retention and the remarkable higher lung CA retention are 
intriguing and deserve further study. Some non-specific CA accumulation in bone, spleen 
and lungs could be the result of 68Ga dissociation from the CA as well as natural 
accumulation of the agent in these organs. For example, a loss of the 68Ga radionuclide 
from the CA while very unlikely, is possible, due to transchelation processes involving 
transferrin [36]. 
The observed decrease in FDG SUV values in the Tg mice compared to non-Tg 
littermates indicates hypometabolism in both the forebrain and hindbrain of the Tg mice. 
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The cerebellum is commonly used as a reference region, and has been shown to lack Aβ 
pathology; however, it is possible that the rate of glucose metabolism in this region is 
reduced regardless. This result is in contrast with one study [37], but in agreement with a 
more recent study [30] showing unilateral decrease in FDG SUV values in multiple brain 
regions in 13 month old 5XFAD mice compared to controls (including the cerebellum). 
Therefore, when using the cerebellum as a reference region, no significant differences 
between the Tg mice and non-Tg littermates were observed. However, the latter study 
[30] did remarkably discover significant differences between Tg mice and control as 
early as 2 months of age when using the ratios (SUVR) of basal-forebrain/basal-ganglia, 
hypothalamus/neocortex and thalamus/neocortex [30]. The lack of significant differences 
in AD mouse models when using otherwise well accepted CAs utilized in the clinic is not 
uncommon. In fact in contrast to one study using 5XFAD [37] FDG, 11C PiB and 18F-
FDDNP all failed to show significant results in at least two different AD model mice [38, 
39]. Our results are in agreement with the above, since we only evaluated the cerebellum-
relative SUVR values.  The reason for the discrepancies emanates likely from the 
variability of VOI selection between studies, and the specific conditions prior to imaging 
(temperature and food control). 
The current study has several advantages over the previous examination of the 
related CA [20]. The use of PET is far more clinically translatable than NIR imaging. 
PET is commonly used in the clinic, and is considered much more sensitive than its 
nuclear medicine counterpart, SPECT. In addition, in this study we examined the CA 
uptake and washout at three different ages and observed consistent preferential increased 
uptake of the CA by the Tg mice at all ages.  These results indicate that the agent could 
be used to discriminate between the AD mice and control mice using a static scan.  In 
fact, the control mice used for this study were non-Tg age matched (unlike our previous 
work utilizing the parent strain C57Bl/6) providing a better comparison due to the similar 
genetic make-up and potential non-pathologic phenotypes in the disease and non-disease 
groups. While the amount of CA administered was not dependent on the subjects’ weight 
the SUV analysis corrects for variations in both a subject’s weight and administered dose. 
The ratio of SUVs measured from the forebrain and hindbrain, namely SUVR was 
dependent on neither the injection dose nor subjects’ weight since those cancel out in the 
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calculation. Furthermore, SUVR analysis could indirectly reduce some phenotypical bias 
unrelated to AD pathology by using a reference tissue specific to each individual mouse.  
Potential weaknesses of our study involve the utilization of a fairly short half-life 
(~68 minutes) isotope 68Ga which not only decays twice as fast as the more commonly 
used 18F but also has a higher peak energy and therefore longer root mean squared 
positron travel range. The former limits the detection timeframe post CA administration 
to only a few hours, and the latter increases the blurring effect, which reduces the 
accuracy of pair annihilation localization and resolution. However, the current design of 
the radioligand allows for the use of other radioisotopes (e. g. 64Cu) with more favorable 
properties (half-life of 12.7 h) for longer time delays post injection. The low activity 
measured in the brain was concerning given the possibility of spill-over signal from the 
extraneous non-brain tissue (e.g. skull, muscle and skin). However, the likelihood of 
spill-over signal accounting for observed differences within the brain was refuted by the 
lack of significant differences between the Tg and non-Tg mice data of the extraneous 
non-brain tissue at all time points. Finally, the use of heparinized saline for 
catheterization prior to CA administration, while necessary, could have reduced the CA 
capacity to bind to and enter cells. This is because heparin could competitively inhibit the 
adsorption of the CPP [40]. 
Future experiments will involve image registration for more specific brain region 
analysis as well as graphical analysis tools such as the Patlak parametric graphical 
analysis technique for irreversible tracer kinetics [41]. The latter will be considered for 
the calculation of the differences in flow rate constant across the BBB between Tg and 
non-Tg age matched littermates (following cleavage, the CA should be retained 
“irreversibly” within the time frame of imaging). Based on the success of this work, 
translation to further testing in larger animal models of AD (e.g. transgenic rats, dogs) 
and finally humans is warranted. In conclusion, this study provides further evidence to 
support the targeting of CatD to differentiate between 5XFAD mice and control mice 
from 2 to 9 months of age.  
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Chapter 5  
5 Conclusions and Future Directions 
5.1 Conclusions 
The work described within this dissertation is relevant to the research community 
searching for potential biomarkers for the early diagnosis of Alzheimer’s disease (AD). 
The individual studies that have been described encapsulate the realization, planning, 
execution and outcome of the intelligent design of a functionalized molecular imaging 
contrast agent with multi-modality capabilities. 
Starting from the ground up, a cellular biological niche was discovered in humans 
with the possibility of being utilized as a biomarker for AD. Specifically, Cataldo et al. 
presented an observation nearly 25 years ago [1] of the enhancement and involvement of 
the lysosomal system, especially Cathepsin D (CatD), in human brain regions that have 
yet to develop local AD pathology. This finding suggests that identification of this 
protease could provide complementary information for the probable diagnosis of 
prodromal AD using a CA that targets this particular enzyme. 
The CA structure, chemical characterization and optimized synthesis procedure 
has been previously described [2] and was not elaborated-on further in the thesis. Limited 
toxicity studies as well as cellular uptake experiments and ex-vivo evaluation of CA 
uptake were also accomplished and published prior to the work [3] presented in this 
thesis. Briefly, the CatD targeted contrast agent was composed of a cell penetrating 
peptide (CPP) that allows the bidirectional penetration of the agent across the blood brain 
barrier (BBB), into and out of the brain delivering cargo such as an imaging probe. The 
CPP was conjugated to a CatD cleavage site that was in turn conjugated to the imaging 
probe. The imaging probe was composed of a fluorescence dye (originally Oregon Green, 
later IRDye800) as well as a DOTA cage that allows the chelation of different metals 
(e.g. Gallium or Gadolinium).  
 151 
 
The many economic, temporal and ethical complications with studying new 
therapeutic options or diagnostic probes on humans make up the quintessential corner 
stone behind pre-clinical studies. Therefore, animal models provide a world of options 
attempting to mirror human disease for the purpose of the ethical investigation of 
diagnostic and therapeutic options in a timely fashion (within the average lifetime of a 
graduate student). There are a plethora of AD mouse models, and it was required to seek 
out the appropriate model to our hypothesis.  As is outlined in Fig. 5-1 a work flow was 
devised in such a way to allow the development, and execution of a study to investigate 
the CatD targeted CA capacity in differentiating the disease modeled animals from their 
control counterparts. As is depicted in the figure, before the CA is tested on an animal 
model, it is important to ensure there is an adequate control, reasonable number of 
animals, and most importantly that the model is appropriate for the objectives set forth. 
This was the first major contribution of this work, which was described in detail in 
Chapter 2.  Specifically, we provided the characterization of CatD expression in three 
different Tg mouse models of AD across a life span of ~5 to 60 weeks after birth in 
comparison with an age-matched wild-type control mouse model. In this study we 
demonstrated that the 5XFAD mouse model is the ideal candidate for targeting increased 
levels of CatD coinciding with AD Aβ42 pathology. In fact the rate of increase in CatD 
positive staining in 5XFAD was higher than Aβ42 in the hippocampus. Similarly, but to a 
lesser extent, the 2X mouse model displayed a significant increase in both CatD and Aβ42 
pathology compared to WT and the 3X mouse strain. The 2X also presented with a higher 
rate of change in CatD positive staining compared with that of the Aβ42. This work 
justified moving forward with the aggressive AD model, the 5XFAD mouse model that 
proved both age and AD mutation to be significant contributors to the significant 
differences between the 5XFAD CatD expression and the other Tg mouse models as well 
as the WT controls.  
The work presented in Chapter 3 which was accepted for publication in the 
Journal of Alzheimer Disease in 2014 was the first exciting truly in-vivo application of 
our contrast agent using a NIR modification (2nd generation CA design) on 5XFAD mice 
and wild type control mice imaged using a unique time domain optical scanner (GE 
Healthcare, Milwaukee, Wisconsin). Evaluating the signal measured from the mice bare 
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but intact head shortly after CA administration we investigated the uptake and washout 
dynamics following the administration of either the CatD targeted or two separate control 
CA versions; one that lacked the CPP, and another that lacked the CatD targeting moiety. 
Interestingly the CatD targeted CA had the highest uptake and longest retention within 
the brain compared to the non-targeted and non-penetrating CA in both 12 months old Tg 
and age-matched wildtype controls. The main observation made was the significantly 
different washout coefficient calculated as the exponential decay coefficient of NIR 
signal measured over time for mice aged 12 and 5 months old. In contrast, there were no 
significant differences in washout dynamic between the Tg and WT mice when using the 
control agents, only when using the complete CatD targeted CA. These data 
demonstrated that the CPP peptide does indeed allow the agent to cross the BBB into the 
brain where it is retained longer compared to the agent with no Tat peptide. In addition, 
the relatively short retention time of the agent with the CPP alone, confirms that agent 
that enters the brain does indeed leave the brain rapidly as predicted. The extended 
retention of the agent with the CatD cleavage site and CPP, compared to the CPP alone 
validates our model of how the agent functions; that proteolitically removing the CPP 
causes retention of the agent in the brain. 
The final chapter (4) was made in preparation for a publication describing the 
synthesis and testing of a radioactive 68Ga chelated CatD targeted CA (3rd generation CA 
design) using the Inveon microPET scanner (Siemens Medical Solutions, Knoxville TN, 
USA). We imaged 5XFAD mice at 2, 6 and 9 months of age shortly before the 
administration of the CA intravenously (dynamic list-mode scan). The reduced pathology 
observed in the 5XFAD mouse cerebellum (consistent with humans) justified the use of 
this region to normalize the standard uptake values (SUV; normalized to subject’s weight 
and injection dose) from the cerebrum (forebrain and midbrain) giving the SUVr 
parametric values that were analyzed over the course of the 3-hour long scans. Though 
there were no significant differences in the washout coefficient shortly after injection, 
there was a delayed, but significantly different uptake in the 5XFAD mice compared to 
the non-transgenic, age matched control mice. This was quantified by least squares linear 
fitting of the data. Additionally, averaging the signal over the course of the last 30 
minutes of the scans provided significantly higher SUVr values in the 5XFAD mice 
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compared with the age-matched non-transgenic littermates. There were no apparent 
differences between the mice renal/hepatic clearance according to those organs signal 
accumulation. Overall, both age as well as AD mutations proved significant contributors 
to the significant differences between the 5XFAD and controls, mirroring the CatD 
staining observed using immunohistochemistry.  
 In conclusion, this work establishes that the 5XFAD mouse model presents 
increased CatD protein levels as measured by Western blots as well as 
immunohistochemistry. Furthermore, our novel CatD targeted CA has the capacity to 
differentiate between the 5XFAD mouse model and age-matched normal controls using 
both optical NIR techniques and microPET imaging. Taken together, this work validates 
the idea of CatD expression correlating with Aβ deposition, and the design of a targeted 
CA to detect increases in CatD in vivo.  This agent was able to successfully differentiate 
AD mice from control, demonstrating that it may indeed be useful for diagnosis in 
humans. 
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Figure 5-1. Experimental work flow. The work flow is divided into preliminary work 
investigating the different available animal models, followed by imaging studies to 
investigate the capacity of the designed CA in differentiating the Tg mouse models from 
controls. Finally, if indeed differentiation is deemed possible using an imaging modality, 
which is easily translatable to clinical tools (e.g MRI or PET), then the CA may be 
considered further in additional toxicity studies and other animal models if found 
necessary. The original goal to successfully achieve an MRI evaluation of the CA and 
provide means to differentiate Tg mice with non-Tg controls was not successful. The 
failure was in part because of the limited sensitivity (e.g relaxivity), and the limited 
concentration and/or volume of CA allowed to be injected.  
  
5.2 Future Directions 
Future directions for this study include: improved understanding of the CA 
pharmacokinetics, developing MRI detection, improved modeling using a large animal 
model and finally a move to humans. 
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5.2.1 Compartment Modeling 
The handling of a CA by the body (pharmacokinetics) can be very complex, as 
several processes (such as absorption, distribution, metabolism, and elimination) work to 
alter CA concentrations in tissues and fluids. The implications of the CA accumulation at 
the target site of action or other organs on resulting effects such as toxicity 
(pharmacodynamics) are crucial for the safety considerations in future clinical use. The 
Pharmacokinetics as well as the pharmacodynamics of our CA must be evaluated to 
determine its metabolism and clearance from the body. Excluded from Chapter 4, but 
may be available for publication as a supplementary figure, was the accumulation of our 
68Ga in different clearance organs such as the liver and bladder. This information could 
be used and is valuable in determining the half-life of the agent within the body. The 
body processes involved in CA metabolism can be and should be simplified to predict the 
CA behavior while in circulation throughout the body. One way to make these 
simplifications is to apply mathematical principles to the various processes. This 
mathematical model is the compartmental modeling approach that can be extended to our 
data in order to provide additional information about how our CA works, and how we can 
improve its utilization. The data presented in Chapter 3 and 4 could be used to model the 
pharmacokinetic and pharmacodynamics of our contrast agent. While Chapter 4 
discussed data that can be used directly for the quantification of CA accumulation in 
several organs, Chapter 3 presented data that included the use of two control CAs; 
namely a non-targeted CA and a non-penetrating CA. The modeling can be facilitated by 
our two different control CAs with different BBB permeabilities, allowing us to separate 
kinetic coefficients from one compartment (e.g blood pool) to another (e.g. brain).  
This is exemplified in the hypothesized compartment modeling showing in Fig. 5-2. 
Given the compartment modeling shown, a set of ordinary differential equations can be 
put forth and a solution may be examined using the data acquired with the optical scanner 
as is shown in Appendix 4. The fact that our CA utilizes a diffusion trap to eliminate (or 
greatly reduces the egress of the agent from the brain) by having the CPP removed 
following interaction with the CatD enzyme, would be realized by a significantly lower 
kinetic rate from the brain compartment back into circulation.  A complication in this 
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approach is the optical “activatable” nature of the contrast agent (while it is not an 
activatable agent, the fluorescence efficiency is higher following cleavage), leading to the 
necessity of having a separate compartment for any cleaved CA that experiences higher 
fluorescence characteristics. Furthermore, this change in fluorescence can skew (if not 
accommodated for by the set of equations properly) the approximation and/ or solution to 
the set of equations.  
 
 
Figure 5-2. Compartment Modeling for the CatD targeted CA and the two separate 
control CAs. The CatD targeted CA (red) follows a different possible path than that 
traveled by the non-targeted CA (blue) as well as the non-penetrating CA (green). The 
CatD targeted CA can become cleaved at which point it may follow kinetic pathway 
and/or at least experience similar kinetic rates to those experienced by the non-
penetrating CA. 
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5.2.2 MicroPET Parametric Analysis 
The analysis of MicroPET data as outlined in Chapter 3, namely the SUVR is a 
reliable method to generate SUVs that are normalized and therefore compensate for any 
differences as a result of injected dose (e.g. bioavailability, and concentration 
dependencies) as well as body weight (e.g. dilution factor). We reported the relative SUV 
using the “hindbrain” (cerebellum and a portion of the true hindbrain are likely the 
technical anatomical brain regions) as the reference brain region. While this was justified 
by reduced pathology in these regions, it may not be ideal. Regardless of the logical 
benefits of SUVR analysis, it is based on the SUV unit which has been argued to lack 
easily interpretable biological meaning [4]. Alternatives methods have been developed 
based on compartmental modeling and pharmacokinetic analysis leading to graphical 
analysis techniques as such as those proposed by Logan et. al. [5] and Patlak et. al. [6]. 
Logan plot analysis could provide the binding potential of a reversible ligand to its target 
which is related to the amount of targeted receptors or enzymes. Patlak analysis is 
commonly used for the evaluation of radioactive tracer kinetic flow rate (denoted as Ki) 
of CA relocating into a compartment (e.g. brain) irreversibly within the timeframe of the 
imaging. The benefit of the graphical analysis methods is their independence from a 
correctly assumed or otherwise a known compartment model. Future directions will 
include re-examination of the data taking advantage of graphical parametric analysis such 
as Logan’s binding potential (using the cerebellum as a reference region in lieu of an 
arterial input function information), or Patlak analysis of Ki [7]. A sample image of a 
Patlak graphical parametric image for a 6 month old 5XFAD mouse following the 
administration of our CatD targeted CA is shown. Future examination of the data using 
this approach will be sought. Furthermore, larger animals could allow the direct sampling 
of the arterial input function information (blood collection) allowing a more accurate 
modeling and parametric analysis.   
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Figure 5-3. SUV values versus graphical analysis (Patlak). Images showing the SUV 
as well as the Patlak Ki kinetic coefficient values in the brain of a 6 months old Tg 
5XFAD mouse following administration of our CatD targeted CA   
 
5.2.3 In-Vivo MRI Contrast Agent Uptake 
At the current time, the Gd3+-DOTA-CatD version of contrast agent has not been 
successfully implemented in-vivo due to limited detectability requiring high 
concentration CA administration, which has proven difficult considering possible 
diminished solubility in biologically friendly buffer solution (some precipitation occurs in 
Phosphate buffer solution, as well as saline). The possibility of utilizing Intralipid (fat 
emulsion) as a solvent has been considered, given its advantage over water-based 
solvents for other drugs. These have not been adequately attempted as they require 
further optimization (e.g. of rate of injection and concentration of Intralipid). 
Additionally, our attempts at detection so far used the 9.4T Agilent animal MRI scanner. 
However, like all other T1-weighted CAs, there is likely benefit in going to lower 
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magnetic strength scanners for the improved relaxivity of the CA and therefore improved 
contrast. Both the solubility of the CA should be improved allowing safe administration 
of higher concentrations of the CA, as well as imaging in lower magnetic field (e.g. 1.5T) 
for improved sensitivity and T1-weighted contrast. A sample image of a ~13 month old 
Tg 5XFAD mouse injected with 800 nmol of our CatD targeted CA is shown below 
(before and ~5 minutes after administration). Unfortunately the mouse used in this 
experiment expired for unknown reasons, illustrating the safety concerns that still need to 
be addressed at the concentrations necessary for MRI detectability. 
 
Figure 5-4. MRI experiment. The Spin Echo T1-weighted images shown above present 
a coronal slice from a 3T scan before (prescan) and after (post-scan) CA administration 
showing the body vascular component (red arrows), cerebral vascular component (green 
arrow) as well as contrast near the lateral ventricle (blue arrows). These images are meant 
as qualitative observation only and no quantification has been sought at the moment. 
5.2.4 3D Fluorescence microscopy CA localization  
Because of the dual-modality nature of our CA, we could use ex-vivo fluorescence 
microscopy to study the localization of CA retention at very high resolution across the 
whole specimen or just the brain. The CryoViz™ (BioInVision Inc. Cleveland, OH, 
USA) system collects high resolution 2D images sequentially creating a cross sectional 
3D volume. We will explore the possibility of using this system to better understand the 
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exact location of our CA at different time points across the whole brain. In Fig. 5-5 
below, one can see the differences between the increased fluorescence observed diffusely 
in a 13 month old Tg mouse (5XFAD) compared with an age-matched non-Tg control. 
Both mice received an injection, expired, and frozen for use with the CryoVizTM  system. 
The time delay from injection to being frozen was under 10 minutes for both mice and 
yet clearly there is some observable difference in fluorescence, likely the result of 
increased CA retention. 
 
Figure 5-5. CryoVizTM experiment. Ex-vivo sample 2D image from the13 month old Tg 
(5XFAD) mouse is shown on the left and age-matched non-Tg mouse on the right 
following 800 nmol Gadolinium-Green fluorescence (Oregon Green ™) CA 
administration.  
5.2.5 Toxicology and Safety of Contrast Agents 
The potential toxicity of our CatD targeted CA has been examined in a very limited 
fashion by titration of different concentration incubated with a cancer cell line testing for 
trypan blue diffusion into the cellular bodies suggestive of cellular death [2]. Before we 
can use this agent in humans we will need to formally evaluate its toxicity in mice, and 
then in large animal models. These studies will rely on the PK/PD studies above, which 
will demonstrate the likely in-vivo concentrations of our agent.  They will be critical to 
move this contrast agent from a pre-clinical to a clinical phase. Further characterization 
of the safety of the CA at different concentrations would also be of significant importance 
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especially considering the solubility challenge in order to avoid any possible embolism 
which may have been the cause of death of at least one mouse injected with a large 
amount of our CA (>X100 times the concentration used in both Chapter 2 and 3). 
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INTRODUCTION 
Programmed cell death is an important outcome of a multitude of cellular signals 
and underlying pathological conditions. Apoptosis is a fundamental type of cell death 
process involving the activation of proteases, most importantly caspase 8 and 3 which 
mediate and commit the cell to die. Apoptosis can be triggered using ultraviolet (UVB: 
280-320 nm) light causing DNA damage [1] or exposure to lethal thermal shock [2].  The 
artificial induction of increased apoptosis in tumours is an effective cancer therapy 
approach, and the reduction of apoptosis may improve prognosis of ischemia and 
neurological pathologies [3]. Magnetic Resonance Imaging (MRI) and spectroscopy 
(MRS) are both powerful tools for clinical diagnosis. While MRI is able to detect 
changes in-vivo in MR image contrast that are thought to reflect the morphological 
features of apoptosis, these occur late in the process [4].  Paramagnetic Chemical 
Exchange Saturation Transfer (PARACEST) [5] imaging contrast agents (CA) have been 
shown to be sensitive to physiologic parameters such as pH and temperature. These CA 
are indirectly detected by selective saturation of exchangeable agent bound protons [6]. 
There are three main recognized pathways of cell death and one mode may dominate 
another depending on the injury and type of cell [7]. DNA damaging agents as well as 
neurodegenerative disorders are dominated by apoptosis [8]. Apoptosis may be detected 
using a CA targeted to caspase 3, capable of translocating into cells. It is our belief that 
cells undergoing apoptosis can be detected using microscopy and MRI, following 
increased retention of a caspase 3 targeted CA containing a lanthanide metal, and a 
fluorescent dye, conjugated to a cell penetrating peptide.  
MATERIALS AND METHODS 
Contrast Agent Synthesis and Characterization 
We synthesized a novel CA containing a cleavage site specific to Caspase 3 (a 
central mediator of the apoptosis pathway) which contains components for both MRI 
(Tm3+-DOTAM) and fluorescent (Oregon Green ® dye) detection (Fig. A1-1).  The CA 
has also been conjugated to a cell penetrating peptide (CPP) facilitating transport into, 
and out of a cell. Active Caspase 3 within cells irreversibly removes the CPP segment 
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from an internalized CA, in effect, reducing the transport kinetics of the cleaved CA out 
of the respective cells, increasing retention.  
 
Figure A1-1. Contrast agent synthesis. The first step in the synthesis of the caspase 3 
sensitive probe (structure 4) was a peptide coupling (HBTU, DIPEA, DMF) between the 
DOTAM-derived carboxylic acid 1 and the peptide 2 attached to the resin.  Conjugate 3 
was purified by semi-preparative HPLC, was characterized by high resolution mass 
spectrometry and was subjected to conjugation with Oregon Green and metallation with 
TmCl3 · 6H2O.  Desired probe 4 was obtained in 10% overall yield and was characterized 
by high resolution mass spectrometry.  
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Experimental design 
As depicted in Fig. A1-2, prostate cancer cells (PC3M) were either irradiated with 
ultraviolet radiation (UVB; 40 W/m2 312 nm), exposed to thermal shock (45°C for 30 
minutes), or maintained without any insult. Immediately after irradiation, cells were 
incubated overnight (24 hours) with the CA (concentration of 0.68 µM for confocal 
microscopy and 3.1 µM for PARACEST MRI).   
In-vitro experimental design 
 
Figure A1-2: Experimental design. Prostate cancer cells were either exposed (T) to 
injury (UVB 40W/m2 or thermal shock [320]) or not (-T), and incubated with the CA 
overnight and then collected for microscopy and MRI analysis. 
Confocal microscopy 
Bright field and fluorescent confocal imaging (LSM510, META-NLO;Carl Zeiss, 
Inc) of the centrifuged treated (+T) and non-treated (-T) cells prepared as described (Fig. 
A1-2) allowed visualization of the cells and fluorescent quantification (N=4) of the 
internalized CA as well as nuclear staining suggesting chromosome condensation 
associated with cell death. 
Magnetic Resonance Imaging – OPARACHEE 
MRI detection of cell lysates (2×106 cells per ml for all samples) was achieved using 
a 9.4 Tesla, 31 cm diameter bore Agilent (Palo Alto, CA) small animal MRI scanner 
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(N=1). Two images were acquired using a fast low angle shot (FLASH) pulse sequence 
(TE/TR=2.5/5.3 ms, 25.6 mm x 25.6 mm field of view, 128×128 matrix, 3 mm thick 
slice, 5 s pre-delay), where the second image was preceded by a WALTZ-16 preparation 
pulse (480 ms, 6 µT) centered on the bulk water frequency to generate contrast [9] using 
the on-resonance paramagnetic chemical exchange effect (OPARACHEE). 
RESULTS 
Apoptosis Induction and Oparachee Contrast 
Green fluorescence was expressed diffusely within the cells (Fig. A1-3A and A1-
3B). However, fluorescent imaging clearly demonstrated a preferential uptake/retention 
(75 % vs. 6 %) by the irradiated cells (Fig. A1-3B) compared to the control cells (Fig. 
A1-3A).  
 
Figure A1-3:  UVB Treated cells +T+C (A; green fluorescence from CA) undergoing 
apoptosis (B; Hoechst stain showing nuclear fragmentation) presented preferential 
retention of the CA as seen by microscopy compared to control cells -T+CA(C; green 
fluorescence from CA) which appear “normal” (D; Hoechst staining is not indicative of 
substantial nuclear fragmentation). Scale bar is 200µm. Lethal Shock treated cell lysates 
also presented higher contrast (E) compared to control (F). TE/TR=2.5/5.3 ms, 25.6 mm 
x 25.6 mm field of view, 128×128 matrix, 3 mm thick slice, 5 s pre-delay. 
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The percent (mean ±standard deviation) of UVB treated cells (Fig. A1-3A,B) having 
internalized the CA (53.9±16.2 %) was higher (p>0.05) than the control cells (Fig. A1-
3C,D; 18.0±12.7 % ). OPARACHEE contrast of heat-shock treated cells incubated with 
CA (+T+CA, Fig. A1-3E: 61% across ROI), was higher than the contrast measured for 
non-treated cells with CA (-T+CA, Fig. A1-3F: 28% across ROI). 
DISCUSSION 
This study demonstrates preferential uptake of a novel MRI contrast agent 
targeted to Caspase 3 in cells irradiated with UVB light to induce apoptosis.  Detection of 
the agent by MRI using OPARACHEE suggests in-vivo detection is possible.  In the 
future, the contrast agent will be utilized in an in-vivo murine model of brain cancer to 
study the spatial and temporal distribution of apoptotic cells prior to and following 
radiation treatment.  
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Appendix 2: Optical Scanner setup observations and Time-
Domain fluorescence lifetime analysis considerations 
OPTICAL SCANNER SETUP 
When scanning using the Optix eXplore a few careful steps should be taken to 
maintain the distance between the detector and the top of the sample (or animal) with 
little variation. Differences will occur as a result of the source - detector distance. If one 
is imaging with multiple ROIs (e.g. more than one mouse) one must consider the relative 
height of the different targets.  As an example, an examination of the effect of the level 
(height) of the bed on optical signal was performed.  In the figure below, no changes 
were made between images aside from lowering the bed from its original position such 
that the horizontal guideline on the surface of the head (A) was moved to be above the 
head by about 1 cm (B). There is a clear reduction in the fluorescence signal as expected 
due to the optical divergence of light from the source. This effect was particularly 
important when using a Y-shaped nose cone to image two mice at the same time, since 
both require the same level of detector-to-sample distance that could be verified using the 
scanner setup as seen on the side-view image below. 
 
Figure A2-1: Adjustment of scanning bed height. 
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When it comes to changing the step size (distance between scanning points –> 
resolution), there were no significant differences in measured signal. Larger step sizes 
should be considered for smaller temporal resolution as the RASCAL scanning (rapid 
scanning and correction of multiple sequence alignments)could take up to a few minutes 
for an ROI drawn over the head of the mouse as below (showing the results of the same 
mouse with difference spatial step sizes following administration of the CatD targeted 
CA).    
 
Figure A2-2: Adjustment of scanning resolution 
 
FLUORESCENCE LIFETIME ANALYSIS 
An important but rarely used strength of the eXplore Optix optical scanner is the 
time-domain feature, where unlike continuous light optical scanners, it can capture the 
lifetime characteristics of the fluorescent signal. This feature has been used previously to 
evaluate the depth of the dye, the concentration, as well as the environment where the 
fluorescent dye is residing (e.g. lipids) [1-4]. The fluorescence lifetime is a unique feature 
specific to each fluorescent dye and its environment. We have briefly examined the 
fluorescence lifetime of our CAs and notice an interesting finding – a difference in the 
characteristic lifetime of the complete (CatD targeted CA) versus the non-penetrating 
(cleaved CatD targeted CA). Therefore it may be possible to examine the enzymatic 
kinetics using a fast fluorescent lifetime analysis in regions expected to have 
overexpression of the target enzyme (e.g. AD brain). This effect is shown in the next 
figure where the fluorescence life time is plotted (intensity over time):  
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Figure A2-3: Temporal Point Spread Function plots of the NIR signal. 
 
Examining the cleaned Temporal Point Spread Function (TPSF) (using Optiview built in 
algorithms) several observations can be made: T1and T2 (yellow and blue respectively) 
are from pre-scan data points over the brain of the mouse prior to injection. T3,T5,T7 and 
T9 (white, pink, dark blue and red respectively) are from the brains of mice injected with 
the non-CPP agent. Lastly T4, T6, T8, T10 (grey, teal, brown and green respectively) are 
from the brains of mice injected with the CPP-containing agent. The peak of the 
fluorescence lifetime corresponds (assuming all parameters were used correctly) to the 
depth, or arrival time. The slopes of the lines thereafter are representative of the lifetime 
of the fluorescence. It is noteworthy, that CatD targeted CA (CPP-containing agent) have 
a significantly different (p < 0.01) x-axis intercept (8.79 ± 0.16) compared to those of the 
non-CPP (non-penetrating) agent (10.05 ± 0.12). Because the molecular structure of the 
non-CPP is the same as that of a cleaved CatD targeted CA, future studies could examine 
the use of this technique to evaluate the enzymatic cleavage of the contrast agent as it 
circulates in the mouse body.  
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Appendix 3: Supplemental information for chapter 4 
EXTRANEOUS NON-BRAIN RADIOACTIVITY SPILL-OVER INTO 
VOLUME OF INTEREST 
Time Activity Curves (TAC) for the Tg mouse brain at 6 and 9 months of age 
were increasing over time. In order to test that this significant difference was not as a 
result of any peripheral signal washing into adjacent brain tissue voxels, Volumes of 
Interest (VOI) were drawn over lateral tissue surrounding the brain (skull, skin, muscle) 
and tested for any significant differences between the Tg and age-matched non-Tg 
littermates. As can be seen below in Fig. A3-1 no differences were noted, but a consistent 
increase in signal over time was noted for both groups. This increase overtime may be the 
result of true CA accumulation in the respective tissues or de-chelated 68Ga accumulation 
in bone. 
 
Figure A3-1: periphery SUV data. Calculated SUV from the TAC from VOI drawn 
over the peripheral tissue lateral to the brain for both Tg (red) and nonTg (blue) at 6 and 9 
months of age. 
Furthermore, in order to test whether the signal in the brain can be detected by the 
microPET scanner even after removal of all (most) the blood content from the brain as 
well as dissociation from any surrounding tissue, the following procedure was performed 
prior to an hour long static scan. Following CA administration via tail vein, one six 
months old 5XFAD Tg mouse was perfused by heparin followed by heparinized saline, 
dissected carefully to remove the brain and washed x3 in heparinized saline. The brain 
was then imaged with the resulting sample images in Fig. A3-2 below (unrelated mouse 
brain SSFP MRI anatomical image is shown for reference only). Because this was an 
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exploratory experiment not requiring quantification, no repeats of this attempt were 
pursued.  
 
Figure A3-2: Dissected brain signal shortly after injection. Activity (Bq/ml) 
detected from a dissected perfused heparinized-saline washed brain is displayed over the 
axial, sagittal and coronal planes using sample non-related anatomical MRI image as 
reference only.  
BIODISTRIBUTION 
As a result of the possible requirement of larger sample size, these data were not 
included in Chapter 4. However, it may provide interesting information with respect to 
the bioavailability and distribution of our CatD targeted CA in the body.  
METHODS AND MATERIALS 
Adult female mice (10 months old Tg and age-matched non-Tg littermates) were 
anesthetized under 2% isoflurane during tail vein catheter insertion, CA injection, cardiac 
blood extraction and during perfusion with PBS. Three mice per group (N=3) were 
administered an average of ~3 MBq of 68Ga-GLP-1 peptide. Mice were sacrificed at 1 
hour post injection (p.i) by carbon dioxide followed by cardiac puncture for perfusion 
with cold heparinized saline and PBS, and organs dissection. The brain, muscle (thigh), 
bone (femur), heart, lungs, liver, spleen, kidneys were excised, washed in cold PBS, 
weighed, and counted in a high purity Ge gamma counter (Ortec GWL-190-15-S, 
detection range 51.32-2111.36 keV at 1.4-2.3 keV resolution, linear range of detection 0-
4030 Bq). Injected dose (ID) was determined by measuring the activity of a diluted 
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injected dose CA solution (N=5). Activity of the samples was determined with an energy 
window of 507.18-515.43 (Energy of pair annihilation product photons is 511keV). To 
ensure all activity was captured accurately, samples were counted to a dead time of less 
than or equal to1%.  Probe uptake was expressed as percent injected dose per gram tissue 
(%ID/g) and all activity was decay-corrected to the time of injection. 
RESULTS 
The biodistribution of the 68Ga-labeled CatD Targeted CA, 1 hour after i.v tail 
administration of the CatD CA is shown in Table 1 for dissected vital organs as the 
percentage of the injected dose per gram tissue (%ID/g) for both the 11 month old Tg and 
age matched non-Tg (N=3). In general, the liver and lungs showed a very high uptake 
compared to all other organs displayed in Table 2. The spleen and kidney followed 
second and third respectively. There were no significant differences in the accumulation 
of the CA in bone, muscle, lungs, heart, spleen, liver and kidneys (P > 0.1) between 
groups. Furthermore, the brain-measured activity (mean ± standard deviation) was 0.03 ± 
0.01 and 0.08 ± 0.04  %ID/g for non-Tg and Tg respectively (P = 0.07). The reason for 
the non-significant differences measured in the brains of the mice could be the result of 
minor human error (contamination of brain sample with blood) or unequal perfusion state 
of the mice making variability higher within each group, diminishing the differences 
between the two groups averages. 
Table 1. Biodistribution in Tg and non-Tg mice at 1 hour p.i. 
%ID/g 
 Non-Tg Tg P 
Brain 0.03 ± 0.01 0.08 ± 0.04 0.07 
Bone 0.49 ± 0.34 0.68 ± 0.53 0.31 
Muscle 0.68 ± 0.26 0.26 ± 0.24 0.21 
Heart 0.51 ± 0.19 0.72 ± 0.23 0.14 
Lungs 51.28 ± 77.14 81.51 ± 127.9 0.37 
Spleen 32.67 ± 25.07 31.07 ± 15.39 0.46 
Liver 62.21 ± 25.73 53.06 ± 25.22 0.34 
Kidney 1.95 ± 0.43 2.48 ± 1.47 0.29 
N=3  
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Appendix 4: Compartmental Modeling 
To further examine the possible pharmacokinetics expected considering the 
hypothetical method of action, activation and accumulation of the Cat-D targeted CA as 
well as the associated controls a four compartment model was designed to qualitatively 
explore the signal dynamics over time (t). Previous methods have been applied in studies 
based on dual-tracer compartmental modeling for imaging primary cancer receptor 
concentrations in detail. The approach described herein was adapted to differentiate 
between functionalized (CPP) versus un-functionalized CAs, as well as targeted versus 
untargeted CA uptake over time.  The compartment model is seen in Fig. A4-1a. The 1st 
compartment represents the blood content of the intact CA (non-cleaved)    ( ), the 2
nd 
compartment represents the brain content of the intact CA (non-cleaved)    ( ), the 3
rd 
represents the brain content of the cleaved CA           ( ), and the 4
th compartment 
represents the blood content of the cleaved CA           ( ). With the exception of kel 
and kel_cleaved (which govern the rate of clearance of either the intact CA or the cleaved 
CA respectively) all other k values indicate the compartment from which the CA 
originates (first subscript number) to which the CA flows to (second subscript number). 
k12 and k21 indicate flow into and out of the brain respectively, k23 and k14 indicate 
enzymatic cleavage of the Cat-D targeted CA either in the brain or the blood respectively, 
and k34 indicate the escape of cleaved CA from the brain back into circulation.  
The following system of differential equations was developed to govern the rate 
of change of CA concentration in each compartment: 
    ( )
  
       ( )  (           )   ( ) 
 
    ( )
  
       ( )  (       )   ( ) 
 
           ( )
  
        ( )               ( ) 
           ( )
  
              ( )        ( )                      ( ) 
 177 
 
 
2D Fluorescence Signal= ( )            (   )            
                {[   ( )             ( )]}  
                {[   ( )             ( )]} 
where the 2D fluorescence signal represents the weighted sum of the observed 
fluorescence signal from the brain tissue (See 1. above) and from the blood vessels (See 
2. above) surrounding and supplying or draining the brain and head as a function of time, 
t. Furthermore, each fluorescence signal originating from the brain (           ) or from 
the blood (           ) are proportional (by an arbitrary detection efficiency δ=1 
normalized for the purpose of this qualitative model analysis) –to the respective 
concentration of either a cleaved or un-cleaved CA (the former having a larger 
fluorescence by a factor of β = 1.6 as was determined experimentally; see Fig 3-2B). The 
detection efficiency (δ) might be determined from the relationship between concentration 
of agent and the optical signal – in which case the linear relationship was evaluated (Fig 
3-2C&D). The extent to which a Tg (5XFAD) AD mouse model can cleave the Cat-D 
targeted CA depends on its over-expression (proportional) of the enzyme concentration 
(increased amount of gene expression or through changes in stability of the protein) 
respectively. In this case the over-expression factor was estimated to be Ω >2 (Based on 
having at least twice as much CatD protein by Western blots evaluation (Fig 2-5). 
For the non-penetrating CA dynamics the four compartment model collapses onto a one 
compartment model with                          = 0. This can be expressed as follows 
and visualized in the figure (Fig. A4-1a Compartment model in green): 
           ( )
  
                      ( ) 
from which one could extrapolate from the data the value of            accordingly. 
For the non-targeted CA dynamics the four compartment model collapses yet again, 
however, this time onto a two compartment model with                        = 0. This 
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can be expressed as follows and visualized in the figure (Fig. A4-1a Compartment model 
in blue): 
    ( )
  
       ( )  (       )   ( )  
 
    ( )
  
       ( )  (   )   ( ) 
this in turn provides the grounds to estimate the values of    ,     and     accordingly 
(with     presumed to be relatively close to           ) by fitting the available data. It is 
assumed the 9 amino acid long targeting sequence (attached between the CPP and the 
NIR dye conjugates and differentiates between the non-targeted versus the complete CA) 
does not affect the aforementioned coefficients significantly, however may provide 
insight to estimate the enzymatic cleavage coefficients (       ) and the cleaved CA 
(non-penetrating) capacity to “escape” retention from the brain (   ). Therefore, it can be 
seen that for the complete CPP CatD targeting CA, the four compartment model can be 
explored by observing the estimated fluorescence signal as modeled and qualitatively 
comparing with the in-vivo results. It may be possible to further understand two key 
features crucial to the success of the experimental CA for the detection of AD: 
1. A drug/CA capacity to enter through the BBB is often very challenging. 
Comparing the non-penetrating to the non-targeting CAs dynamics we can get an 
idea of the BBB penetrating capacity of the CPP allowing estimation of the BBB 
penetration into/out of the brain (i.e of    ,    ). 
2. The specificity of a drug/CA and consequentially its capacity to target a specific 
receptor, enzyme or other targets (binding potential) is very important and has 
been shown to correlate to the receptor/targeted enzyme concentrations (e.g 
CatD). By comparing the non-targeting to the complete CAs one can explore the 
cleavage/binding capacity of an agent to the target molecule (i.e of the enzymatic 
cleavage coefficients        ). 
More considerations and work is required to put this analysis to the test, and provide 
accurate and meaningful data. However the possibility to gain pharmacokinetic and 
pharmacodynamics information using this approach is exciting.  
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Figure A4-1 Modeling and simulations. (A) The CA kinetic compartment model for the 
Cat-D targeted (Red), non-targeted (Blue), and non-penetrating (Green) CAs. 1 
Represents the blood content of the intact CA (non-cleaved), 2 Represents the brain 
content of the intact CA (non-cleaved), 3 Represents the brain content of the cleaved CA, 
4 Represents the blood content of the cleaved CA. Arrows represents possible directions 
of CA movement from one compartment to another. (B) Curves of the estimated average 
fluorescence as would be measured following administration of either the Cat-D targeted 
(Red), non-targeted (Blue) and non-penetrating (Green) CAs over time in WT mice only. 
Comparison between older Tg (5XFAD; in red) and WT (Control; in blue) fluorescence 
signal as would be measured following the administration of the Cat-D targeted CA (C), 
non-targeted CA (D), and non-penetrating CAs (E) are shown with Gaussian noise 
increasing with time (x-axis). An arbitrary value for α was chosen to be 90%. 
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